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Abstract  
Despite many studies on the action of yellow light in acne, it is still unclear whether it 
improves inflammatory acne or has photoimmunologic activity against pro-inflammatory 
pathways like toll-like receptor 2 (TLR2) and its down-stream cytokines e.g. TNF-α. This 
work sought to determine whether 530 nm IPL could cause a clinical improvement in acne 
and if its photo-mechanism of action involved modifications of the expressions of TLR2, 
TNF-α, IL-10 and IL-8. 
 
Twenty-eight adult patients with mild to moderate acne vulgaris involving their backs 
received four 530-950 nm IPL treatments at two-week intervals.  Assessments performed 
at baseline and one week after the final IPL session included inflamed and non-inflamed 
lesion counts, Leeds assessments and sebum excretion rate (SER). Biopsies within the 
treatment area were taken at these two time points and two days after the first irradiation. 
TLR2 expression was examined by immunohistochemistry and TaqMan® Low Density 
Arrays were used to measure changes in expression of TNF-α, TNFR, IL-8 and IL-10.  
 
The data from 21 patients was included in the final clinical analyses. Inflamed lesions fell 
significantly by 28.0% (p = 0.002), but was not associated with significant changes in the 
Leeds score, SER or non-inflamed lesions. TNF-α expression fell by 17.6% (p = 0.031) at 
the end of therapy, and appeared to correlate with the percentage change in lesion counts 
in the subjects evaluated. TLR2 expression fell by 2.6% (p < 0.001) a week after the final 
irradiation, but bore no relationship to lesion counts. Neither IL-10 nor IL-8 was 
significantly affected. 
 
Though 530nm IPL significantly reduces inflammatory lesions, treatment efficacy will 
have to be improved to make it a viable treatment option. Its mechanism seems to include 
an anti-TNF-α effect, independent of IL-10 up-regulation. This is a novel mechanism, not 
been previously described for 530nm IPL. Updated hypotheses are suggested in order to 
explore this phenomenon further. 
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Chapter 1 
 
BACKGROUND 1  
Acne Pathophysiology and its Therapeutic Targets 
                                                                                                                             
 1 
1.  Acne Pathophysiology and its Therapeutic 
Targets  
1.1  Introduction 
As Western medicine evolves, alterations in the sub-cellular biological pathways have 
become the pivotal focus in the study of human ailments.  Recent therapies are designed to 
manipulate and harness these pathways, coaxing a state of physiological imbalance back to 
health.  The concept of ‘targeted’ therapeutics is not recent but rather, relatively crude 
tools have become more refined and continue to develop. In 2009, the US Food and Drug 
Administration approved the highest annual level of ‘small-molecule’ pharmaceuticals 
such as biologics [1]. Dermatology is now quite familiar with the use of biologics (e.g. 
anti-interleukin 12/23 and anti-tumour necrosis factor-α antibodies) [2] and more recently 
vemurafenib, a BRAF oncogene inhibitor said to modestly prolong survival in BRAF-
V600E oncogene mutation-positive stage IV melanoma patients [3]. Molecular biology has 
discovered genetic targets, targeted diagnostics and targeted therapies. This has allowed us 
to re-think disorders and examine the probable reasons for a lack of success in treating 
them. Molecular techniques have also enabled closer analysis of therapeutic modalities 
with poorly characterised mechanisms of action.  
 
Acne vulgaris management has also been studied using a reverse-engineering approach. 
The most heavily implicated factors in acne pathogenesis are comedogenesis, infundibular 
Propionibacterium acnes colonization, hormonally influenced seborrhoea, genetic 
susceptibility and inflammation [4-8].  Established management strategies tackle a 
combination of these aetiological factors with oral and topical antibiotics, anti-androgens, 
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anti-bacterials, anti-inflammatories, exfoliants and sebum secretion regulators. Many of 
these are quite useful but have a slow-onset of action fraught with undesirable side effects 
such as dryness, bleaching of hair and clothing, birth defects and the development of 
antibiotic resistance [9-11].  The result is poor patient compliance and left untreated in 
predisposed individuals, acne results in disfiguring scars and keloids, which are difficult to 
manage once established.  
 
These difficulties have caused us to seek therapeutic alternatives such as laser and light 
devices [12, 13]. Intense pulsed light (IPL) is one such device. It is a polychromatic, 
adjustable, incoherent light source that has been successfully used to treat acne either on its 
own or in combination with a photosensitizer which augments its action [10, 14-16]. In 
vitro studies suggest that red light (620-750 nm) is anti-inflammatory by inhibiting 
cytokine release from macrophages [17] while blue light (450-495 nm) photo-inactivates 
P. acnes. However, specific published references regarding the mechanism of action of 
intense pulsed light are few.  
 
1.2 Acne pathogenesis: Classical and Neo-classical Concepts 
The classical concept of acne pathogenesis is largely based on a vast body of evidence 
from eminent dermatologists and scientists such as WJ Cunliffe [18], AM Kligman [8], JS 
Strauss [19] and G Plewig [20]. In this model, microcomedone formation is the initiating 
event [8].  These non-inflamed lesions are caused by retention hyperkeratosis of the 
epithelium within the sebaceous follicle. The resultant comedone produces a mechanical 
obstruction to sebum outflow and provides an environment suitable for Propionibacterium 
acnes proliferation. P. acnes metabolises these lipids, producing free fatty acids which are 
comedogenic and irritant to the surrounding dermis [8].  On-going hyperproliferation 
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disrupts the comedonal wall, releasing epidermal and fatty acid debris into the dermis. This 
incites an inflammatory response producing inflamed, polymorphic, acne lesions [8]. 
Then, the prevailing view was that diet had an obscure role to play in acne pathogenesis 
[8], but a single study on the effect of chocolate consumption on acne [21], now hotly 
refuted [22], suggested otherwise.  
 
In the ‘neo-classical concept’, a specific T-cell mediated inflammatory response is the 
initiating event in acne pathogenesis [23], followed by comedone formation.  Previously, a 
lymphocytic infiltrate in the vicinity of early lesions (< 24 hours) had been noted but was 
deemed to be an early post-comedonal event [24, 25].  The mechanism of inflammation is 
hypothesized to be a Type IV hypersensitivity reaction where P. acnes moieties are the 
probable antigenic compounds [26, 27]. This model is still inadequate as mere suppression 
of inflammation does not suppress acne lesion formation, signalling the need for further 
study. 
 
Seborrhoea is still a necessary co-factor within the pathogenetic pathway and 
comedogenesis is triggered by the initial inflammatory response. Genetic factors have been 
given greater emphasis now that diagnostic tools are widely available to discover them. 
The following section is a re-construction of the neo-classical concept from initiation to 
resolution of the acne lesion. Thereafter each pathogenetic factor: P. acnes, 
comedogenesis, seborrhoea and genetic susceptibility will be expanded and pro-
inflammatory therapeutic targets identified.  
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1.2.1 Neo-classical View: Evolution and Dissolution of the Acne Papule  
1.2.1.1 Initiation 
In genetically susceptible individuals, pilosebaceous follicles are inherently more sensitive 
to circulating androgens.  At the onset of puberty, the rise in circulating and local 
androgens ‘switches on’ sebaceous glands within predisposed follicles encouraging 
sebocyte differentiation, proliferation and lipid production [4, 28]. Hence, larger sebaceous 
glands that secrete more sebum develop. Add to this a diet rich in dairy, simple 
carbohydrates and monounsaturated fats, the ensuing hyperinsulinaemia increases 
peripheral production of androgenic metabolites, worsening the seborrhoea. In acne-prone 
skin,  interleukin 1 receptor (IL-1R) is up-regulated on keratinocytes within the epidermis, 
enabling minute concentrations of IL-1, which would have otherwise been overlooked by 
normal cells, to trigger an immune response [23, 29] and stimulate hyperkeratinisation of 
the infra-infundibulum and sebaceous ducts [8]. This follicular ‘hypervigilance’ represents 
the baseline state of the acne prone pilosebaceous unit.  
 
The skin’s microflora would have been processed and presented by dendritic cells to 
lymph nodes in early life, producing a bank of memory T-cells. Once an individual-
specific titre of microbial stimulant e.g. P. acnes, is bound by toll-like receptors (TLRs) 
and defensins, then cytokines and chemokines are released by the recruited lymphocytes, 
neutrophils and mononuclear cells. The cytokines then attach to their receptors within the 
epidermis, infundibulum and sebaceous glands to initiate an inflammatory cascade. 
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1.2.1.2  Progression  
TLRs on keratinocytes, sebocytes and dendritic cells activate signalling cascades that 
enlist transcription factors and signal transducing phosphokinases such as nuclear factor 
kappa B (NFκB) and mitogen-activated phosphokinase (MAPK) [30].  In response to these 
messages, a host of chemokines are then transcribed including tumour necrosis factor α 
(TNFα), IL-8 and IL-6 that in turn, recruit leucocytes. These lymphocytes, monocytes, 
neutrophils and macrophages then release more cytokines.  Keratinocytes within the 
epidermis, infundibulum and sebaceous duct are stimulated to proliferate and resist 
desquamation by interleukin-1 alpha (IL-1α) and IL-1β, forming a cornified blockade to 
the outflow of sebum. This marks the beginning of the comedone.  
 
If the patient is also experiencing stress such as a family crisis, the neuropeptide substance 
P is released. Substance P augments the response of sebaceous glands to cytokines such as 
IL-1α, IL-6 and TNFα and prepares the surrounding vasculature for the chemotactic phase 
of an inflammatory response by up-regulating cellular adhesion molecules such as 
intercellular adhesion molecule (ICAM) and vascular adhesion molecule (VCAM) [31, 
32]. Stress also causes an increase in corticotropin releasing hormone (CRH) which is pro-
inflammatory [33, 34], sebo-stimulatory [35] and pro-comedogenic [36].  
 
As a consequence, escalating ductal blockage by sticky keratinocytes leads to the eventual 
disruption of sebaceous and infundibular ducts producing dermal irritation by released 
fatty acids. Damaged keratinocytes and TLR2 provocation contributes to dissolution of the 
extracellular matrix through the release of matrix metalloproteinases (MMPs) from 
monocytes [37], sebocytes and keratinocytes [38]. The resultant lesions present as papules, 
pustules and nodules.  The severity of these acne lesions is dictated by the size of the 
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initial cellular infiltrate, the volume and volatility of the sebaceous lipids [39] and the 
underlying magnitude of androgenic stimulation.  
 
1.2.1.3 Resolution 
Cutaneous surveillance mechanisms in the form of immune-modulatory cytokines such as 
IL-10 are released to modulate the response. However, these measures are rendered 
ineffective in those affected by acne vulgaris who have either lower circulating levels of 
IL-10 [40] or a slow release compared to normal controls [41].  Incorporating the 
‘keratinocyte activation cycle’ as described by Freedberg et al. [42] in the context of 
wound healing, the activated epithelial cells that release IL-1α causes the release of 
chemotactic cytokines such as IL-6, TGFα, IL-8 and GCSF, that in turn send multiple 
signals for cellular proliferation, re-epithelialisation and endothelial selectin expression. 
Eventually, as extracellular matrix is synthesised, the basement membrane is restored and 
TGFβ levels increase. These autocrine and paracrine signals form a negative feedback loop 
resulting in deactivation of keratinocytes [42]. The wound then heals and the papule 
resolves. 
 
Persistent lesions may occur because the deactivating signals are not all present. A 
chronically disrupted basement membrane or high levels of the activating cytokines may 
continue to stimulate this process. Holland et al. [26, 43] demonstrated that patients with 
scarring acne have a greater proportion of memory T-cells at the beginning of the 
inflammatory process. They also have more CD68+ macrophages lingering in their acne 
papules many hours after a similar infiltrate in individuals with non-scarring acne would 
have waned.  This chronicity leads to delayed healing of dermal wounds and hence 
scarring [26, 43]. 
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Table 1.1: Therapeutic Targets for Visible Light within Acne Inflammation. A list of major 
targets that can affect inflammation. 
Pathogenetic Group Targets 
Pro- inflammatory Cytokines IL-8, IL-6, TNFα, ICAM-1, VCAM  
Anti-inflammatory Cytokines IL-10, TGFβ 
T-cells CD4, CD8 
Growth Factors GCSF 
 
 
 
1.3 Propionibacterium acnes (P. acnes) 
1.3.1 Is P. acnes a Primary or Secondary Therapeutic Target?  
Anti-bacterial and antibiotic therapies have been dutifully prescribed based on 
observational studies which show that P. acnes undoubtedly plays a role in acne 
pathogenesis:  
(i) There is a progressive increase in P. acnes counts from pre-adolescence to early 
adulthood [44]  
(ii) Persons with active acne have higher densities of P. acnes compared to normal 
controls [45] 
(iii) The face and upper trunk have significantly higher P. acnes and sebum levels 
compared with the lower trunk and extremities, which is in keeping with the 
common distribution of acne vulgaris [46]  
(iv) P. acnes can stimulate hamster sebaceous lipogenesis via prostaglandin J [47] 
(v) The density of P. acnes positively correlates with the sebum excretion rate 
(SER) [45] as well as the total mass of several sebum components [46]  
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(vi) P. acnes is able to incite a robust inflammatory response and a specific T-cell 
response [48] 
(vii) Antibiotic resistance can be associated with difficult-to-treat acne [9, 49]   
 
However, whether P. acnes colonisation is a primary or secondary aetiological event in 
acne lesion initiation is still debatable [44].  The presence and quantity of P. acnes cultured 
from skin of individuals with and without acne do not always correlate with the existence 
or severity of acne [50, 51] and after therapy, improvement does not always coincide with 
a reduction in P. acnes colony counts [52]. It is noteworthy that tetracyclines are said to be 
effective because of their anti-inflammatory action and not their direct anti-bacterial 
properties [53].  The dual effect of tetracyclines reduces both the antigenic load and the 
inflammation caused by P. acnes. 
 
1.3.2 P. acnes and Innate Immune Response Targets 
Micro-organisms like P. acnes can prompt the secretion of a variety of cutaneous anti-
microbial peptides e.g. defensins and cathelicidins. These mediate  bactericidal or 
bacteriostatic actions through cell membrane disruption [54]. There are two main defensin 
subfamilies: α and β, where β-defensins predominate in human skin [55]. There are many 
types of β-defensins including human β-defensin 1 (hBD1), hBD2, hBD3 and hBD4 [56]. 
Defensins are housed in neutrophilic granules [55] and released as pro-peptides, which are 
then cleaved to release an active cationic moiety that interacts with the negatively charged 
bacterial surface proteins [57]. The hydrophobic portion of the peptide integrates with the 
bacterial membrane leading to cytoplasmic leakage, inhibition of nucleic acid synthesis 
[55] and complete cellular disruption [57].  Defensins are regulated by a complex 
relationship between skin flora, toll-like receptors (TLRs), nucleotide-binding 
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oligomerisation domain (NOD) receptors, cytokines, chemokines and members of the 
specific and adaptive immune responses [57]. hBD1 and hBD2 can bind to chemokine 
receptors such as CCR6 attracting dendritic cells, monocytes and T-lymphocytes [55]. 
Stimulators of hBD2 expression include IL-1α, IL-1β, TNFα, protease inhibitor 3 and 
lipocalin (anti-microbial compound found in tears) [54, 58, 59].  The addition of IL-1R 
antagonist to cultures containing bacterial lipopolysaccharides suppressed the increase in 
hBD2 mRNA expression [58].  These findings suggest that the innate immune response 
mediated by keratinocytes is through IL-1 production. 
 
The inflammatory effects of P. acnes do not require the organism to be alive or present in 
its entirety [60, 61].  Keratinocyte expression of TLR2 and TLR4 in vitro was increased in 
cultured cells in the presence of supernatants containing membranous peptidoglycans and 
lipopolysaccharides, cytosolic contents or membrane proteins [62]. The peptidoglycan-
lipopolysaccharide moiety had a more stimulatory effect compared to the other cellular 
components.   
 
1.3.3 P. acnes as a Photodynamic Target 
Both P. acnes and P. granulosum synthesise coproporphyrin III (CPIII) as their major 
porphyrin [63, 64]. Both the P. acnes bacterium  and CPIII molecule can stimulate IL-8 
release from keratinocytes in vitro,  inciting inflammatory acne [65]. Irradiation of P. 
acnes with a suitable wavelength of light leads to photoactivation of CPIII, followed by 
destruction of the organism, resulting in an improvement in acne [66].  The maximal 
excitation peak of CPIII is at 403 nm (Soret band) [64] with smaller peaks at 500 and 530 
nm [67].  Regarding photodynamic efficacy, CPIII is 1.1 and 20 times more efficient at 
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producing singlet oxygen than other endogenous porphyrins such as haematoporphyrin or 
eosin [68].   
  
 
Table 1.2:  Therapeutic Targets induced by P. acnes  
Pathogenetic Group Targets 
P. acnes moieties TLR2, TLR4, IL-8, IL-6, IL-1α, hBD2, 
Prostaglandin J 
Porphyrins Coproporphyrin III, metalloporphyrins 
 
 
 
1.4  Comedogenesis  
In 2000, Cunliffe et al. [7] confidently stated “Hypercornification is an early feature of 
acne and precedes inflammation”.  Jeremy et al. [23] cast doubt on this dogma as they 
reported a significant population of memory and effector T-cells in clinically normal 
pilosebaceous follicles prior to comedo formation. In their study, timed observations of 
papules less than 6 hours old revealed augmentation of the pre-existing adaptive immune 
response without disruption of the basement membrane and no obvious hyperproliferation. 
Earlier literature on the genesis of the acne papule is partially supportive of an inciting 
inflammatory event [25, 32, 69], but one can hardly dispute the fact that comedones are a 
feature of acne and require treatment. An understanding of comedogenesis will help to 
identify potential therapeutic targets for IPL.  
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Comedogenesis is a result of abnormal hyperproliferation and shedding of corneocytes into 
the pilosebaceous duct [7]. Over the past 40 years, abnormal shedding has been suggested 
to be secondary to alterations in corneocyte tight junctions and desmosomes [70, 71], intra-
ductal linoleic acid deficiency [72] and recently, an accumulation of lipid peroxides, break 
down products of sebum [73].  Guy, Green and Kealy [74] observed that the infundibulum 
of pilosebaceous units in facial skin hyperproliferated under the influence of interleukin 1 
alpha (IL-1α) and could be blocked by the use of IL-1 receptor antagonist (IL-1ra). Further 
exposure of these infundibula to a clinically therapeutic concentration of 13-cis retinoic 
acid reduced the rate of cell division [74], and hence ductal obstruction, in keeping with 
the known topical effects of retinoids in acne [75]. Furthermore, earlier studies which 
showed that biologically active IL1α-like material has been isolated from open comedones 
[76]. Cutaneous keratinocytes express IL-1α and IL-1β receptors where IL-1α receptors 
predominate in the epidermis and IL-1β receptors are more prevalent in sebaceous acinar 
walls [77, 78].  Renne et al. [79] found that IL-1β released by cultured keratinocytes 
promoted inflammation by increasing the release of interferon γ  (IFNγ) by T-cells. Hence 
keratinocytes through IL-1α and IL-1β is a key promoter of both comedogenesis and 
inflammation.  
 
Cunliffe and colleagues [7] hypothesised that comedones, like hair follicles, naturally go 
through cyclical periods of exacerbation and resolution based on observed changes in the 
expression of Ki67 and K16. Downie et al. [80] modelled a resolving acne lesion  and 
showed that isolated sebaceous glands, harvested from post-surgical chest and breast skin, 
de-differentiated to keratinocyte-like morphology after exposure to IL-1α, TNFα and 
IFNγ. Therefore pro-comedogenic cytokines also orchestrate the resolution of a comedone. 
This process of de-differentiation was previously described by Strauss & Kligman [81] in 
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1958, where it was noted that sebaceous glands traumatised with phenol, long-term 
occlusion or repeated needling, developed a keratinocyte-like morphology. 
 
 1.4.1  Pro-comedogenic Targets and P. acnes  
Ingham et al. [82] used normal human epidermal keratinocytes (NHEK) harvested from 
neonatal foreskin showed that P. acnes was able to significantly provoke IL-1α production 
by keratinocytes.  P. acnes is also able to increase keratinocyte proliferation, as indicated 
by increased Ki67 expression in the epidermis of skin explants [83]. Ki67 is a nuclear 
protein present within cycling cells [84] and in non-involved skin of acne patients, Ki67 is 
up-regulated in the acroinfundibulum [85].   Thus, it might be inferred that P. acnes, which 
colonises the infra-infundibulum, contributes to comedogenesis. However, rather than 
observing increased keratinocyte proliferation, Akaza et al. [86] noted strain specific 
reductions in Keratin 1 (K1), K10, K6 and K16 mRNA levels after exposure to different P. 
acnes isolates in vitro despite a statistically significant increase in pro-inflammatory 
cytokine release. It is possible that the inconsistencies amongst these studies could be 
attributable to the use of cultured keratinocytes [82, 86] versus more biologically 
representative models such as skin explants [83].   
 
 
Table 1.3: Therapeutic Targets in Comedogenesis  
Pathogenetic targets Targets 
 IL-1α , IL-1β 
Ductal hyperproliferation P. acnes 
 S. epidermidis 
Pro-comedogenic TNFα, IFNγ, IL-1α 
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1.5 Androgenic Hormones, Sebaceous Glands and Seborrhoea   
1.5.1   The Skin as an Endocrine Organ  
The skin produces hormones de novo from cholesterol and can also metabolise them [87, 
88], making it an obvious target for medical intervention. A significant proportion of these 
hormones and many of the resident enzymes are dedicated to androgen-metabolism. 
Androgen receptors have been localised to many sites within the skin: keratinocytes, 
fibroblasts, endothelial cells and both peripheral and central portions of the sebaceous 
gland [89].  Sebaceous glands have a particular role to play as they express a variety of 
receptors, implicated in acne pathogenesis, for androgens [90], oestrogens [91], thyroid 
stimulating hormone (TSH) [90], histamine [92], prostaglandins [93], corticotrophin 
releasing hormone (CRH) [33, 94], melanocortin-1 [95-97] and peroxisome proliferator-
activated receptors (PPAR) [98-100]. Androgen receptors on keratinocytes and sebocytes 
present a possible mechanism by which androgens stimulate hyperkeratinisation and 
seborrhoea [101]. In these sites, testosterone is converted to its potent metabolite DHT via 
two isoforms of 5α- reductase, type I and type II [102], where type I predominates [103, 
104]. Thiboutot and colleagues [87] studied hair follicles in breast skin from 82 donors and 
found that 5α reductase activity was highest in the sebaceous gland and duct followed by 
the follicular infra-infundibulum and lastly the epidermis. 5α-reductase activity is greater 
in acne-prone skin (face) when compared to other sites [103] and was slightly higher in 
individuals with acne than those without [105].   
 
Three beta– and 17β-hydroxy steroid dehydrogenase (17β-HSD) are enzymes required for 
androgen metabolism within the skin (Figure 1.1). Like 5α reductase, they also have 
greater activity in sebaceous glands compared to the dermis and epidermis [106, 107].  
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However, 5α reductase has 2-3 fold higher activity than 17β-HSD in sebaceous glands 
[108], but there is little difference in their activities in cultured epidermal and infra-
infundibular keratinocytes [105]. Both enzymes have greater activity in men [105, 109] 
and are not associated with the presence of acne in women [105].  Furthermore, despite 
their increased activity in acne prone areas [106], their up-regulation in acne subjects is not 
statistically significant [105]. Referring to Figure 1.1, it is clear that antagonists of any of 
these enzymes, or hormone receptors (DHT, testosterone or DHEAS) are potential 
therapeutic targets and the ultimate aim would be to deliver these antagonists directly to 
the skin and /or sebaceous glands. 
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Figure 1.1: Androgen and Sex Hormone Metabolism in the Skin      
KEY: 3β-HSD – 3β-hydroxysteroid dehydrogenase; 17β-HSD – 17β-hydroxysteroid 
dehydrogenase;  DHEAS – dehydroepiandrosterone ; DHT– dihydrotestosterone; P450c17 – 
cytochrome P450 17-hydroxylase; P450scc - P450 side-chain cleavage enzyme; StAR – steroid 
acute regulatory protein facilitates the transfer of cholesterol from the outer to the inner 
mitochondrial membrane.  17β HSD II predominates in the sebaceous glands. Adapted from 
Thiboutot et al. [87, 105, 108, 110] and Chen et al. [88]. 
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1.5.2   Androgens and Seborrhoea 
Seborrhoea has long been associated with the presence of acne [111, 112] which is very 
much under androgenic control: 
i. Adults with complete androgen insensitivity, a condition in which mutations in the 
androgen receptor gene renders them ‘insensitive’ to circulating androgens [113]  
producing a phenotypic female but genetic male, do not excrete appreciable levels 
of sebum [114] 
ii. Males castrated prior to the onset of puberty do not develop acne [115] and 60% of 
pre-pubertal boys treated with topical testosterone exhibit increased sebum output 
[116] 
iii. Post-adolescent castration or oophorectomy in acne patients results in the gradual 
resolution of their acne [115] and their sebum excretion rates fall below that of 
normal subjects [117, 118]   
 
1.5.3  Androgens, Acne and Gender 
It should follow that males have a higher incidence and greater severity of acne when 
compared to females. Some epidemiological studies confirm this [119-121] but, there is 
not a strict positive relationship between androgen levels, the presence of acne and its 
severity in men [108].  
 
Females with severe acne have significantly higher levels of a circulating androgen 
precursor, dehydroepiandrosterone (DHEAS), than their compatriots with mild to 
moderate acne or normal controls [122-124]. Carmina et al. [122] and Lucky et al. [123] 
report a very specific association between acne severity and DHEAS serum 
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concentrations. A similar association was not found with other androgenic hormones (i.e. 
testosterone and progesterone) amongst women with varying severities of acne. These 
findings have been confirmed in vitro where SZ95 sebocytes of female-origin were 
incubated with various substances including progesterone, pregnenolone, DHEA and IGF-
1 [125]. Of these, DHEA induced maximal testosterone production [125].  A useful 
extension of this study would be to compare the response of male-derived and female-
derived SZ95 sebocytes. Some smaller studies involving women with post-adolescent acne 
disagree. They identified significantly higher levels of free testosterone and DHT in acne 
patients than normal controls [108, 126].  Hence, it is clear that both DHT and DHEAS are 
implicated alone or separately in the development of acne vulgaris highlighting the ability 
of a number of androgenic compounds to cause acne although they may not exhibit the 
same potency. 
 
Regarding inflammation, cultured human sebocytes express significantly higher levels of 
IL-6 and TNFα (mRNA & protein) when cultured with DHT [127]. In a murine system, 
Weinstein et al. [128] showed that androgens were not immunostimulatory. Rather, they 
caused an inhibition of antigen presentation in male mice and androgen-supplemented 
female mice. In humans, this observation is partially supported by Holland et al. [119] as 
females with mild acne had a measurable difference in their peripheral blood immunocyte 
counts when compared to normal controls but the male cohort did not exhibit similar 
increases unless their acne was moderately severe  or worse [119]. They postulated that 
this phenomenon meant that males did not mount a protective response until it was too late 
– when their acne was already quite severe, accounting for their greater representation in 
groups with moderate and severe acne. 
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1.5.4  Sebum 
Sebum changes in quality and quantity with age, such that the volume of sebum excreted 
increases in adulthood and declines with advancing age (41+ years) [129-131].  Few 
studies have examined the composition of sebum directly from the sebaceous glands [132, 
133].  Nasr [132] reported that skin surface lipids closely approximate to sebum but the 
cadaveric sebaceous glands that he examined (from 53 people of various ages) did not 
contain free cholesterol. He surmised that cholesterol may be synthesised by the ductal 
keratinocytes and secreted onto the skin surface. A large percentage of pre-pubertal skin 
surface lipid is made up of cholesterol and cholesterol esters but adult sebum contains 
shorter-chain length fatty acids (C16), squalene, triglycerides and fatty alcohols [98, 134-
136]. This difference may reflect a surge in the cutaneous consumption of cholesterol at 
the onset of puberty for the production of androgens and other hormones.  
 
Amongst the fatty acids, high levels of ∆6 C16 fatty acids are present, including sapienic 
acid and its derivative sebaleic acid, a polyunsaturated substrate of palmitic acid [137]. 
These two fatty acids are unique to humans and are converted to a potent chemoattractant, 
5-oxo-octodecadienoic acid, in neutrophils and keratinocytes via lipoxygenase enzyme 
activity [137].  The increased sebum excretion rate (SER) and change in its composition in 
pre-pubertal children was accompanied by greater propionibacterial densities [129, 138]. 
Notably, in an investigation by Mourelatos et al., children who maintained a low SER 
throughout the 2½ year study did not develop acne [138]. Triggers for this localised 
process are currently uncharacterised but hypothetically, due to the observed synchrony 
between puberty and acne, is likely to be also under the control of the hypothalamo-
pituitary-adrenal axis. People without acne or with mild acne may secrete more protective 
FFA components, such as lauric acid, a 12-carbon fatty-acid, which accounts for only 1-
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2% of the FFA moiety in sebum but  is 4–60 times more potent than benzoyl peroxide 
against P. acnes, S. epidermidis and S. aureus in vitro [139].  An experimental ointment 
containing lauric acid was able to reverse intradermal inflammation caused by P. acnes in 
murine epidermis [139]. 
 
An individual’s propensity for inflammatory acne vulgaris is heavily modulated by 
environmental and dietary factors. As IPL is unable to directly influence a person’s diet, 
the roles of dietary factors in acne pathogenesis [140-142], androgen expression [143, 
144], lipogenesis [145] and sebum composition [142, 146] will not be discussed here but 
are explained more fully in our review article [147] (Appendix 4).  
 
 
Table 1.4: Therapeutic Targets within Sebogenesis   Key: CRH, corticotrophin releasing 
hormone; FFA, free fatty acids; MC-1, melanocortin 1.  
Pathogenetic Group Targets 
Androgens DHEAS, DHT,  Testosterone, Androstenedione 
 Androgen receptors 
Sebaceous glands Receptors, enzymes, prostaglandins 
Sebum CRH, MC-1, cholesterol, FFA, triglycerides 
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1.6 Genetic Susceptibility 
A number of studies carried out in adolescents and young adults from Iran, China, France 
and the UK [120, 148-150] report a strong familial tendency for acne, where the index 
cases tend to present at a younger age [120].  A cohort of British patients with ‘adult 
persistent acne’ (26 – 78 years) also had increased rates of similarly affected first degree 
relatives when compared to normal controls [151].  The increased risk of developing acne 
in the presence of a positive family history ranges from 2.3 [149] to 4.69 [120].  A 
retrospective study of 1,557 pairs of monozygotic and dizygotic twins living in the UK 
showed significant familial clustering [152].  Forty-one per cent of those with acne had 
children similarly affected, 47% had siblings and 25% had parents also affected [152]. In 
the unaffected (86% of the cohort), the percentages of children, siblings and parents with 
acne were 17%, 15%, and 4% respectively.  To date there have been only a few published 
genetic candidates to account for this heredity.   
 
1.6.1 CAG Repeats 
The androgen receptor gene (Xq11-12) has 8-35 CAG trinucleotide repeats in the 
transactivation domain [153].  The length of this repeat sequence inversely correlates with 
the sensitivity of the androgen receptors. Therefore, persons with longer CAG repeats have 
lower incidences of androgen-mediated disease such as prostate cancer, polycystic ovaries 
and acne [121, 153, 154].  Yang et al. [121] and Pang et al. [153] found male acne patients 
tended to have 23 or less CAG repeats and normal controls had more. A similar 
association in females was seen only in Pang’s study despite having a similar ethnicity and 
sample size to Yang’s study, therefore the strength of this association remains unclear.   
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1.6.2 Other Polymorphisms 
Polymorphisms in genes for TNFα [155, 156], TNFR2 [157], TLR2 [157], IL-1α [155], 
cytochrome P450 1A1 (which codes for retinoic acid metabolising enzymes) [158, 159], 
CYP17 – 34T/C (another P450 gene that codes for 17α-hydroxylase) [110, 160], CYP21 
(gene coding for 21-hydoxylase) [161] and fibroblast growth factor receptor 2 (FGFR2) 
[162] are possible contenders for the modulation of acne severity.  
 
FGFR2 mosaicism may be associated with epithelial dysregulation resulting in cancers of 
the breast, uterus and skin [163] and has been identified in a localised acneiform naevus in 
a single individual [162].  FGFR mosaicism is also responsible for the nodulocystic acne 
seen in Apert’s syndrome, a dominantly inherited condition characterised by craniofacial 
abnormalities and syndactyly [164]. Melnik, Schmitz & Zouboulis [164] have made an 
elegant case for FGFR2’s role in acne pathogenesis and how its manipulation is crucial to 
the mechanism of action of antibiotics, anti-androgens and retinoids.  Here, fibroblasts 
synthesise FGF7 and FGF10 in response to DHT [164].  FGF7 and FGF10 produced by 
fibroblasts are ligands for FGFR2b found on suprabasal keratinocytes and sebocytes and 
DHT augments FGF7 and FGF10 transcription [28].  FGFR2b binding leads to 
transcription of IL-1α, which encourages hyperkeratinisation of epithelia as well as 
proliferation and fatty-acid synthesis in sebocytes [164].  Whilst this hypothesis is a 
possibility, as yet, there are no in vitro or in vivo studies to substantiate it.  
Polymorphisms are normal variants of a gene and therefore the polymorphisms mentioned 
above may not represent a disease state.  In 1975, an overview of acne by Kligman [8], 
stated that acne was “…a polygenic disorder in which the phenotypic expressions 
represent the sum of many genes each of which is not strongly active by itself… (does) not 
follow simple Mendelian patterns (and) can be strongly influenced by external agencies 
                                                                                                                             
 22 
and have variable expression.”  In spite of swathes of new information, there have been no 
real revelations about the precise genetic factors associated with acne in almost 40 years. 
Hence, the all-encompassing term ‘genetic susceptibility’ is often used when discussing 
acne pathogenesis.  
 
Since acne is so common amongst humans, is it possible that it is an evolutionary double-
edged sword? Is it a distant and ultimately more complex relative of the sickle cell trait 
which offers some protection against certain types of malaria in endemic countries, but can 
be deadly in homozygous carriers [165]?  Bloom [166] theorises that the unsavoury 
appearance of typical adolescent acne serves to avert early mating and improves at a time 
which coincides with psychosocial maturity and greater readiness for parenthood. Kligman 
[8] also cites papers which take a more mechanistic view. They propose that by adulthood, 
the follicular epithelium becomes less permeable to irritant fatty acids and ‘hardened’ to 
external irritants leading to the resolution of acne.  
 
 
Table 1.5:  Potential Genetic Therapeutic Targets 
Pathogenetic Group Targets 
Androgen receptor polymorphisms  CAG repeats  
Androgen metabolism CYP17 ,  CYP 21, P450 1A1 
Fibroblast regulation FGFR2 
Immunological disruption TNF-α, TNFR, TLR2,  IL-1α 
Evolutionary modulation ? 
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1.7 Conclusion 
A number of the therapeutic targets identified are implicated in innate and adaptive 
immune mechanisms, comedogenesis and sebogenesis. Later, molecules from these lists 
will be identified as having the potential to be IPL-modifiable. The following chapters also 
discuss the principles of IPL devices and the available evidence for the use visible light in 
acne therapy thus identifying some gaps in our knowledge with respect to IPL as a 
therapeutic alternative. 
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Chapter 2 
 
BACKGROUND 2  
The Basis for Visible Light in Acne 
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2. The Basis for Visible Light Use in Acne  
2.1 Introduction 
Light as a therapeutic alternative in acne management is not a new concept.  Sunlight has 
long been considered a natural remedy for acne and physician-administered UVA and 
UVB were once used as alternative treatments for acne [167]. UVB is known to promote 
cellular apoptosis and disrupt Langerhans cells’ antigen presenting function by reducing 
their dendricity and antigen presenting molecules (e.g. MHC II) [168-171]. UV radiation 
has now fallen out of favour due to the wide availability of more effective treatments 
without the additional photo-carcinogenic effect associated with it.  Visible light (400 -700 
nm) has a greater depth of penetration than UV light and hence is able to reach the deeper 
sites of acnegenesis such as the sebaceous duct and gland [172-174].  
 
Commonly cited justifications for the use of light-based therapies to treat acne are that 
they widen the therapeutic options available, offer treatment to those unable to take or 
have failed standard therapy, may improve compliance, does not add to the problem of 
antibiotic resistance and reduces the need for long-term antibiotics [175-178]. An 
assortment of laser and light sources has been used to treat acne with variable success 
[179, 180]. Comparing lasers and broad-spectrum light sources, the latter is advantageous 
in that they are cheaper to run, versatile and portable [181]. Intense pulsed light (IPL) is a 
broadband incoherent light source which utilizes xenon lamps to emit photons at various 
energies along a continuous spectrum (500 -1300 nm) via a computer-controlled capacitor 
bank [182, 183]. Many IPL systems allow a range of treatment parameters through the 
manipulation of cut-off filters [182]. This filtered light irradiates target tissues to produce 
thermal, mechanical or chemical damage of target chromophores such as melanin within 
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the epidermis and haemoglobin in the vasculature, whilst sparing surrounding tissues [184, 
185]. Thus, IPL systems are used for a number of indications including hair removal, 
photorejuvenation, dyschromia, rosacea, telangiectasia, vascular malformations, actinic 
keratoses and acne [181, 186-190]. The rest of this chapter describes light-skin 
interactions, IPL parameters and their effect on clinical performance and finally, a brief 
summary of clinical trials examining incoherent visible light use in acne.  
 
2.2 Light-Skin Interactions 
The observed clinical outcome in irradiated tissue is equally dependent upon the properties 
of the tissue being irradiated and the radiant source [191, 192]. The desired result arises 
from a combination of chemical, mechanical, thermal and immunological interactions, the 
extent of the insult and the tissue’s healing response.  
 
2.2.1 The Effect of Light in Light-Skin Interactions 
2.2.1.1 Photothermal Reactions 
In photothermal reactions, absorbed light is converted to heat. The temperature attained, 
the sustained duration at that temperature, and time between subsequent episodes of 
heating induces local changes and pathological processes in the tissue [191, 193]. These 
changes are summarised in Table 2.1.  
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 2.2.1.2 Photomechanical Reactions 
Short pulses which deliver high energies can cause rapid heating and expansion of the 
target tissue leading to rupture. Clumping of nuclear chromatin, epidermal and dermal 
vacuolisation can occur. Elastic recoil of the tissue can cause additional secondary 
damage. These mechanical/acoustic effects are exploited in the treatment of renal calculi 
via shock wave lithotripsy [193]. 
 
2.2.1.3 Photochemical Reactions 
This requires the presence of an endogenous or exogenous chromophore. Photons are 
absorbed by the chromophore, converting it to an excited state. In this state, cross-linking, 
bond-breaking, free-radical formation or destruction of the chromophore may occur. In 
photodynamic reactions, a photon of light reacts with a photosensitive dye e.g. 
coproporphyrin, in the presence of oxygen to produce oxygen free radicals [191]. The free 
radicals injure cells and subcellular organelles such as mitochondria.  
 
2.2.1.4 Photoimmunological Reactions 
This term refers to the immunomodulatory effects of non-ionising electromagnetic 
radiation (light) on cytokines and immuno-competent cells [194]. The use of UVA and 
UVB as immunosuppressants in inflammatory skin diseases is well-documented as is their 
ability to induce skin cancer. Visible light can also induce useful and pathological immune 
reactions e.g. solar urticaria [195]. 
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Table 2. 1: Photothermal Effects of Laser-Tissue Interactions. Adapted from Thomsen [193] 
Photo-thermal 
Interaction 
Temperature 
at Onset (ºC) 
Histopathologic Result 
Low-temperature 
damage 
40 + Reversible cell injury, enzyme & 
protein denaturation, cell death, cell 
shrinkage, membrane rupture 
Higher-temperature 
damage 
58+ Hyalinization of collagen, elastin 
denaturation  
Water-dominated  
Processes 
100 + Water vaporisation, vacuolar rupture 
(popcorn effect), tissue ablation through 
fragmentation 
High Temperature 
Ablation 
300 – 1000+ Tissue ablation & carbon vaporisation 
 
 
2.2.2 Influence of the Skin in Light-Skin Interactions 
The optical properties (scatter and absorption), thermal capacity, mechanical properties 
(elasticity, tensile strength), composition (water, endogenous and exogenous 
chromophores), anatomy (physical arrangement of organelles within the tissue) and 
physiology (metabolic status) of the skin affect the attainment of the desired end point 
[193].  
 
At the stratum corneum-air interface, 5% of incident photons are reflected (Fresnel’s 
reflection) whilst the remainder traverse the epidermis into the turbid dermis [172, 196]. 
Depending upon the component wavelengths of the incident light, select structures within 
the epidermis and dermis absorb, scatter and transmit the remaining photons (Figure 2.1) 
[197].   Optical properties of dermal collagen fibres and the subcutaneous fat below 
determine how much scatter occurs and hence the final depth of penetration of incident 
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light [172, 198, 199].  Temperature changes within human skin can change the lipid’s 
fluidity, orientation and stacking order, altering the skin’s optical pathways [198]. These 
complex and varied optical properties of skin contribute to the constant flux noted in 
estimations of the dose of delivered light [174, 191].   
 
                                                                                                                                                                                                                                                                                                                                                                                 
 
Figure 2. 1:  Schematic Representation of the Optical Pathways in the Skin [172, 196, 197].   
KEY: SC – stratum corneum; A - absorbed radiation.   Adapted from Anderson & Parrish [172] 
and Krishnaswamy & Baranosky [197]. 
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2.2.3 Chromophores 
“Chromophores” are the bonded, unsaturated atoms in a molecule that dictate its 
absorption properties. The epidermis contains many chromophores including melanin, 
urocanic acid, nucleic acids, water and amino acids. The dermis consists of a 
proteinaceous matrix of collagen, elastin and fibroblasts in which capillary plexi and 
appendages sit [199].  Collagen surrounds key chromophores such as haemoglobin, 
bilirubin and water [172, 198]. 
 
2.2.3.1 Melanin  
Absorption peaks for melanin and its metabolites lie within the 250 – 1200 nm range with 
the largest absorption peak at 335 nm followed by a sharp reduction at longer wavelengths 
[200]. The method of induction of melanin and the individual’s native skin phototype 
dictate its absorption properties [191, 201].  Melanin particles released as a result of 
irradiation (410 - 610 nm light)  produce ‘immediate pigment darkening’ and are less 
absorbent than melanin released in response to radiation between 610 and 720 nm [200]. 
Between 650 and 850 nm, darkly pigmented skin (Fitzpatrick skin type VI) scatters less 
and absorbs more radiation than lightly pigmented skin (Fitzpatrick skin types I – IV) 
[199]. At 980 nm, each skin type exhibits similar absorption coefficients indicating that 
absorption by melanin at or beyond this wavelength is minimal [172].  
 
The absorption spectra within the visible light and near infra-red ranges show that melanin 
is a competing chromophore for oxyhaemoglobin and its absorptive properties supersede 
oxyhaemoglobin at wavelengths longer than 630 nm (Figure 2.2). Thus, the use of visible 
light (400 – 700 nm) in darkly pigmented skin to target dermal structures is likely to be 
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associated with an unacceptably high risk of excessive thermal injury to the epidermis, the 
main reservoir of melanosomes. 
 
2.2.3.2 Haemoglobin 
Absorption curves for haemoglobin (Hb) vary widely with small deviations in its structure 
[202].  OxyHb, deoxyHb, metHb and foetal Hb all have very different absorption 
coefficients for a given wavelength. For example, Kimel et al. [202] quoted an 8% 
difference between adult oxyHb and foetal oxyHb at 596 nm whereas adult deoxyHb has a 
4% lower coefficient than foetal deoxyHb at the same wavelength. To complicate matters 
further, intravascular temperatures after laser irradiation were dependent upon the vessel 
diameter and wall thickness [202].  Therefore, we can surmise that autonomic stimulation 
e.g. drugs, mood and physical exercise, can cause vasodilatation or constriction, will affect 
how light interacts with intravascular haemoglobin. This should be taken into account 
when assessing the treatment efficacy of IPL and other light-based therapies. 
 
2.2.3.3 Water 
The skin may contain as much as 80% water. Thus water acts as a major chromophore and 
determines many of the skin’s thermal properties [193]. Water’s main absorption peak is at 
3,000 nm [203], but strongly absorbs any wavelength over 1300 nm [193].   Tissues 
approaching water’s boiling point (100ºC) are prone to intracellular vacuolar formation, 
desiccation and disruption from rapidly expanding steam [193]. Lasers emitting within the 
infra-red spectrum e.g. Erbium YAG (2,940 nm) and CO2 lasers (10, 600 nm) exploit these 
properties and are used for tissue ablation, coagulation and cutting [203, 204]. 
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Figure 2. 2:   Standardised Spectral Output of a Typical Xenon Lamp  (iPulse, Cyden Ltd). 
This was measured in 20 nm bandwidths as a percentage of the total energy beneath the curve.  
Cut-off filters have excluded ultraviolet light. Ash et al. [182] have overlaid the absorption curves 
for melanin (black), oxyhaemoglobin (red) and water (blue) to illustrate chromophore absorption 
characteristics. Note oxyhaemoglobin is the favoured chromophore between 510 and 620 nm, 
thereafter melanin supersedes both oxyhaemoglobin and water until approximately 1100 nm (not 
shown).  
 
2.3 The IPL Apparatus 
2.3.1 IPL Parameter Definitions 
In addition to light-skin interactions, intrinsic parameters of the IPL device also alter 
dosimetry and ultimately, clinical performance. The medical applications of any IPL 
device are dependent upon the theory of ‘selective photothermolysis’ [173, 193, 205].  If 
photothermolysis is to be selective, three criteria need to be fulfilled: (1) the wavelength 
chosen must be sufficiently and almost exclusively absorbed by the target chromophore; 
(2) the pulse duration must be less than the thermal relaxation time (approximately 200 - 
Oxyhaemoglobin 
Melanin 
Water 
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600 ms for skin) to reduce collateral damage and; (3) the energy delivered must be 
sufficient to cause destruction of the target chromophore [203]. Wavelength, spectral 
output, time-resolved spectral output, fluence, pulse duration pulse profile and 
spot/footprint size are defined and explained with respect to their relevance in light therapy 
below. 
 
1. Wavelength: is the distance from peak to peak or trough to trough in a sinusoidal 
waveform. It is usually expressed in metres (m). To tailor a sufficient clinical 
effect by confining the greatest thermal damage to specific targets, the wavelength 
should match the highest absorption peak of the target chromophore (e.g. 595 nm 
for oxyhaemoglobin) [202]. 
 
2. Average Spectral Output: describes the component wavelengths emitted by the 
lamp. Those below 500 nm are associated with increased risk of retinal damage. 
Cut-off filters have a key role to play in the accuracy and effectiveness of the light 
distributed. Spectral output should match the target chromophore whilst avoiding 
other chromophores in the skin to prevent collateral damage. The spectral output 
of an IPL device is necessary to perform comparisons between equipment [185]. 
 
3. Time-resolved Spectral Output:  describes the portion of the entire pulse during 
which effective wavelengths are being emitted at their most advantageous 
intensities [184, 202]. 
 
4. Fluence: a measure of energy delivered per unit area in  joules per m2 (J/m2) [206].  
An appropriate fluence would be one which thermally destroys the target 
                                                                                                                             
 34 
chromophore without causing damage to the surrounding tissues. The change in 
fluence over time in seconds is the fluence rate or energy density, expressed as 
Watts per m
2
 (W/m
2
) [206]. 
 
5. Pulse Duration: is the time, in milliseconds (ms) required for a waveform to reach 
its full magnitude and may also refer to the sum of sub-pulse durations in a pulse 
train [184]. The pulse duration is critical especially where it has to be matched 
with the thermal relaxation time of the target to get maximum clearance.  The 
stated pulse duration should, but may not consist of thermally effective radiation 
[182].  
 
6. Electrical Discharge Pulse Shape: describes the energy entering the xenon lamp. 
This energy may be constant (square pulse) or variable (‘free discharge’) [182]. 
 
7. Footprint: describes the spot size or beam emitted from the lamp. Narrow beams 
become depleted with depth while larger beams achieve greater depths of 
penetration and hence have an increased treatment efficacy [207].  
 
 
2.3.2 Nature of an IPL Device 
In an IPL device, an electrical charge is applied to a large capacitor or capacitors arranged 
in series or parallel [182].  Under the control of a computer, this energy is released to the 
gas-filled (xenon or argon) flashlamp envelope. The electrical energy is converted to 
electromagnetic radiation (light) as excited gas particles return to their resting state 
releasing photons of light. The wavelengths emitted by the hand piece are controlled by 
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interposing filters that allow only the desired wavelengths to be transmitted.  A typical 
circuit diagram of a flashlamp’s power supply is illustrated in Figure 2.3.  
 
 
Figure 2. 3: Typical Circuit Diagram of Flashlamp Power Supply. Adapted from Ash et al. 
[182] 
 
2.3.3 IPL Device Classification 
IPL devices can be classified by their electrical discharge pulse shape [182] as a free 
discharge, constant current or grouped pulsed system. The features of each type of system 
and potential weaknesses in their design are discussed below.  
 
2.3.3.1 Free Discharge Systems 
Many free discharge systems e.g. Chromolite (Chromogenex Technologies Ltd., Swansea, 
UK), do not produce long pulse durations hence their optical output varies with time 
(Figure 2.4a).  Spectrophotometry measurements by Ash et al. [182]  revealed that 
 
Energy stored here 
Light emitted here 
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Chromolite claimed to have a 15 – 17 ms pulse duration, however, only 3 – 4 ms of this 
consisted of useful energy, the rest being largely low-intensity near infra-red radiation 
[182]. Hence, the thermal relaxation times (TRTs) of the pulse do not match that of blood 
vessels or hair follicles (25 – 55 ms).   
 
To combat this effect, manufacturers of free discharge systems have designed these IPLs 
to deliver a train of high energy, short pulses to match the TRTs of these structures. This 
strategy however may lead to prolonged treatment regimens and far more adverse events 
as the shortened energy discharge time does not allow for thermal relaxation of the target. 
Other chromophores may collect a high amount of this energy leading to excessive 
erythema, burning and possibly scarring [182]. ‘Flooding’ of the flashlamp may also cause 
an undue proportion of emitted light as shorter wavelengths and the production of heat. 
Such systems tend to compensate with skin cooling. Operator dependent skin cooling 
introduces additional variability and affects the shot-to-shot energy delivery. 
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Figure 2.4: Typical Oscilloscope Tracings for a Free Discharge and a Constant Current IPL 
Device  (a) A free discharge IPL tracing (Chromolite, Chromogenex Ltd.) (b) The ‘square pulse’ 
discharge profile of a constant current IPL (iPulse, Cyden Ltd.).  Each tracing has been plotted on a 
graph against time.  Illustration adapted from Ash et al. [182]. 
 
2.3.3.2 Constant Current Systems 
The constant current or ‘square pulse’ systems generate energy the same way as free-
discharge IPLs do. However, the energy is delivered at an optimal, constant level 
throughout the pulse via a partial discharge capacitor, forming a ‘square’ rather than the 
skewed bell curve seen with free discharge systems [184].  The light energy is released 
steadily across the pulse that lasts for 10 – 50 ms, compared with 3 – 4 ms constant phase 
of the free discharge system (Figure 2.4b).  Consequently, these square pulse systems can 
be quite efficacious at lower fluences.  Additionally, the relatively low but constant light 
energy reduces the risk of epidermal damage and in theory, almost eliminates the need for 
skin cooling [182]. But, even in constant current systems, much of the energy may be 
wasted if discharged at unhelpful wavelengths from the xenon flashlamp.    
 
Free Discharge 
oscilloscope tracing 
Constant Current 
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2.3.3.3 Grouped-pulse Systems 
Grouped-pulse systems utilise short-pulse stacking to produce longer pulse durations. This 
however does not avoid the exponential decay of the energy at the end of the pulses, 
leaving the more clinically useful discharge at the beginning of the pulse (Figure 2.5).  
  
 
 
Figure 2.5:  Spectral Distribution Graph of a Grouped Pulse Free Discharge IPL (Ellipse, 
DDD, Denmark).  Each trace was taken at time intervals of 1 millisecond, producing groups of 
sub-pulses discharging even spectral outputs over the entire train of sub-pulses. Illustration and 
caption adapted from Ash et al. [182] 
 
2.3.4 IPL Device Variability  
Even where IPL devices have similar average spectral outputs, they cannot be viewed as 
being equivalent in efficacy. Hence, correlating inter-study outcomes can be difficult 
where identical devices have not been used. There is also some doubt surrounding the 
accuracy of the claims of IPL manufacturers.  
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Town et al. [184] inspected 18 IPL machines (manufactured in Europe with the exception 
of 1) and discovered that 2 manufacturers exaggerated the size of the applicators; only 8 
devices had a medical CE mark; 11 of 30 IPL heads discharged fluences more than 20% 
below the displayed level and 8 were more than 10% above that displayed. Admittedly, the 
manufacturers’ methods of measuring energy density may have differed from those used 
by authors of this study.  Marked differences were also noted between the claimed and/or 
displayed pulse durations and the measured values for non-medical CE marked devices 
[184].  IPLs with medical CEs were consistent. Only 2 of 18 IPLs had a true square pulse 
tracing and 3 utilised pulse-stacking to achieve a near constant current system waveform. 
One IPL system claimed to have a triple pulsing system, but the machine tested produced 
only 2 pulses, therefore only delivered approximately 67% of the advertised energies.  
Seven of 30 IPL applicators emitted greater than 1% UV light, despite the cut off filter 
wavelengths being significantly higher. Only 34.5% of filters were within 20 nm of their 
stated cut-off filter wavelength.   
 
2.3.5 Adverse Effects of IPL  
Unwanted extension of IPL’s photothermal effects may occur. Blue light is heavily 
absorbed by epidermal melanin leading to post-inflammatory hyperpigmentation and pain 
[208]. Wavelengths of 632 – 940 nm have very little effect on keratinocytes [209], but are 
a source of free radicals and heat [210]. 
 
UV radiation induces DNA mutations through thymine dimerization [182, 211]. Even with 
the removal of UV light by filtering, visible light may potentially encourage lipid 
peroxidation and micronuclei formation, markers of oxidative stress and DNA damage 
[211, 212], which is directly proportional to the light intensity [210]. Botta et al. [213] 
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compared micronuclei formation induced by visible light (400 – 800 nm) with a UVA/ 
visible light combination (300 – 800 nm) in cultured keratinocytes. Though UVA caused 
greater DNA damage, visible light also caused statistically significant genotoxicity which 
increased with the fluence. Similarly, an IPL device (520 – 750 nm, 2.5 ms single pulse, 9 
J/cm
2
, 3600W/cm
2
)
 
was compared with UVA (90mW/cm
2
) and UVB (130mW/cm
2
) [211]. 
Though IPL did not cause DNA damage as UVB did, there was a 6-fold increase in lipid 
peroxides 15 minutes post-irradiation, which was double that for UVA alone [211]. 
Conversely, Pflaum et al. [214] conducted similar experiments and noticed DNA 
containing single strand breaks was very rare in keratinocytes and completely prevented 
using a 400nm cut-off filter.  Also, the magnitude of the damage was partially dependent 
upon the amount of endogenous porphyrins within the cells. In the context of acne 
vulgaris, it is conceivable that patients with higher concentrations of porphyrin-producing 
P. acnes within the treatment area may experience more side-effects but potentially greater 
improvement in their inflamed lesions. 
 
Cells repair this damage via excision, daughter strand repair [215] and thymine-dimer 
repair through photolyase restriction enzymes in the presence of 300 – 600 nm light 
(termed  photoreactivation) [216].  In young patients, this repair process is complete within 
24 hours of irradiation [215]. 
 
2.3.6 An Ideal IPL Device 
Based on the preceding discussion, an ideal IPL device in the clinical setting is a constant 
current system delivering the desired filtered wavelengths to the target chromophore, 
coagulating it with no or minimal collateral damage. This effect should be predictable and 
equivalent to that stated in the manufacturer’s specifications for the chosen device.  It 
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should have the versatility to be manipulated by a trained operator where the desired 
spectral output, pulse duration and fluences are consistently reproduced throughout the life 
of the hand piece.  
 
2.4 Clinical Efficacy of Incoherent Light in Acne 
The current literature surrounding incoherent visible light therapy in acne must be 
examined considering the dynamic nature of three components: light source, subjects and 
treatment schedules.  Many studies were open and uncontrolled therefore several authors 
mentioned the need for more randomised controlled studies with an extended follow-up 
period [217-219].  Whether or not prolonged follow-up would have been truly possible in a 
typically young population, where some subjects would have invariably experienced 
steadily worsening acne, is debatable. Competing regimes are discussed according to their 
predominant wavelengths i.e. blue, red, yellow or broad-spectrum light (Outlined in Tables 
1–3, Appendix 2). 
 
Blue light induced a 26 – 70% improvement in inflammatory lesion counts but had a 
minimal effect on non-inflammatory lesions [52, 220-224]. On average 40 – 80% of 
patients can expect to appreciate a clinically observable improvement in their acne [220, 
221, 225-228].  Therefore, blue light is a relatively successful method of treating 
inflammatory acne in suitable patients. Direct comparisons with conventional therapies are 
few. Gold et al. [224] found that the efficacy of blue light therapy (Blu-U™ Blue Light 
Photodynamic Therapy Illuminator Model 4170, DUSA Pharmaceuticals, MA, USA; λ not 
stated) was comparable to 1% clindamycin solution when evaluated after a month.  The 
consensus on the prolongation of the response to blue light is mixed. If assessed, 
improvement does not appear to extend beyond 2 months after cessation of therapy [220-
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224].   The combination of blue and red light is able to reduce inflammatory lesion counts 
by 50 – 80% [229-231] which is similar to the rates quoted for blue light alone. However, 
the addition of red light appears to add endurance to the duration of the improvement [230-
232].  
 
Where red light was used as monotherapy, there are opposing reports on the duration of its 
efficacy [217, 233]. Two months post-therapy, Na et al.’s [233] cohort experienced a 
nearly universal relapse 2 months after therapy whereas Zane et al. [217] (PDT 1200, 
Waldmann Medical Division, Villingen-Schwenningen, Germany; λ = 580-740nm) 
described continued improvement of their global acne grade when measured at the same 
time point.  It must be noted that Na et al. used a home-use hand held device (SoftLaser 
SL30, Beurer GmbH, Germany; 630 – 670 nm) that delivered a much lower total fluence 
than Zane et al.’s device. This may explain why Sadick et al.’s [232] cohort, who also used 
hand held devices (Omnilux Clear-U™, Phototherapeutics Inc., CA, USA; λ= 415 and 633 
nm)  managed to maintain a reduction of their mean inflammatory count of 70% 8 weeks 
after cessation of therapy as their devices delivered much higher irradiances. A possible 
interpretation of these findings is that red light tends to produce a prolonged remission of 
inflammatory acne once the intensity/strength of the exposure exceeds a currently 
undefined threshold level.  
 
Sigurdsson et al. [234] treated 23 patients with mild to moderate acne vulgaris on the body 
with broad spectrum lamps filtered (Robax, Schott, Germany) to emit three wavelength 
profiles. The lamp housing (Philips HP3136, Netherlands) was fitted with different high-
pressure arc lamps: full-spectrum light + UVA (Philips HPA 400W), violet light (Philips 
HPM-10 400W + UVILEX 390-filter, Desag, Germany) and green light (Philips thallium 
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lamp + KV-470 filter) in an attempt to see which was most effective. Full-spectrum and 
violet light both produced similar, statistically significant reductions in the number of 
inflammatory lesions. Of note, in this experiment, the fluences of violet light for both full-
spectrum and violet light were similar, suggesting that the photoactive portion lies in the 
violet range. They also performed split-chest or split-back experiments treating with 
combinations of their light sources. There is no mention of the use of shielding to carry out 
these split-field experiments and predictably, intra-patient comparisons found no 
difference between any of the wavelength profiles. At the end, they concluded that though 
violet light showed the most promise, visible light was not effective as monotherapy. 
 
Yellow light may be able to elicit similar treatment efficacies as those reported for blue 
light; however there is much less data supporting incoherent yellow-spectrum light sources 
in acne. Sami et al. [218] was able to elicit a 41.7% decline in inflammatory counts one 
month after weekly IPL (Epi-C Plus®, Funo, Italy; 550 – 1200 nm, 22 J/cm2, 30 ms pulse) 
but Chang et al. [14]  (Ellipse Flex IPL, DDD, Hǿrsholm, Denmark; 530 – 750nm, 7.5 – 
8.0 J/cm
2
) did not demonstrate a similar improvement. This outcome is not surprising as 
all subjects were inexplicably given full-face benzoyl peroxide and unilateral IPL 
irradiation [14]. Such a regime obscures the true contribution of the light source as 
monotherapy. Also, in Sami et al.’s study, the total energy and number of treatments were 
delivered were double that stated in Chang’s paper i.e. once weekly treatments for 6 weeks 
vs. 3 weeks. Choi et al. [181] described a single-blind split-face trial comparing the effects 
of 585-PDL with a 530 – 750 nm Ellipse Flex IPL system (Ellipse Flex IPL, DDD, 
Hǿrsholm, Denmark) on mild acne. Initially, IPL caused a greater improvement but at 4 
and 8 weeks after the 4
th
 and final treatment, PDL had slightly better reductions in 
inflammatory and non-inflammatory lesions. Using the Leeds Revised Acne Grading 
                                                                                                                             
 44 
scale, their mean acne severity fell from 2.5 to 1.0 unit for PDL and 1.3 units for IPL 8 
weeks after the last treatment [181]. This illustrates that yellow light may have an effect on 
mild acne with prolonged improvement in the medium term.  
 
2.4.1 Summary of Incoherent Light in Acne 
Blue light is efficacious in acne vulgaris however, the effects are confined to inflammatory 
acne, are moderate at best, and the duration of the improvement is restricted to about 4 
weeks. Of course, it should be noted that many studies did not extend their follow-up 
beyond this period, or those that did lost a significant number of their cohort to follow-up. 
Blue and red light act synergistically producing larger improvements in mean lesion 
counts, including comedones, when compared to blue light alone. The studies using red 
light modalities universally achieved a minimum reduction of 50% in inflamed lesions or 
the acne severity score. The inclusion of red light appears to prolong the efficacy of blue 
light, extending it to 8 weeks. The literature on yellow incoherent light is scarce and less 
conclusive. Two of three studies attained a reduction in inflamed lesions of at least 66% 
when measured 1 month after completion of therapy. Only one of these three studies 
reported non-inflamed as well as inflammatory lesion counts.  
 
2.5 Conclusions 
As several publications demonstrate, light is a pharmacological agent which can induce 
specific changes in the skin. These photothermal, photomechanical, photochemical and 
photoimmunological effects are dependent upon the composition and content of the skin 
through which it passes and the colour, width, strength and duration of the irradiant beam. 
These latter light-dependent properties are dictated by the physics of the apparatus that 
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produces them, where a constant, controlled beam consisting of the desired wavelengths 
can produce clearance of the acne lesions without unwanted photo-induced side-effects. 
Together, these form the basis for the use of visible broad-spectrum light in acne.  
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3. Potential Mechanisms of IPL’s Action in 
Acne 
3.1 Introduction 
Acne vulgaris is an inflammatory disease modified by endogenous and exogenous factors. 
However, prior to 2012, published observations on the mechanism of specific wavelengths 
of IPL in acne, in vivo or in vitro, were lacking. A single study by Fan et al. (2012) 
investigated the mechanism of 420 nm IPL in a Sprague-Dawley rat acne model [235]. 
They based their study on the ability of 420 nm light to photoactivate endogenous CPIII in 
P. acnes causing photodynamic destruction of the bacteria and resultant improvement in 
inflammatory acne.  In their model, inoculation of P. acnes isolates into the ear of the 
treatment group resulted in an increase in the expression of TNFα (4 fold) and MMP-2 (2 
fold) while control groups did not exhibit a significant increase in either cytokine. In the 
intervention group, mRNA expression of TNFα and MMP-2 returned to baseline after 6 
irradiations with 420 nm IPL. The untreated group did not experience a similar reduction 
and hence the authors concluded that 420 nm IPL’s anti-inflammatory effect was 
secondary to P. acnes destruction. Thus, IPL is able to directly cause a photochemical or 
photodynamic reaction and secondarily induce an immunological effect. Relevant studies 
investigating the use of incoherent visible light in acne will be discussed from the 
perspective of light-skin interactions. This is followed by greater focus on the cytokines 
and receptors with the greatest potential of being modulated by 530 nm IPL. 
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3.2 Visible Light – Acne Interactions  
3.2.1 Photochemical/ Photodynamic Interactions  
Blue light has a well-known antimicrobial effect [68, 236] that is dependent on 
photoinactivation of P. acnes through a coproporphyrin-mediated photodynamic reaction. 
This leads to intracellular membrane disruption, leakage and cell separation [236]. In fact, 
blue light may be such an effective photoactivator of coproporphyrin that the addition of 
an exogenous photosensitiser may not improve its efficacy [208, 237].  In an in vitro study, 
Ashkenazi et al. [236] quantified the inhibition of bacterial growth after 3 illuminations 
with narrow band blue light (NBBL; Clear Light™, Lumenis Ltd., Yokneam, Israel; 407 – 
420 nm; 20 mW/cm
2
 or 75 J/cm
2
) with a 1 day interval between each treatment.  Colony 
counts were reduced by 5 orders of magnitude.  Conversely, in vivo studies that assessed 
P. acnes inhibition by colony counts, cultures and PCR assays pre- and post- light 
treatment (blue and red) failed to show a quantitative reduction in P. acnes despite clinical 
improvement [52, 222, 225].  Pollock et al. [238] treated selected areas on the backs of 10 
acne patients with diode laser PDT (CeramOptec GmbH, Bonn, Germany, λ= 635 nm, 25 
mW/cm
2
, 15 J/cm
2
). This caused a significant reduction (68.97%, p< 0.05) of 
inflammatory lesions but P. acnes colony counts were not significantly reduced at the end 
of the 3-week treatment period. P. acnes can recolonize as early as 10 days post-treatment 
[239] thus the absence of a change may be due to timing of the assessments.   
 
3.2.2 Photothermal Interactions 
Elman & Lask [240] treated 19 volunteers with broad spectrum light and heat (Clear 
Touch™, Radiancy Inc., NY, USA; λ= 430 – 1100 nm, 3.5 J/cm2).  The peak emission 
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wavelengths were not stated, but were said to be predominantly green/yellow light.  The 
investigators observed a steady reduction in inflamed and non-inflamed lesions up to 2 
months post therapy with mean lesion count reductions of 85%. Basing their hypothesis on 
the Arrhenius equation (temperature increases of 10°C double the rate of a chemical 
reaction), they surmised that the addition of heat accentuated any improvements made 
using visible light alone. Elman and Lask [240] did not venture any views about the 
underlying mechanism. As heat-killed P. acnes is still immunogenic [241], direct bacterial 
heating is unlikely to play a role in resolving acne lesions. However, vascular coagulation 
and the induction of heat shock proteins are two potential mechanisms of action.   
  
3.2.2.1  Photocoagulation 
Vascular coagulation destroys the conduit for inflammatory cell migration and thus may 
indirectly contribute to IPL’s anti-inflammatory mechanism of action. Treatment of 
cutaneous vascular malformations, telangiectatic vessels and diffuse redness is dependent 
upon a light source’s ability to heat intravascular haemoglobin to at least 70˚C leading to 
coagulation of aberrant vessels [185]. Pulse width is important as larger vessels  (150 – 
300 μm) may not be coagulated at their bases even in the presence of high fluences [185]. 
This is especially relevant regarding the choice of apparatus as free-discharge IPLs are less 
efficient at sustaining useful pulse widths to completely coagulate larger targets [182]. In 
the absence of clinical data, predictions of tissue temperatures, and hence an adjustment of 
treatment parameters, can be made using mathematical models [173, 185, 242].  
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3.2.2.1.1 Photocoagulation and Sebaceous Glands 
IPL and coherent light sources have been successfully used to treat sebaceous gland 
hyperplasia with and without an exogenous photosensitizer [243-246]. In vivo confocal 
microscopy performed immediately after treatment of a hyperplastic sebaceous gland with 
585 nm PDL revealed that the damage was confined to the blood vessels and improvement 
in the hyperplastic epithelium became discernible 2 weeks after [244]. This study [244] 
suggests that sebaceous gland shrinkage occurs after photocoagulation of its vascular 
supply.  In the context of acne vulgaris, both Chang et al. [14] and Glaich et al. [247]  
mention self-reported  reductions in oiliness after yellow-spectrum light therapy but sebum 
measurements were not done to substantiate these claims.  Unfortunately, objective 
sebutape measurements by Orringer et al. [219], who used PDL (NLite Laser, ICN 
Pharmaceuticals, Calif., USA; 585nm), did not reveal any changes in sebum output.  
 
3.2.2.2 IPL and Heat Shock Proteins 
IPL, through heat shock protein 70 upregulation, may induce a wound healing response in 
human and murine skin [248-250], leading to acne resolution (see Chapter 1, Section 
1.2.1.3).  
 
Heat shock protein (HSP) release is an evolutionarily conserved ability of organisms to 
respond rapidly to stressors such as sudden increases in temperature (heat or cold), 
oxidative stress and toxins [251, 252].  HSPs protect the cell by forming complexes with 
unfolded or denatured peptides and proteins produced as a result of the stressor [252].  
HSPs ensure correct re-folding or re-assembly of these proteins and increase the tolerance 
of exposed cells to further injury [252]. The function of HSPs is not confined to cell 
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protection but also has a role in the regulation of cell growth and proliferation. HSPs are 
commonly classified according to their molecular weights in kDa e.g. HSP 60, 70 and 90 
[253].  
 
The evidence of IPL’s action on heat shock protein expression is limited. Small animal and 
human studies suggest that IPL can induce heat shock proteins.  A study evaluating the 
immunohistochemical expression of  HSP70 in 9 women after a course of 560 nm IPL 
(make and model not stated; 560 nm cut-off, 28–35 J/cm2) over 5 months showed a ‘slight’ 
increase in the number of dendritic cells expressing HSP70 [249].  Helbig et al. [254] 
obtained skin explants from 35 volunteers and exposed groups of five to three different 
light sources: 585 nm light emitting diode (LED), 633 nm LED (LEDA SCR, Quantel-
Derma, Erlangen, Germany; 20 – 120 Jcm-2)  and 1540 nm Er: glass laser (Aramis, 
Quantel-Derma, Erlangen, Germany; 2 mm spot, 30 Jcm
-2
). The LED output was delivered 
at various fluences in pulsed and non-pulsed modes. After irradiation with an Er: glass 
laser, HSP70 was uniformly up-regulated in the epidermis of explants, which was maximal 
between days 1 and 3. The 585 nm and 633 nm pulsed LED did not elicit a similar 
response.  This study [254] suggests that high-intensity pulsed LED may not necessarily 
induce HSP70. However, Wang et al. [250] reported that irradiation of murine skin with 
IPL (action spectrum not stated) up-regulated HSP70 expression. Taking these studies 
together, IPL more than likely increases HSP70 expression in human skin. 
 
3.2.3 Photoimmunological Interactions 
Light has a variety of immunological actions that vary with the predominant wavelength of 
light. An in vitro study using 530 nm IPL showed up-regulation of IL-10 in cultured 
keratinocytes [255] and pulsed dye laser is known to increase TGFβ1 expression in treated 
                                                                                                                             
52 
 
skin [13]. Both of these cytokines have anti-inflammatory effects. Shnitkind and 
colleagues [256] incubated two immortalized keratinocyte cell lines (HaCaT and hTERT) 
with TNFα and IFNγ and then exposed them to narrow-band blue-light (NBBL) and/or 
UVB. The expression of IFNγ’s downstream cytokines, IL-1α and ICAM-1 were 
measured. NBBL alone reduced IL-1α and ICAM-1 concentrations by at least 70% in both 
cell lines. Its effect was synergistically augmented by UVB.  
 
Boros-Gyevi et al. [257] presented an interesting abstract at the 2009 Annual Meeting of 
the American Academy of Dermatology. They sought to determine whether broad-
spectrum IPL (wavelengths not stated) had any effect on delayed type hypersensitivity 
reactions (DTH) in photo-damaged and normal skin. The DTH was induced by Mantoux 
testing and measured by the number of CD1a+ Langerhans cells in skin biopsies taken 
before and after IPL irradiation. After a course of IPL (3 treatments at 3 week intervals), 
the number of CD1a+ Langerhans cells was higher in IPL-treated photodamaged skin than 
untreated chronically photodamaged skin. Cell numbers were also high in normal, photo-
protected skin [257].  Based on these findings they concluded that IPL was able to induce 
an immunological reaction. Though a full publication of this abstract is still outstanding, 
their findings suggest that IPL may have a direct immuno-stimulatory or ‘immuno-
redemptive’ role in skin physiology.  As previously mentioned (Chapter 1), it has been 
theorised that the cellular infiltrate in acne pathophysiology is reminiscent of a DTH 
reaction [26], suggesting the possibility that IPL exacerbates rather than suppresses the 
inflammatory reaction. Further study, such as that presented in this thesis, will be required 
to clarify this issue. 
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3.2.4  Summary 
It is evident that different wavelengths of light have divergent biological effects. Table 3.1 
revisits the therapeutic targets identified in Chapter 1 and lists the most likely light-skin 
interactions responsible for light’s efficacy in acne.  
 
 
Table 3. 1:  The Potential Mechanisms of Action of IPL against Acne Pathophysiology’s 
Therapeutic Targets  
Pathogenetic  
Factors 
Therapeutic Targets 
Visible Light-Acne  
Interactions 
P. acnes CPIII,  TLR2/TLR4 
 
Photodynamic 
Photoimmunological 
Pro-inflammatory 
Cytokines  
IL-8, IL-6, TNFα, IL-1β 
ICAM, VCAM 
Photocoagulation 
Photothermal 
Photoimmunological 
Anti-inflammatory 
Cytokines 
IL-10, TGF-β Photoimmunological 
T-cells 
CD4 (Th), CD8 (Tc), CD3+ 
CD4- CD8- (Ts) 
Photoimmunological 
Photocoagulation 
Ductal 
Hyperkeratosis 
IL-1α, IL-1β 
*GCSF, *EGF 
Photothermal 
Photoimmunological 
*EGF, GCSF - unknown 
 
Growth Factors 
 
GCSF 
 
Unknown 
 
Sebaceous Gland 
 
Sebocytes 
 
Photothermal 
Sebogenesis 
Prostaglandins, CRH, PPARs, 
steroidogenic enzymes 
Unknown 
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Pathogenetic  
Factors 
Therapeutic Targets 
Visible Light-Acne  
Interactions 
Genetic Susceptibility 
CAG repeats, AR, FGFR,  
CYP17, CYP21, TNFR2, 
TLR2, FGFR2 
? Photothermal DNA 
damage 
 
 
 
3.3 Photo–therapeutic Targets for Yellow IPL 
The trial in this thesis focuses on the actions of a broad-spectrum yellow IPL source. 
Light-skin interactions pertinent to yellow-spectrum light are: (1) Photodynamic 
inactivation of P. acnes (2) Photocoagulation of blood vessels surrounding the 
pilosebaceous gland and (3) Direct and indirect photo-immunomodulatory effects.  As 
previously discussed, clinical improvement does not always coincide with a reduction in P. 
acnes colony counts [52, 222, 225], therefore, like Fan et al. [235], indirect assessment by 
measuring inflammatory cytokine expression is a reasonable way of assessing IPL’s 
immunomodulatory effects.  
 
Five of the nine pathogenetic factors listed in Table 3.1 are potentially addressed by the 
photo–immunological mechanisms attributed to visible radiation. TLR2, TNFα, IL-8 and 
IL-10 contribute to each of the three phases in acne pathogenesis: initiation, evolution and 
resolution.  They are discussed in more detail below followed by a unifying hypothesis of 
yellow IPL’s mechanism of action in acne. 
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3.3.1 Toll-like Receptors 
Toll-like receptors (TLRs) detect highly conserved molecules or patterns on the cell 
surface of microbes. These patterns are called pathogen-associated molecular patterns 
(PAMPs) [258]. Pattern recognition receptors (PRRs) bind PAMPs resulting in either 
activation of a signalling cascade which drives a specific immune response or non-
specifically renders the bound microbe more susceptible to phagocytosis and destruction 
through complement activation [259]. Toll-like receptors (TLRs) are signalling PRRs 
[258, 259] consisting of two domains.   
 
Outer TLR domains are structurally diverse and consist of leucine-rich repeats producing 
at least ten different classes of receptor (TLR1–10) in humans [62, 259-262]. They are 
generally extracellular but some TLRs (3, 7 and 9) are intra-vacuolar [263]. Diversity 
within the extracellular domain of TLRs dictates the ligands to which they bind. See 
Figure 3.1. 
 
TLR4, one of the first mammalian TLRs described, binds lipopolysaccharides (LPS) in 
gram-negative bacteria (e.g. E. coli), lipoteichoic acid and heat-shock proteins (HSP60 and 
HSP70) released from necrosed or virally lysed cells [258, 261, 263, 264]. The ligand for 
TLR10 is still unknown. TLR2 recognises an unusually broad range of cellular 
components including gram-positive cell wall peptidoglycans (PGNs), atypical 
lipopolysaccharides [265], lipoteichoic acid, lipoarabinomannans from mycobacterial cell 
walls [62, 260, 266] and HSP 70 [264]. This versatility and specificity is due to its 
cooperation with TLR1 and TLR6 [258].  
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TLR’s have an intracellular domain, the Toll/IL-1 receptor (TIR) that is highly conserved 
and similar across all TLR family members. Stimulation of signalling pathways via TLRs 
mobilises gene transcription of immunomodulatory chemicals (IL-6 and TNFα), 
costimulatory molecules on antigen presenting cells (iNOS) and anti-microbial peptides 
such as defensins [258, 259, 267].  These signalling pathways may be either unique to each 
TLR or ‘communal’ and often involve IL-1R as well.  Despite the commonality amongst 
the beginnings of TLR pathways, activation of each results in diverse and differential 
cytokine expression [268].  For example, monocytic and dendritic (CD11+) TLR2 
stimulation induces IL-6, TNFα and IL-12 secretion [266]. TLR7 and TLR9 stimulation 
primarily stimulates type I interferon (IFN) production, which is appropriate for their viral 
ligands [269]. However, the gene products which control this specificity are still unknown 
[268]. 
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Figure 3.1: Diagrammatic Representation of Ligand Specificities of Selected TLRs [258, 262, 263, 270, 271].       
 TLR5  TLR4 
CD14 
  TLR1  TLR2 TLR6 
Peptidoglycan 
Lipoprotein 
LPS (leptospira) 
LPS (G-) 
LTA (G+) 
RSV F protein 
dsRNA 
Flagellin 
ssRNA,  
CpG DNA 
Midazoquinolones e.g. 
imiquimod 
  TIR domains 
Cytosol 
Extracellular Compartment  
  Vacuole 
TLR 3   TLR 7, 8, 9 
Note: TLR2 heterodimerises with 
both TLR1 and TLR6 resulting in 
a diverse number of ligands. TLRs 
3, 7, 8, & 9 are intra-vacuolar 
receptors whilst the rest are 
transmembranous. CD 14 is a co-
recognition molecule for TLR2 
and TLR4.  KEY: G+, gram 
positive; G –, gram negative; LTA 
– lipotechoic acid; LPS –
lipopolysaccharide; TIR – Toll/ IL-
1 receptor; RSV - respiratory 
syncytial virus.  
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3.3.1.1 Toll-like Receptor Localisation 
Epidermal keratinocytes and corneocytes are the first anatomical barrier and therefore play 
a major role in innate immunity. TLR1–6 and TLR 9 are expressed by all keratinocyte cell 
lines [263, 272]. However, it is stimulation of TLR2 – 5 and TLR9 that cause cytokine and 
chemokine release [273] supporting the finding that TLR1 and TLR6 require TLR2 for any 
meaningful function. In human skin, TLRs are found on a variety of other cell types 
including SZ95 sebocytes (TLR2, 4 and 6) [274, 275], monocytes (TLR2) [30] and 
dendritic cells  (DCs) (TLR1–5, 7–9) [266]. As would be expected for a highly specialised 
immunological system, different dendritic subsets have different TLRs and therefore 
respond to different ligands [266]. Regarding the sites involved in acne, sebocytes express 
TLR2, 4 and 6, and TLR2 has also been found on macrophages surrounding the 
pilosebaceous unit.    
 
3.3.1.2 P. acnes Binds Preferentially to TLR2  
Live and heat-killed strains of P. acnes can induce keratinocytes and monocytes to release 
pro-inflammatory cytokines [30, 86, 276] and anti-microbial peptides [54, 58] through toll-
like receptor (TLR) activation. An atypical gram positive bacterium like P. acnes could be 
recognised by either TLR2 or TLR4 on epidermal and dendritic cells [30]. But, a number 
of studies suggest that P. acnes preferentially binds TLR2. 
 
P. acnes-induced cytokine production by monocytes is largely TLR2-dependent [30].  Kim 
et al. [30] were unable to detect IL-6 production after intra-peritoneal seeding of TLR2 
knockout mice with P. acnes but wild-type, TLR1
-/-
 and TLR6
-/-
 mice responded 
appropriately [260]. Also, pre-incubation of human monocytes with anti-TLR2 reduced 
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IL-12 production by 65% [260] but this reduction was not reproduced when an anti-TLR4 
antibody was used [260]. Thus, these experiments show that TLR2 is the main receptor 
that recognises P. acnes products in these models.  
 
Stimulation of the inflammatory TLR2 pathway by P. acnes is more robust in comparison 
to non-pathogenic bacteria. The induction of TNFα and IL-12 release from peritoneal 
macrophages after P. acnes stimulation is double that of S. epidermidis, a non-pathogenic 
commensal [277, 278]. However, the anti-inflammatory activity of S. epidermidis is 
significantly greater as IL-10 induction was 2.5 times the amount elicited by P. acnes 
[277]. This may represent the mechanism by which skin commensals exist without 
eliciting an inflammatory response.   
 
3.3.1.3 TLR2 Suppression is Beneficial in Acne 
TLR2 is more strongly expressed than TLR4 in acne-involved epidermis [62] and 
peripheral blood monocytes [279] when compared to normal controls.  Pre-incubation of 
keratinocytes with anti-TLR2 and anti-TLR4 antibodies cause partial abolition of hBD2 
and IL-8 production [60]. The authors explained this phenomenon as being due to the 
presence of TLR2 co-receptors (TLR1 and TLR6), which were still able to mediate certain 
signalling pathways. Dispenza and colleagues [279]  hypothesised that  the long-term 
efficacy of isotretinoin in acne may be due to TLR2 suppression. Using flow cytometry, 
they measured TLR2 expression on PBMCs 6 months after completion of a 20 week 
course of isotretinoin (n= 8). TLR2 expression was reduced by approximately 50% (p< 
0.01) compared to baseline levels [279].  They suggested that correction of the 
‘dysregulated’ innate immune response contributes to long-term remission of the disease 
after isotretinoin therapy. 
                                                                                                                             
60 
 
3.3.1.4 Toll-like Receptor 2 Signalling  
Now that TLR2 has been established as the key TLR in the disordered immune response in 
acne patients, a short description of TLR2 signalling will establish that its stimulation is 
likely to be the initiating event in acne pathogenesis.  
 
After lipopeptide or peptidoglycan portions of bacterial cell walls bind to the extracellular 
portion of TLR2/6 or TLR2/1, MyD88 (Myeloid Differentiation primary response protein 
88) is recruited to the TIR domain of the receptor along with MAL, the bridging adaptor 
[259, 280-283] (Figure 3.2). This interaction facilitates the binding of the death-domains 
of MyD88 and IRAK 4 (IL-1 Receptor Associated Kinase 4) which then binds and 
phosphorylates IRAK1. The MyD88/IRAK4/IRAK1 complex then activates TRAF6 (TNF 
Receptor-Associated Factor 6) and IRAK1/TRAF6 dissociate from the toll receptor.  
 
TRAF6 recruits TAK1 (TGFβ Activated Kinase 1) and TAB 1 & 2 (TAK1 binding 
proteins 1 & 2) [282]. ECSIT (Evolutionarily Conserved Signalling Intermediate in Toll 
pathways) also binds to TRAF6 and indirectly modulates the function of TAK1 [284],  
playing a role in the generation of reactive oxygen species [285]. The TRAF6/ TAK1/ 
TAB1/ TAB2 complex enters the cytosol, leaving IRAK1 behind on the cell membrane for 
degradation.   
 
TRAF6 is then degraded by ubiquitination enzymes, e.g. Ubc13 and Uev1A,  and the 
TAK1/TAB1/TAB2 complex can induce signal transduction via two separate pathways,  
NF-κB (Nuclear Factor kappa B) or MAPK (Mitogen-Activated Protein Kinase) [286, 
287]. In the NF-κB pathway, TAK1 phosphorylates the IKK (IκB Kinase) complex that in 
turn phospho-degrades IκB (inhibitor of κB). The nuclear localisation sequence of NF-κB 
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becomes exposed and it is now free to enter the nucleus to regulate transcription.  In the 
MAPK pathway, its members are sequentially phosphorylated, activating ELK-1 (Ets-like 
protein 1) and AP-1 (Activator Protein 1) [288]. These transcription factors enter the 
nucleus to regulate gene transcription.  
 
3.3.1.4.1 NF-κB and MAPK Pathways in Acne 
NF-κB and AP-1 activation has been demonstrated in acne lesions. Kang et al. [289] 
observed that AP-1 was significantly up-regulated in acne involved skin compared to 
normal skin and found clear nuclear localisation of NF-κB within perifollicular and 
epidermal keratinocytes over and above that seen in adjacent biopsies of uninvolved skin 
and normal control skin. Elevated NF-κB expression was accompanied by significant 
increases in mRNA levels for IL-8 (3,015 fold), IL-1β (16 fold), IL-10 (46 fold) and TNFα 
(2.6 fold) compared with non-lesional skin. In vitro, Grange et al. [290] incubated HaCaT 
and primary keratinocyte cultures with P. acnes (strain ATCC 6919) and found that both 
AP-1 and NF-κB promoter regions of the IL-8 gene were activated.  Demonstration of the 
activation of both these pathways provides additional evidence for the central role of TLR2 
signalling secondary to P. acnes binding in acne pathogenesis. 
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Figure 3.2:  TLR2 Signalling. After TLR2 binds the stimulating ligand e.g. PGN from P. acnes, a 
number of membrane bound kinases (IRAKs) phosphorylate TRAF6. This eventually leads to 
phosphorylation of IκB, freeing NF-κB for nuclear translocation.  Inflammatory gene transcription 
(e.g. IL-6, IL-8, IL-12 and TNFα) follows.   
 
KEY: AMPs, antimicrobial peptides; ECSIT, evolutionarily conserved signalling intermediate in 
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GPB, gram positive bacteria; IκB, inhibitor of κB; JNK, c-Jun N-terminal kinase; MyD88, myeloid 
differentiation primary response protein 88; NEMO, NF-κB essential modulator; NEMO = IKKγ; 
P, phosphorylation; TAB2, TAK binding protein; TAK, TGF-β activated kinase; UEVA1/UBC, 
ubiquitination enzymes. Adapted from Liew et al. [283], Cell Signalling Technology [291], Takeda 
et al. [282] and Kaisho et al. [259]. 
 
 
3.3.1.4 Control of TLR2 Signalling 
TLR2 expression and signalling is regulated by extracellular, intracellular and trans-
membrane mechanisms [283] at various stages during signal induction, transduction and 
gene expression .However, all of these checkpoints may not be functioning within the 
same tissue. One mechanism of preventing ligand binding is through the use of decoy 
receptors. Soluble splice variants of TLR2 and MyD88 act as receptor decoys. TLR2 
soluble receptors mop up excess TLR2 ligands preventing excessive activation of the 
bound receptor [283] whereas a soluble form of MyD88 is preferentially recruited to 
IRAK4 rather than full-length MyD88 (Figure 3.3). 
 
If ligand binding has occurred, soluble MyD88 and TOLLIP (Toll Interacting Protein), 
prevent phosphorylation of IRAK1, aborting the NF-κB pathway. TRAILR (TNF-related 
Apoptosis Inducing Ligand Receptor) is a trans-membrane protein which stabilises the NF-
κB complex and prevents translocation to the nucleus. IL-10, another TLR2 regulator, is 
transcribed as a result of TLR2 signalling. Through negative feedback mechanisms, IL-10 
can prevent NF-κB nuclear localisation and the release of IL-8, MMP-9 and MMP-2 in 
pro-inflammatory cells [292, 293]. 
                                                                                                                             
64 
 
 
Figure 3.3:  Negative Regulation of TLR2 Signalling.  TLR2 signalling is regulated at several 
levels: ligand binding, signal transduction, NFκB activation and gene transcription.    
KEY: TOLLIP, toll interacting protein; TRAILR, TNF-related apoptosis inducing ligand receptor 
(Adapted from Cell Signalling Technology [291] and Liew et al. [283]).   
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3.3.2 Interleukin–8 and P. acnes  
Vowels et al. [294] found that  P. acnes strain 6919 and its culture supernatant were able to 
significantly stimulate monocytic cell lines (U937 & ThP-1) to produce IL-1β, TNFα and 
large quantities of IL-8 protein. However, stimulation of peripheral blood monocytes from 
10 acne and 5 normal subjects did not show any differences in cytokine release [294]. 
Basal et al. [295] and Caillon et al. [40]  conducted similar but larger studies comparing 
acne patients with age and sex-matched controls. In both studies PBMC from acne patients 
released significantly higher levels of IL-8 compared with normal controls after P. acnes 
stimulation.   In Caillon et al.’s cohort [40], higher concentrations of P. acnes (10 – 
100µg/ml) vs. low concentrations (0.1µg/ml) stimulated significantly higher quantities of 
TNFα from acne-derived PBMCs.  
 
Schaller et al. [65] looked at the cytokine profile produced by a keratinocyte cell line 
(TR146) after stimulation with live and heat-killed isolates of P. acnes harvested from 
comedones. IL-8 mRNA levels were far higher than those for IL-1α, IL-1β and TNFα.  
Interestingly, viable P. acnes induced a 5-fold increase in IL-1β expression and a 15-fold 
increase in IL-8 and GM-CSF when compared with heat-killed bacteria.  The other 
cytokines showed no difference between the two groups. A similar study involving P. 
acnes stimulation of a monocyte cell line also revealed significant increases in IL-8 
secretion [296].  
 
Together, these studies agree that IL-8 release after P. acnes stimulation is dose-
dependent, TNFα is up-regulated and heat-killed bacteria lose some of their 
immunogenicity. Therefore, photothermal destruction by IPL may be relevant.  
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3.3.3 TNFα in Acne 
TNFα is a soluble pro-inflammatory protein which exists as a cell-bound 26 kDa protein or 
a soluble 17 kDa protein [297].  In its biologically active form, a TNFα trimer binds to its 
receptors (TNFR1 or TNFR2) present on virtually all nucleated cells [297].  TNFα binding 
to its receptors can have various effects but is heavily skewed towards an inflammatory 
response.  TNFR1 activation stimulates pro-inflammatory and pro-apoptotic pathways 
[297, 298] whereas TNFR2-ligand binding results in the activation of inflammation via the 
AP-1 and NF-κB pathways. TNFα has NF-κB and AP-1 binding sites within its promoter 
region allowing for escalation and amplification of an incipient inflammatory response 
[298]. Hence, TNFα can be both pro- and anti-inflammatory, conferring complexity to its 
signalling cascade with a number of opportunities for cross-talk between adaptor 
molecules and transcription factors [298, 299]. 
 
Whole P. acnes and smaller polypeptide moieties are able to markedly increase the release 
of TNFα in acne patients [295]. In an in vitro study, SZ95 sebocytes incubated with TNFα 
synthesised more cholesterol and fatty acids [300]. TNFα can promote collagen breakdown 
through MMP-2 and MMP-9 release [300-302]. Thus, TNFα suppression may be 
beneficial in the treatment of inflammatory lesions, seborrhoea and acne scarring.  
 
Direct TNFα inhibition as a therapeutic option for acne has been tried. Campione and 
colleagues published a case report of a young man with nodulo-cystic lesions that 
regressed after 24 weeks on etanercept, a TNFα receptor inhibitor [303]. Remission was 
maintained for the 3 month follow-up period, but this was too short to make a reasonable 
comment on any effects with regard to scarring. They did not comment on the patient’s 
seborrhoea.  Isotretinoin has also been found to inhibit TNFα’s transcription factor, NF-
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κB, via TRAIL (TNF-Related Apoptosis Inducing Ligand), in vivo and cultured sebocytes 
[304]. Another anti-acne agent, doxycycline, attenuates the increase in pro-MMP-2 
released by dermal fibroblasts incubated with TNFα and P. acnes lysates [300].  
 
 
3.3.4 Interleukin 10 
Interleukin 10 (IL-10) is an immunomodulatory 18kDa polypeptide [305]. It was initially 
known as ‘cytokine synthesis inhibitory factor’ released by murine T-helper type 2 (Th2) 
cells [306]. This inhibitory factor was found to inhibit IFNγ release from Th1 
lymphocytes. Macrophage activation, cytokine release and apoptosis are also inhibited as a 
result of IL-10 binding [307]. Later, it was discovered that IL-10 could also suppress Th2 
lymphocyte function, enhance antigen presentation and MHC II expression, induce pro-
inflammatory cytokines as well as regulate B- and T-cell development and maturation 
[292, 308, 309]. Thus, whilst being anti-inflammatory, IL-10 can also have pro-
inflammatory actions which are dependent upon the timing of its release during an immune 
response, the target cell and, the portion of its receptor participating in the reaction [310].  
 
3.3.4.1 IL-10 in Acne 
IL-10 is produced by a number of cells including CD4+ and CD8+ T-cells [269], B-cells 
[311], keratinocytes, dendritic cells (DCs), macrophages, neutrophils [307, 312, 313] and 
mast cells [314]. However, IL-10 receptors (IL-10R) are most abundantly expressed by 
peripheral blood cells such as monocytes, B- & T-lymphocytes and macrophages [308, 
315].  
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Using ELISA (enzyme-linked immunosorbent assay) to detect cytokine secretion from 
peripheral monocytes harvested from venous blood, Caillon et al. [40] showed that P. 
acnes stimulation of CD14+ mononuclear cells from acne patients reduced the secretion  
of IL-10 by 46% compared to  normal controls (p< 0.05). Addition of IL-10 to the acne 
patient derived-monocytes improved their phagocytosing ability and reduced their 
secretion of IL-8 and TNFα [40].  The degree of IL-10 deficiency in the blood donors did 
not correlate with their acne severity. In contrast, using skin explants, Tenaud et al. [276] 
noted higher staining intensity for IL-10 in the epidermis of acne vs. normal skin. When 
incubated with adapalene, immunostaining for IL-10 fell significantly, along with that of 
TLR2 and Langerhans cells, which the authors assumed was related to its mechanism of 
action in acne [276]. 
 
Yellow spectrum IPL may show efficacy in this regard as it has been shown to up-regulate 
IL-10 expression in keratinocytes. Irradiation of HaCaT keratinocytes with yellow IPL 
(555 – 950 nm, 8 J/cm2) increased IL-10 protein levels by almost 6-fold (p< 0.05). 
However, TNFα protein levels also rose by approximately 60% (p< 0.05) [255].  These 
conflicting results emphasise the need for an understanding of IL-10’s signalling pathways 
to clarify IPL’s cutaneous effects in vivo. 
 
3.3.4.2 IL-10 Signalling via JAK-STAT  
IL-10 is transcribed upon stimulation of the TLR2 receptor by its ligands [270, 312] 
primarily through activation of the p38 MAPK pathway [316-318].  When an IL-10 
homodimer binds to its receptor (IL-10R, a tetramer of identical subunits of IL-10R1 and 
IL-10R2), this initiates cross-linking of IL-10R1 and IL-10R2 followed by recruitment of 
Tyk 2 (Tyrosine kinase 2 ) by IL-10R2 [315]. See Figure 3.4.   
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Tyk2 trans-phosphorylates the IL-10R1 subunit and JAK1 (Janus kinase 1), which is 
normally bound to the intracellular portion of IL-10R1 at rest [307, 315]. JAK1 then 
phosphorylates specific tyrosine residues (Y446 and Y496) on the intracellular portion of 
IL-10R1, allowing it to serve as a docking site for STAT3 (Signal Transducer and 
Activator of Transcription 3) [315, 319]. JAK1 also phosphorylates STAT3, which forms a 
homodimer. The STAT3 dimer translocates to the nucleus and binds to specific promoter 
sequences of IL-10 response genes which dictate genetic control of the cell-cycle and anti-
inflammatory proteins.  In vitro studies have demonstrated that STAT3 is partially 
responsible for many of IL-10’s anti-inflammatory activities [307, 308, 320]. STAT1 and 
STAT5 are also implicated in IL-10 signal transduction. Like STAT3, they form homo- 
and hetero-dimers before translocating to the nucleus to dictate transcription of anti- and 
pro- inflammatory cytokines [308].  
 
3.3.4.2.1 Anti-inflammatory Actions of IL-10 
IL-10 exerts its anti-inflammatory effects through a number of molecules present in 
monocytes and macrophages. One of these molecules is suppressor of cytokine signalling 
3 (SOCS3) that inhibits the JAK/STAT pathway, suppresses T-cell differentiation and 
regulation, and binds to the cytoplasmic portion of cytokine receptors leading to their 
inhibition [321, 322].  
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Figure 3.4:  Model of IL-10 Signal Transduction in a Monocyte.  At rest, the tetrameric IL-10 
receptor associates with JAK1 (Janus kinase 1) on the intracellular domain of IL-10R1. An IL-10 
homodimer binds to IL-10R1, recruiting Tyk2 (tyrosine kinase 2) to IL-10R2 with subsequent 
phosphorylation of JAK1. STAT3 binds to the phosphorylated docking site on IL-10R1 and is 
phosphorylated by JAK1. STAT3 homodimerises, translocates to the nucleus and binds to IL-10 
response element genes to control gene transcription e.g. SOCS3.  In inflammatory cells, SOCS3 
negatively regulates the TLR inflammatory pathway and the JAK-STAT pathway (adapted from 
SABiosciences, www.SABiosciences.com on 26.09.2011 & Genego, Thomson Reuters, 
www.genego.com/map_531.php on 28.9.2011). 
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Regarding the suppression of TNFα activity, IL-10 reduces the transcription of TNFα, 
enhances soluble TNFR release and reduces the expression of surface TNFR on 
inflammatory cells such as monocytes and lymphocytes [323]. In keratinocytes, IL-10 can 
prevent nuclear localisation of NFκB1, inhibiting the transcription of pro-inflammatory 
cytokines [293], and hence participates in the suppression of TLR2 signal transduction. 
 
3.3.5 Summary: Phototherapeutic Targets for Yellow IPL 
Of the toll-like receptors, TLR2 preferentially binds P. acnes. In inflammatory acne, 
binding of P. acnes moieties leads to the transcription of inflammatory cytokines and 
amongst the pro-inflammatory cytokines, in vivo and in vitro studies have shown that IL-8 
and TNFα are highly expressed after P. acnes stimulation. Transcription is largely 
regulated through the activation of distinct factors, NF-κB and MAPKs. Of these, the NF-
κB pathway reliably leads to a pro-inflammatory response whereas MAPK activation may 
result in inflammatory and/or anti-inflammatory effects.  
 
TLR2 signalling is tightly controlled in vivo by several mechanisms and cytokines 
including IL-10. The anti-inflammatory actions of IL-10 include suppression of TNFα 
release, down regulation of TNFR and inhibition of cytokine signalling via SOCS3.  Acne 
patients may be IL-10 deficient [40] and this possibly contributes to the pro-inflammatory 
state seen in acne vulgaris.  
 
Studies have shown that accepted anti-acne agents such as nicotinamide [290] and 
erythromycin [296], significantly reduce IL-8 expression possibly through inhibition of 
TLR2 signalling. Also all-trans retinoic acid significantly down regulates TLR expression 
[279, 324]. TNFα has been detected at very high levels in  acne papules [325] and 400 – 
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420 nm IPL inhibits TNFα expression in the rat ear acne model [235] possibly in response 
to photodynamic destruction of P. acnes.  
 
IPL (530 nm) has the potential to treat several arms of acne pathogenesis via photothermal/ 
photocoagulation, photodynamic and photoimmunological mechanisms.  Photodynamic 
and photothermal destruction of P. acnes can result in a reduction of TLR2 activation and 
hence a reduction in IL-8 and TNFα transcription with subsequent down-regulation of 
TLR2 and TNFR. 530 nm IPL may also up-regulate IL-10 transcription in vivo [255] and 
photocoagulation can reduce the migration of inflammatory cells to the pilosebaceous 
glands causing an overall anti-inflammatory effect. These potential mechanisms are 
summarised in Figure 3.5.  The receptors represented in this model are also present on 
monocytes, macrophages and sebocytes hence a similar mechanism is thought to take 
place in these cells, producing an overall anti-inflammatory effect.  
 
The aims of the clinical and laboratory arms of the studies designed to determine yellow 
IPL’s efficacy and clarify which photo-immunomodulatory mechanisms are taking place. 
These are listed in the final section of this chapter.   
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3.4 Hypotheses and Aims 
 
3.4.1 Clinical Study 
Clinical trials have shown promising results when yellow coherent and incoherent light 
sources have been used to treat acne. They show a reduction in inflammatory lesions but 
have failed to objectively demonstrate an accompanying reduction in the SER. This, in 
addition to the expected anti-inflammatory action of 530nm IPL, has led to a hypothesis 
that it is an effective treatment for acne vulgaris. Thus, an open, prospective, single cohort 
trial was designed to determine whether IPL as monotherapy would be able to bring about 
observable changes in the clinical severity of acne.   
 
3.4.1.1 Clinical Study Aims 
To evaluate the clinical efficacy of IPL based on its ability to reduce: 
a) Inflammatory lesion counts 
b) Non-inflammatory lesion counts 
c) Global acne severity  
d) The sebum excretion rate 
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3.4.2 Laboratory Study 
The direct and indirect photoimmunological effects of 530 nm IPL are hypothesised to be 
as follows: 
1. IPL down regulates TLR2 expression 
2. IPL reduces transcription of the inflammatory cytokines TNFα and IL-8  
3. IPL increases IL-10 transcription 
4. IPL reduces TNFα and TNFR due to increased IL-10 signalling  
 
3.4.2.1 Aims for Laboratory Study 
To determine whether 530 nm IPL exerts its effects by: 
1. Down regulating TLR2 expression in acne patients 
2. Increasing IL-10 expression 
3. Reducing the expression of IL-8, TNFα and TNFR 
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Chapter 4 
 
Methods and Materials 
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4.  Methods and Materials  
4.1 The Clinical Study  
4.1.1 Rationale for Clinical Parameters 
In keeping with several studies assessing the clinical efficacy of light therapy [52, 219, 
326], indicators of acne severity such as a global score (the Leeds Revised Acne Grading 
System) [327], photographs, lesion counts and SER were used to assess the clinical effect 
of IPL. The back was selected as the treatment target because this could easily be protected 
from the sun thus eliminating incidental sunlight exposure as a confounder. It was also a 
more cosmetically acceptable site from which to take 3 biopsies. The Energist ULTRA 
VPL™ (Figure 4.1a) is a medical CE marked grouped pulse IPL whose high-intensity 
output is controlled by a computerised capacitor bank [183].  The spectral output of the 
Energist VPL™ has been shown to be consistent and reliable [184] and thus, this IPL 
device was used in  our study.   
 
4.1.1.1 Lesion Counts 
The basic aim of acne therapy is to reduce the number and severity of acne lesions. Lesion 
counts are an objective way of determining whether lesions increase or decrease, however 
this method is subject to inter-observer variation [328]. It is also possible to use lesion 
counts as an indirect measure of severity by grouping lesions by their type. Therefore, a 
patient with 10 inflammatory cysts is considered far more severe than one with 10 
comedones.  Many global acne-grading systems utilise lesion type as well as absolute 
count to determine a severity score. Therefore, it seemed prudent to assign a global acne 
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score as well as determine the differential effect of IPL on inflammatory and non-inflamed 
papules.  
 
4.1.1.2 Sebum Excretion Rate 
Although correlation does not imply causation, the suggestion that a reduction in the SER 
results in an improvement of acne vulgaris has been well established. Patients with ‘dry’ 
skin have less inflamed lesions than persons with ‘normal’ skin [329]. 13-cis-retinoic acid 
(isotretinoin), known for its potent therapeutic activity against acne, long-term efficacy and 
for its intense drying effects on the skin and mucous membranes, reduces sebum output 
and glandular size by almost 90 % [75, 330] and continues to do so for 5–20 months after 
cessation of therapy. The clinical efficacy and/or mechanism of action of many anti-acne 
agents are judged on their sebo-suppressive effects (for example see article on zinc-
erythromycin [331], tetracycline [332] and visible light [231]). 
 
As previously mentioned, the pulsed dye laser has been used to treat sebaceous hyperplasia 
[244], which suggests yellow IPL may possess some ability to ablate or shrink sebaceous 
glands. If the sebo-suppressive effects are similar to those seen with photodynamic therapy 
[333] and isotretinoin [330], the anatomical alteration could be accompanied by a 
physiological reduction in sebum excretion.  
 
The European Expert group on efficacy Measurement of Cosmetics and Other topical 
products (EEMCO) have outlined a number of methods to classify and measure sebum 
excretion [334].  The sebum excretion rate (SER) and sebum casual levels are the most 
useful methods to measure sebum excretion. The SER describes the quantity of sebum 
excreted by an area of skin over a predefined period and the sebum casual level is an 
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estimate of the skin surface lipids that have accumulated over a period of at least 4 hours. 
Casual levels represent an approximate measure of the oiliness of a person’s skin. Other 
methods such as follicular excretion rate, sustainable rate of secretion, instant sebum 
delivery and follicular density do not always correlate with the SER or the presence of 
sebum and are not discussed further [334].  
 
The more widely used methods to assess the sebum excretion rates include photometric 
techniques e.g. Sebumeter® (C+K Electronic, Köln, Germany) and Lipometer® (L’Oréal, 
Paris) and lipid absorbent tapes e.g. Sebutape® (Cuderm Corp, Texas, USA) and 
Sebufix® (C+K Electronic). The Sebumeter® (C+K Electronic) consists of a 64 mm
2
 strip 
of lipid absorbent plastic, 0.1 mm in thickness, mounted on a spring-loaded probe 
delivering a constant pressure of 10N for each measurement [334]. The probe is placed 
gently against the skin and after a maximum of 30s, as measured by an internal timer, it is 
then inserted into the Sebumeter®. A light is passed through the tape twice, and the 
transmitted light measured by a photocell. The result is measured according to an internal 
standard and the microprocessor expresses the results in µg/cm
2
 (range: 0 - 500 µg/cm
2
) 
[335].  Tools like the Sebumeter® are unable to detect changes in lipid composition and 
can only measure changes in quantity [336]. Lipid absorbent tapes like Sebutape® can be 
attached to the study area and left for a predetermined amount of time, usually an hour. 
Sebum secreted from each follicular opening produces translucent spots on the tape, the 
number being proportional to the number of active follicles and each spot’s size to the 
amount of lipid present. These spots can then be examined visually or using software for 
image analysis.  Advantages of the tape include intra-individual reproducibility, the ability 
to extract and analyse lipid fractions if required and ease of application [337]. 
Disadvantages of the absorbent tape method include underestimation of surface lipids due 
                                                                                                                             
80 
 
to interference by the adhesive, distortion of the follicular imprints on the tape over time 
[338] and the need for supporting software and equipment to analyse the tapes. 
 
Investigators have compared the SER estimations produced by Sebutape® and the 
Sebumeter®.  Pierard-Franchimont et al. [339] conducted an open study that aimed to 
quantify the effect of Effidrate® (La Roche Posay, Belgium) on seborrhoea. Both the 
Sebumeter® SM810 and Sebutape® were used in their study.  The sebumeter was able to 
detect a significant difference in the SER from baseline but the results gained from 
alternative methods were equivocal. They surmised that the sebutape only assessed the 
follicular pool of sebum whereas the sebumeter also measured inter-follicular lipid, giving 
a value for skin surface lipid [339]. Serup [338] quantified the differences in the readings 
produced by the Sebumeter® and Sebutape® in 24 Danish medical students with acne. He 
found that there was a high correlation between the Sebumeter® and Sebutape® readings 
especially when measured 1-hour after degreasing. However, readings from the 
Sebumeter® had 50% less intra-individual variations than the Sebutape® measurements. 
In light of these reasons and the ready availability of the Sebumeter® SM815, this 
apparatus was chosen to assess changes in the SER.  
 
4.1.1.3 Leeds Revised Acne Grading Scale 
In assessing therapeutic efficacy, a reduction in lesion counts is not always accompanied 
by an improvement in perceived acne severity [340]. Therefore, there is a need for 
complementary acne severity scoring systems to give an overall picture of a treatment’s 
efficacy. At least 25 acne-grading systems exist [341]. The more widely used methods 
include the Global Acne Grading Scale or GAGS [342], Allen & Smith’s technique [343], 
The American Academy of Dermatology (AAD) Consensus Classification [344], Cook’s 
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Grading scale [345], Burke & Cunliffe’s Leeds Technique [346] and its later version, the 
Leeds Revised Acne Grading Scale (LRAGS) [327]. 
 
Some systems do not include comedonal acne in their scoring system (e.g. AAD 
classification), some only assess certain anatomical areas, usually the face (e.g. Leeds 
technique) and some assess all acne affected areas together to give a single score (e.g. 
GAGS), or utilize a photographic system such as LRAGS and Allen and Smith’s [343].  
 
In a trial setting, a grading system that utilises a standardised method of measurement, 
which allows for accurate record keeping and retrospective evaluation is advantageous. 
Therefore, a photographic method was chosen for this study. Of the two mentioned above, 
Allen & Smith’s photonumeric system was unsuitable as it only assesses the face whereas 
the treatment area in this trial was the back.  
 
 The Leeds Revised Acne Grading System [327] (LRAGS/ Leeds) relies on subjective 
assessments of acne severity using a published photographic scale (Appendix 2), where 
the face, chest and back have separate grading systems. The LRAGS is a commonly used 
grading system and the Spanish version has recently been validated (2010) [341]. The 
grading system is such that grade 1 represents mild acne characterised by low numbers and 
densities of comedones and papules. As the number, density, extent and nature of the 
lesions worsen a maximum grade of 12 for the face, 8 for the chest and 8 for the back are 
assigned. 
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4.1.1.4 Energist ULTRA VPL™ as a Therapeutic Modality for Acne  
Using the definitions in Section 2.3.6, the Energist Ultra VPL™ (Swansea, UK) currently 
being used in our centre is almost an ‘ideal IPL’. Variable pulsing allows the operator to 
control the fluence delivered to the patient and hence, regulating the level of harmful lipid 
peroxide formation during IPL irradiation. However, the electrical discharge pulse shape is 
a grouped pulse rather than a square pulse and hence the time-resolved spectral output may 
not achieve the target’s thermal relaxation time. 
 
It is equipped with interchangeable applicators that have various dichroic filters (Figure 
4.1b, c). Additional UV filtering is provided by the titanium- or cerium-doped quartz 
flashlamp envelope (the glass encasing for the xenon gas) [182] and a water-cooling 
system around the glass block absorbs infrared wavelengths above 950 nm, reducing non-
specific epidermal heating. The unfiltered and filtered emission spectra for the 530 nm and 
610 nm applicators are illustrated in Figures 4.2 and 4.3.   
 
For the 530 – 950 nm applicator, its peak emission coincides with the first absorption peak 
for oxyhaemoglobin (Figure 4.2), CPIII has small excitation peaks within the 500 – 700 
nm range and wavelengths within the 530 – 950nm range may penetrate up to 1.2 mm into 
the skin [33].  Thus, vascular photocoagulation, reduction of sebaceous gland size and 
photodynamic inactivation of P. acnes are its potential mechanisms of action [177, 179, 
246]. 
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Figure 4.1:  The Energist ULTRA VPL™ Device (a) Machine has a touch-screen interface (b) 
Applicators shown with the red (610 nm) and yellow (530 nm) cut-off filters in situ. (c) Applicator 
with a transparent cover to show components of the applicator & cut-off filters. Figure 3.5a 
courtesy of: Sister H. Pugsley, Dept. of Dermatology, Cardiff University. Figure 3.5b retrieved 
from: http://www.endermologie.co.za/lpg-energist-vplmachne.html on Oct 8, 2010.  Figure 3.5c 
courtesy of: Darren Thomas, Energist Ultra, Swansea, UK, © 2007.   
a a 
b 
Filter sits between 2 
parts here  
c 
Glass block  
Figure 4.1b has been 
removed by author for 
copyright reasons 
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Figure 4.2:  Unfiltered Spectrum of Xenon Flash Lamp. The spectral output at high energy 
(blue line) and low energy (purple line) settings. Courtesy of Darren Thomas, Energist ULTRA, 
Swansea, UK, © 2007. 
 
 
 
Figure 4. 3:  Emission Spectra for the Yellow and Red Filters. Output from the yellow filter 
(530 – 950 nm) is labelled as ‘skin rejuvenation’ and from the red filter (610 – 950 nm) as ‘hair 
removal’.   Courtesy of Darren Thomas, Energist ULTRA, Swansea, UK, © 2007.  
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4.1.2 Clinical Methods 
Ethical approval for this study was granted by the South East Wales Research Ethics 
Committee (reference number 08/WSE04/29) and Research & Development approval was 
granted by the Cardiff and Vale University Health Board, formerly the Cardiff and Vale 
NHS Trust in May 2008 (reference number 08/CMC/4196). The active intervention phase 
included 7 visits that spanned 10 weeks. Thereafter, participants were invited for 2 
optional visits at 1 and 3 months after the last treatment to monitor the prolongation of 
their response to IPL.   
 
4.1.2.1 Subjects and Recruitment 
Male and female volunteers between the ages of 18 and 50 years with mild-moderate acne 
on the back were eligible for the study.  Subjects were invited to enter the study through 
Cardiff University’s online notice board announcements and at Halls of Residence 
between May 2008 and January 2009.  Patients referred to the University Hospital of 
Wales for management of their acne were offered information about the study and general 
practitioners within the Cardiff area were asked to refer patients who they thought may be 
suitable for the trial.  
 
All subjects gave informed consent (Appendix 1) before starting this study.  Demographic 
data including each patient’s age, weight, height, history of smoking and disease duration 
was also recorded. Before consenting to participate, patients were made fully aware of the 
number of biopsies to be taken. The inclusion and exclusion criteria as detailed in the 
study protocol are listed below.  
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4.1.2.1.1  Inclusion Criteria  
1. Mild to moderate acne vulgaris with at least 15 inflammatory and non-
inflammatory lesions, but no more than 3 nodulocystic lesions Thus, not 
exceeding Leeds grade 6 (for the back) 
2. Patients willing to have ONLY their back treated 
3. Skin phototypes I – III 
4. Patients who are willing and able to provide written informed consent, after 
being informed of all the pertinent aspects of the trial  
5. Patients who agree not to use sun-beds or undergo any UV light treatment 
for 4 weeks prior to entering the study and are willing to minimise the 
amount of exposure to direct sunlight for the duration of the study  
 
4.1.2.1.2  Exclusion Criteria 
1. 3 nodules and/or cysts present 
2. Pregnancy 
3. Use of anti-androgen containing contraceptives 
4. Mental incompetence 
5. Keloids or tendency to heal with keloids 
6. Cosmetic treatment to their back: 
a. In the previous year with collagen, dermabrasion and laser 
resurfacing  
b. Alpha hydroxyl acids within 1 month 
c. Microdermabrasion within 3 months 
7. Photosensitivity disorders e.g. solar urticaria 
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8. Porphyrias or allergy to porphyrins 
9. Epilepsy 
10. Systemic retinoid use in the past 12 months 
11. Use of Vitamin A supplements > 2000 IU /day 
12. Use of oral antibiotics and topical retinoids in the preceding 4 weeks. 
13. Systemic medications such as steroids, immunosuppressant, statins and 
preparations containing St. John’s worta 
14. Oral photosensitizers within last 4 weeks  
15. Previous treatment with IPL or lasers to the areas of interest within the last 
12 months 
16. Severe systemic diseases such as impaired renal or liver function; regional 
enteritis or ulcerative colitis; a history of antibiotic-associated colitis; severe 
cardiovascular, neurological disease, or any other disease that may interfere 
with the evaluation of the study medications  
17. Patients with psoriasis, acne rosacea, allergic rashes, bacterial, viral or 
fungal infections or other diseases of trunkal skin  
18. Patients who are unlikely to be available for the duration of the follow-up  
19. Persons involved in another clinical trial for the duration of this study 
 
 
                                                 
a
 Patients temporarily ineligible i.e. items 12,13 & 17, at the time of screening were enrolled after a wash-out 
period of 4 weeks or after resolution of their illness. 
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4.1.2.2 Photography 
Photographs of the participants’ backs were taken by the medical photography unit in the 
Dermatology Department using a specially designed protocol for this study (see Appendix 
2).  The photographs were then used for blinded Leeds grading as described below.  
 
4.1.2.3 Leeds Grading 
Leeds grades were assigned for the back, face and chest at the time of presentation. In 
keeping with the original publication, patients were graded in a well lit room with 
palpation of the lesions. Though the back was the primary treatment area, the face and 
chest were also graded in an attempt to track the natural history of each patient’s acne in 
the absence of intervention. Hence the Leeds grades for the face and chest acted as internal 
controls. To circumvent problems associated with investigator bias, internal validity and 
reproducibility [329], Leeds assessments were performed by 4 independent dermatologists 
unaware of the treatment timings using full-back photographs taken at the baseline visit 
and 1 week after the final IPL session at the end of the study. 
 
4.1.2.4 Lesion Counts 
To ensure reproducibility, a 10 x 10.1 cm template on a transparent acetate film was placed 
on a defined area on the upper back of patients at the baseline and final visits to count non-
inflammatory, inflamed lesions and resolving lesions [23, 25].  Each lesion was colour 
coded: red for inflamed lesions, blue for non-inflamed lesions and black for resolving 
lesions and static lesions. ‘Static lesions’ such as compound melanocytic naevi were used 
as landmarks for placement of the template. 
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4.1.2.5 Sebum Excretion Rate 
Using the method described by Trivedi et al. [98] a SM815 sebumeter (Courage + 
Khazaka Electronic, Köln, West Germany) was used to measure sebum excretion rates 
(SER) at baseline and one week after the end of therapy.  The upper back was cleansed 
with six swabs containing 70% isopropyl alcohol, 3 consecutive swabs per side 
(degreasing) and the time noted. Rode et al. [347] found  that casual levels of sebum 
excretion returned to baseline 2 hours after degreasing and was not statistically different 
from the levels measured 1 hour after defatting. Based on the findings of Rode et al., one 
hour after degreasing, a cassette containing 0.1mm synthetic tape was applied to a 
predetermined area on the upper back for 20 seconds. The measuring head was then 
inserted into the sebumeter, where the transparency of the tape was determined. Light 
transmission through the tape is proportional to sebum content of the area. A 
microprocessor calculates levels of sebum at μg/cm2 of skin. This process was repeated 
twice in adjacent areas and an average SER calculated. The area measured at the baseline 
visit was marked on a diagram to ensure measurement within the same region at the end of 
therapy. 
 
4.1.2.6 IPL Treatments 
The “back” was defined as the area encompassed by imaginary lines joining the superior 
aspect of the scapulae as the upper border and a horizontal line across the lower back at the 
level of the umbilicus was the lower border. The settings, 40 - 42 J/cm
2
, 20 pulses, 5 on, 
10-15 off, were loosely based on those used by Babilas et al. [189]  who reported reduced 
pain during red light photodynamic therapy whilst retaining its efficacy using these 
settings in an identical device. After applying a thin layer of ultrasound gel (for optical 
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coupling), a 530 – 950 nm applicator for the VPL™ Energist Ultra® was used to 
administer non-overlapping pulses to the back of each participant.  A second pass was then 
given perpendicularly to the previous pass.  The back was simultaneously cooled using 
chilled air (SmartCool, Cynosure, USA) to further improve patient tolerability.  One 
treatment was given as monotherapy at 2 week intervals for a total of 4 sessions. 
 
4.1.2.7 Skin Biopsies 
Four millimetre punch biopsies were taken from areas of clinically normal skin, within the 
treatment area under local anaesthesia (1–1.5 ml of 2% lidocaine with 1:1000 adrenaline). 
The timing of the biopsies was as follows: 
1) At baseline  (biopsy 1 or ‘B1’) 
2) Forty-eight hours after the first IPL session  (biopsy 2 or ‘B2’) 
3) One week after the 4th IPL session  (biopsy 3 or ‘B3’)  
 
The subsequent processing of skin biopsies to examine changes in inflammatory and 
sebaceous markers is described in Section 4.2.2.   
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4.2 Laboratory Studies 
4.2.1 Rationale 
A number of techniques could have been used to determine the mechanism of action of 
IPL. Those chosen were based on previous work by researchers who had studied IPL 
mechanisms of action, inflammatory cytokine expression and the effects of acne treatment 
on gene expression.  
 
TLR2 has a fundamental role in the induction and resolution of inflammatory acne. 
Through TLR2 activation, pro-inflammatory cytokines such as TNFα and IL-8, can be 
induced by bacterial colonisation, androgen-sensitive sebaceous glands and activated pre-
comedonal keratinocytes [62, 260, 348].  Conversely, TLR2 negatively self-regulates its 
pro-inflammatory responses by stimulating IL-10 transcription [349]. Investigators such as 
Tenaud et al. [276] and Hunger et al. [350] evaluated the  mRNA and protein expression of 
these molecules using polymerase chain reaction (PCR) and immunohistochemistry (IHC) 
techniques.   
 
Byun et al. [255] determined the change in the expression of IL-10 and TNFα  in IPL-
irradiated HaCaT cells by measuring messenger RNA (mRNA) expression semi-
quantitatively. They also utilised Western blotting to determine protein levels of 
expression. PCR techniques were used in this study to determine whether the expression of 
IL-10 and TNFα were respectively up- or down-regulated after treatment with IPL.   
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4.2.2 Biopsies 
Four millimetre punch biopsies were taken under local anaesthesia (1 – 1.5 ml of 2% 
lidocaine with 1:1000 adrenaline) from the upper back. Jeremy et al. [23] reported that 
clinically normal skin from an acne patient still had a statistically significant increase in 
inflammatory infiltrate which was only detected by microscopy. Hence, it was decided that 
non-lesional skin was to be biopsied to overcome the problems of timing an acne lesion 
throughout its evolution. The biopsies were taken 2 cm away from an adjacent 
inflammatory papule or pustule, and at least 3 cm away from a nodule or deep cyst in an 
attempt to avoid a neighbouring inflammatory process. After obtaining patient consent, the 
skin biopsies were taken at baseline (B1), 48 hours after the first IPL session (B2) and at 
the final visit (B3) which was 1 week after the 4th IPL session.  Therefore, 3 biopsies were 
taken from each subject, allowing comparison of IPL-induced changes before, during and 
after a course of treatment in the same patient.  
 
These punch biopsies were covered with OCT embedding matrix (Raymond A. Lamb, 
Eastbourne, East Sussex, UK), snap frozen in hexane (Fisher Scientific, Loughborough, 
UK) previously cooled with dry ice, and then stored in liquid nitrogen until used.  Seven 
micrometer sections were cut using a cryostat and mounted on Superfrost® Plus glass 
slides. These slides were then wrapped in aluminium foil and stored at -80 ºC until ready 
for use. Haematoxylin & eosin staining at intervals of 20 to 30 sections was carried out to 
identify sections containing portions of hair follicle and sebaceous gland.  
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4.2.3 Immunohistochemistry 
An immunohistochemistry protocol for TLR2 adapted from Ku et al. [351] was used. 
Sections from 10 cases were allowed to reach room-temperature, fixed with 100% dried 
acetone (15 min) and then air-dried (15 min). The samples were then washed three times in 
phosphate buffered saline (PBS, pH 7.2) for 5 minutes each. Blocking of non-specific 
binding was carried out with 10% donkey serum made up in a diluent of 1% bovine serum 
albumin (Sigma Lifesciences, USA) and 1% Marvel (dried skimmed milk, Premier 
International Foods, Ireland) in PBS for 60 minutes. Overnight incubation at 4ºC with anti-
TLR2 antibody (1:50; sc-10739; rabbit polyclonal; Santa Cruz BioTech, USA) was done 
in a humidified box. Negative controls were incubated with the diluent rather than the 
primary antibody. Serial washes in PBS were followed by 60-minute incubations with the 
secondary biotinylated donkey anti-rabbit antibody (1:200, Vector Laboratories, 
Peterborough, UK) and then 30-minute incubations in streptavidin conjugated to 
horseradish peroxidase (1:300, Vector Laboratories, Peterborough, UK).   
 
Further washes in PBS were followed by visualisation with 0.1% hydrogen peroxide and 
3, 3’- diaminobenzidine  (0.01% DAB, concentration 1mg/ml). A brown colour is 
produced by a reaction between DAB and hydrogen peroxide catalysed by the conjugated 
horse radish peroxidase causing DAB to form an alcohol-insoluble brown precipitate. 
Haematoxylin was used as a counterstain (2 min).  The last steps involved progressive 
dehydration in 70% vol/vol ethanol (x 1), 90% ethanol (x 1), 100% ethanol (x 3) and the 
sections were then cleared with xylene (3 washes). Sections were then mounted with a 
distyrene/ plasticizer (butyl, phthalate, styrene, BPS)/ xylene compound (DPX, 
BioChemika, Germany) and allowed to dry. 
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4.2.3.1  TLR2 Image Analysis 
Where all experimental conditions are equal, a change in the intensity of immunolocalised 
material can be directly proportional to a change in the expression of that antigen.  
Intensity grading tends to be subjective and varies greatly depending upon the lighting, the 
section and the individual grading the section. Analysis using computer software leaves 
less room for subjective variation [352]. Image Pro Plus™ v6.0 (Media Cybernetics, Silver 
Spring, Maryland) has been used extensively to digitally grade staining intensity, cell 
counts and area [353-356].  
 
For TLR2, digital images of four representative high power fields (x 20 objective) were 
taken using a Nikon camera mounted on a Carl Zeiss Axioplan microscope using 
Axiovision software. The internal optical density (IOD) per unit area (IOD/ Total 
Epidermal area) was determined for the four sections selected for each biopsy. The four 
values were averaged to give an overall IOD score for each biopsy [356]. 
 
 
4.2.4 Semi-quantitative Polymerase Chain Reaction  
4.2.4.1  RNA Extraction 
Total RNA was extracted from at least 600µm of each biopsy using TRIzol (Invitrogen, 
Paisley, UK) and 200 – 250 µg of glycogen (Roche Diagnostics GmbH, Germany). 
Glycogen is an inert substance that acts as a carrier molecule for the RNA, thus increasing 
the size of the pellet during precipitation steps [357, 358]. 
 
 
                                                                                                                             
95 
 
The steps are as follows:  
1. Cellular disruption at 15 -30°C 
i. 750µl – 1000 µl of Trizol added to biopsy sections  
ii. Samples vortexed briefly and allowed to sit for 5 min 
 
2. Phase separation 
i. 200µl chloroform added  
ii. Vigorously mixed for 15 – 20 secs and allowed to sit for 2-15 min 
iii. Centrifugation at 12,000g for 15 min at 2 – 8°C  
iv. After centrifugation, the mixture separated into 3 phases: Red (phenol-
chloroform) phase, interphase and the upper aqueous (colourless) phase. 
RNA is only in the upper phase  
 
3. RNA precipitation 
i. The aqueous phase was transferred to a clean tube and 200µg of glycogen 
added as per the manufacturer’s instructions  
ii. The solution was briefly vortexed and 500 µl isopropyl alcohol (Fisher 
Scientific, Loughborough, UK) added 
iii. Incubated at room temperature for 10 min 
iv. Mixture was centrifuged at 12,000g x 10 min @ 2 - 8°C 
v. The RNA formed a tiny gel like precipitate at side or bottom of the tube 
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4. RNA Wash 
i. The supernatant removed and the pellet washed with 1 ml of 75% ethanol 
and briefly vortexed 
ii. Centrifuged at 7,500g for 5 min at 2 – 8° C 
 
5. Re-dissolving RNA 
i. The ethanol pipetted off and the pellet air-dried  
ii. The remaining RNA pellet dissolved in 10 – 25 µl RNAase-free water 
depending on the quantity of RNA isolated 
 
4.2.4.2 Reverse Transcription (RT) 
After determining the concentration of RNA retrieved by measuring the optical density at 
260nm (A260) in a spectrophotometer (GeneQuant pro™ RNA/DNA Calculator, GE 
Healthcare, Buckinghamshire, UK), 1µg of RNA from cases 1-6, 9, 10, 12, 14, 18 (n =11) 
was used to generate cDNA templates. Each 20µl reverse transcriptase (RT) reaction 
consisted of 1µl AMV reverse transcriptase (Promega UK Ltd, Southampton, UK), 1µl 
Oligo dT (Promega UK Ltd., Southampton, UK) and 1µl RNAase inhibitor (Promega UK 
Ltd, Southampton, UK), 4µl 5x Buffer (Promega, Madison, USA), 4µl RNAse free water 
(Sigma Aldrich Lifesciences, Dorset, UK) and 4µl 10mM dNTPs (Roche Diagnostics, 
West Sussex, UK).  
 
RNA and Oligo dT were first placed in a thin-walled 200µl tube and heated at 70ºC for 10 
minutes and then cooled to 42ºC in a thermal cycler (MJ Research PTC-200 Peltier 
Thermal Cycler, Waltham, USA). The rest of the RT-reaction mix was then added at 42ºC 
where it remained for 60 minutes followed by a final incubation at 70ºC for 10 minutes.  
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 Though each RT-reaction was conducted using 1µg of total RNA, each sample’s RNA 
concentration differed necessitating the use of reaction volumes from 20 to 50 µl. This 
meant that the more dilute RNA concentrations required larger reaction volumes. In an 
attempt to normalise the cDNA concentrations, the optical density of each sample was 
measured using a GeneQuant pro™ RNA/DNA calculator (GE Healthcare) or a 
Nanodrop™ Spectrophotometer (Fisher Scientific, Loughborough, UK). A concentration 
of 350ng/µl was chosen which represented the lowest cDNA concentration in any one 
sample in a 1:10 dilution.  
 
4.2.4.3 Primers 
Primer sequences were designed from complete cDNA sequences listed on the University 
of California’s Santa Cruz genome bioinformatics website (http://genome.ucsc.edu).  They 
were designed so that they were 20 – 21 nucleotides in length, had 50 – 60% guanine and 
cytosine bases and ended with a G or C at the 3’ end where possible (Table 8.1).  The 
primers were synthesised by Sigma-Aldrich (Dorset, UK) and PCR reactions optimised for 
maximum amplification by varying the magnesium chloride concentration (MgCl2, Qiagen 
Ltd., West Sussex, UK), annealing temperatures and the presence or absence of Q-solution 
(Qiagen Ltd., West Sussex, UK). Q-Solution is a betaine additive that allows more 
efficient amplification of GC-rich sequences or templates which have a high secondary 
structure.  
 
4.2.4.4 Preparation of PCR Mix and Procedures 
For each reaction, the 50 µl PCR mix consisted of 1µl of cDNA (Qiagen Ltd., West 
Sussex, UK) , 1 µl dNTPs (10mM, Qiagen Ltd., West Sussex, UK), 2µl of forward and 
                                                                                                                             
98 
 
reverse primers (0.1µg/ml; Qiagen Ltd., West Sussex, UK), 0.25µl of HotStarTaq® DNA 
polymerase (5 units/ml, Qiagen Ltd., West Sussex, UK), 5µl of 10X CoralLoad PCR 
buffer [contains 15 mM MgCl2, Tris-Cl, KCl, (NH4)2SO4, gel loading reagent, red dye, 
orange dye, 10X CoralLoad concentrate;  pH 8.7; Qiagen Ltd., West Sussex, UK] and 22.5 
µl of RNAse free water (Sigma-Aldrich, Dorset, UK). Additional MgCl2 (5mM, Qiagen 
Ltd., West Sussex, UK) and Q-Solution
b
 (5X concentrated, Qiagen Ltd., West Sussex, UK) 
were also added if required (Table 4.1).  CoralLoad PCR buffer and concentrate contains 
gel tracking dyes allowing PCR products to be directly loaded on to an agarose gel without 
adding a loading buffer.
c
  To prevent evaporation during cycling, a heated lid was used on 
the thermal cycler (GeneAmp® PCR System 9700, Perkin-Elmer, Norwalk, USA and MJ 
Research® PTC-200 DNA Engine Thermal Cycler, Waltham, USA).   
 
4.2.4.4.1 Cycling Parameters 
The annealing temperatures were calculated using the formula:  
(4 x GC) + (2 x AT) - 5ºC 
 
The elongation times were adjusted according to the amplicon size (30 seconds for each 
500 bp). The settings for each primer are listed in Table 4.2.  
                                                 
b
 HotStar Taq Plus PCR Handbook, 02/2008, pgs. 10-11.  
c
 HotStar Taq Plus PCR Handbook, 02/2008, pgs. 10-11 
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Table 4.1:  Oligonucleotide Sequences and Additive Requirements for Semi-qPCR Experiments 
Gene 
 
Accession 
Number 
Primer Sequences 
Forward (above) 
Reverse (below) 
Size 
25mM MgCl2 
/ 50µl 
Q/ 50µl 
 
IL-8 
 
NM_00584 
CTTGGCAGCCTTCCTGATTTC 
CACTGTGAGGTAAGATGGTGG 
 
845 bp 
 
6µl 
 
10µl 
 
IL-10 
 
NM_000572 
CAGCTCAGCACTGCTCTGTTG 
GTCGCCACCCTGATGTCTCAG 
 
549 bp 
 
4µl 
 
10µl 
 
TLR 2 
 
NM_003264.3 
GGGTTGAAGCACTGGACAATG 
GCAGCCTCCGGATTGTTAACG 
 
970 bp 
 
4µl 
 
10µl 
 
APRT 
 
NM_001030018 
GCTGCGTGCTCATCCGAAAG 
CCTTAAGCGAGGTCAGCTCC 
 
250 bp 
 
- 
 
10µl 
 
β-actin 
 
NM_001101 
ATAGCACAGCCTGGATAGCAA 
AGAAAATCTGGCACCACACCT 
 
174 bp 
 
- 
 
10µl 
 
GAPDH 
 
NM_002046.3 
GGTGGTCTCCTCTGACTTCAACA 
GTTGCTGTAGCCAAATTCGTTGT 
 
127 bp 
 
- 
 
10µl 
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Table 4. 2 Cycling Parameters for Gene Quantification Using Semi-qPCR 
 
Gene 
 
PARAMETERS 
 
HotStar Taq 
Activation Step 
Denaturation 
Step 
Primer 
Annealing 
DNA 
Synthesis 
Cycle 
Number 
Final Elongation 
Step 
TLR2 95 ºC x 5 min 94 ºC x 30s 55 ºC x 30s 72 ºC x 1 min 40 72 ºC x 10 min 
IL-8 95 ºC x 5 min 94 ºC x 30s 61 ºC x 1 min 72 ºC x 30s 40 72 ºC x 10 min 
IL-10  95 ºC x 5 min 94ºC x 30s 57 ºC x 30s 72 ºC x 45s 40 72 ºC x 10 min 
GAPDH 95 ºC x 5 min 94ºC x 30s 55 ºC x 30s 72 ºC x 30s 35 72 ºC x 10 min 
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The number of cycles (40) to see a result was based upon extinction experiments which 
indicated that the initial quantities of cDNA for the desired genes were present only in 
minute amounts. Hence, even after 35 cycles, the amplicon was only faintly visible if at 
all. The agarose gel images for TLR2 and GAPDH (endogenous control) depicting this are 
shown in Figure 4.4 below. The experiments illustrated were performed using cDNA from 
Case 5 baseline biopsy (B1), which was chosen because it produced the most obvious 
bands for TLR2 during primer optimisation. 
 
 
 
 
 
Figure 4. 4: Effect of Cycle Number and cDNA Concentration on Semi-qPCR Band Intensity. 
Agarose gel images showing rapid extinction of TLR2 and GAPDH band intensity with a reduction 
in the number cycles. Concentration of 1:10 was approximately 300.1 ng/µl.  
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4.2.4.4.2 Agarose Gel Electrophoresis  
A sample (5 µl) of each PCR product was resolved on a 2% (w/v) agarose gel.  One gram 
of high resolution standard agarose (Geneflow Ltd., Fradley, UK) was dissolved in 50ml 
2X Tris-Acetic Acid-EDTA buffer (50X TAE contained 4.84 g tris hydroxymethyl-
aminomethane  +  11.4 ml of 17.4M  glacial acetic acid + 3.7g of EDTA disodium salt + 
160 ml deionised water) by heating for 1 minute in a microwave. Ethidium bromide (5 µl) 
was then added to the cooled mixture (1µg/ml) and poured into the electrophoresis tray 
(Model AGT-1, VWR International, Leicestershire, UK) to set.  Each PCR product (5 µl), 
which already contained loading buffer, was pipetted into a well of the agarose gel and run 
for 30 minutes at 50V in 2X TAE buffer. The DNA product size was determined by 
running a 100 bp ladder (New England Biolabs, Herts, UK) in an adjacent well.  
 
4.2.4.4.3 Housekeeping Genes 
PCR has the ability to amplify low levels of gene transcript, making it a very powerful 
method of detecting very subtle changes in gene expression [359, 360].  This also means 
that small differences in RNA extraction, efficiency of the RT-reaction and pipetting 
technique amount to many-fold alterations in the final PCR result.  Therefore, it is 
important to use a stably expressed gene that remains unaltered by the experimental 
conditions, against which these changes can be compared. ‘Housekeeping genes’ (HKG) 
are often used in this way. 
 
Semi-quantitative PCR (semi-qPCR) using three HKGs, adenine phosphoribosyl 
transferase (APRT), β-actin and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
was  tested on pre- and post-IPL samples from two patients using varying concentrations 
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of cDNA. As illustrated in Figure 4.5, GAPDH was stably expressed at a reasonable level 
and therefore used as the HKG of choice. 
 
 
 
Figure 4.5:  The Effect of IPL on Housekeeping Gene Expression.  DNA agarose gel showing 
the relative band intensities of three housekeeping genes GAPDH (127 bp), APRT (250 bp) and β-
actin (174 bp) after 35 cycles in biopsies taken at baseline (B1), after 48 hours (B2) and at the end 
of therapy (B3). 
 
 
4.2.4.4.4 DNA Sequencing 
To verify that the correct gene was being amplified by the PCR, products producing strong 
clean bands of the expected size were sequenced using the Big Dye® Terminator v3.1 
Cycle Sequencing Kit (Applied Biosystems). Here, the DNA was precipitated with PEG 
mix (26% polyethylene glycol 8000, 6.6 mM MgCl2, 0.6M NaOAc, pH 5.2) at room 
temperature for 10 min and centrifuged for 25 minutes at room temperature. After 2 
washes with 70% ice-cold ethanol (15,000 rpm, 2 min, 4°C), the pellet was mixed with the 
primer, Big Dye® buffer and Big Dye® mix. After 28 thermal cycles (denaturation at  
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96ºC for 10 seconds, annealing at 50 ºC for 5 seconds and DNA elongation at 60 ºC for 5 
minutes) the mixture was centrifuged again and the remaining pellet washed in 70% 
ethanol. The sequencing reactions were run by the Central Biotechnology Services (CBS) 
Lab using an ABI PRISM
® 
3100 Genetic Analyzer (Applied Biosystems). The sequence 
obtained was then checked against the published cDNA sequences obtained previously 
from the University of California’s Santa Cruz genome bioinformatics website and using 
the Basic Local Alignment Search Tool (BLAST) on the National Centre for 
Biotechnology Information (NCBI) website.   
   
4.2.4.5  Densitometry 
The agarose gels were photographed with 302 nm UV light using the AlphaImager HP® 
Imaging System (Alpha Innotech, Cell Biosciences, Santa Clara, CA). Relative amounts of 
PCR products were determined by measuring the intensity of each band using the ‘spot 
denso’ utility in the AlphaImager software which was called an ‘integrated density value’ 
(IDV).   
 
IDVs were recorded for each experiment (done in triplicate) and then averaged to produce 
a single, mean intensity value for each biopsy. This was called the mean or ‘µ’ IDV [361-
363] .  An IDV value for the no-template control was also measured and subtracted from 
the IDV value of the desired amplicon to correct for the inherent background signal 
emitted by each gel.  
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The formula for Gene A’s expression in biopsy α taken from Patient Y is: 
 = Gene A µIDV in Case Y biopsy α – Gene A µIDV in No-template control   
 
Finally, despite controlling for it, there may have been slight variations in the quantity of 
total genetic material in Patient Y’s biopsies. This variation would be mirrored by a 
difference in the intensity of the bands for the housekeeping gene, GAPDH.   
Hence each IDV has to be normalised against the starting quantity of genetic material:  
 
= Gene A µIDV in Case Y biopsy α – Gene A µIDV in No-template control   
       GAPDH µIDV for Case Y biopsy α 
 
 
Therefore, as an example, the normalised densitometry value for TLR2’s expression in 
Case 7 biopsy 1 would be: 
 
= TLR2 µIDV (Case 7 biopsy 1) – TLR2 µIDV (No-template control) 
       GAPDH µIDV (Case 7 biopsy 1) 
 
 
                                                                                                                             
106 
 
4.2.5 Quantitative PCR 
RT and QPCR experiments were performed by Dr. Ayman Hawrani, Central 
Biotechnology Services (CBS) using a SYBR® Green assay (Agilent Technologies, USA). 
 
The SYBR® Green assay rests on the ability of an asymmetric cyanine fluorescent dye 
(SYBR® Green I) to bind to the minor groove within double-stranded DNA (dsDNA) 
[364].  Unbound, SYBR® Green produces no fluorescence. Therefore, as DNA 
amplification progresses the fluorescent signal increases [364].  The amount of product 
made followed a sigmoid distribution, where the reaction rate peaked in the exponential 
phase and then plateaued as depleted substances in the reaction mix limit the reaction. This 
saturation level is approximately the same for all products in a typical qPCR experiment 
and therefore does not give an accurate reflection of the initial amount of product. At best, 
it can assess the presence or absence of a transcript [364]; however it is often at this very 
point at which semi-qPCR experiments are visible on an agarose gel.  
 
4.2.5.1 RNA Extraction  
In an attempt to maximise the quality of the extracted RNA,  sets of 3 biopsies from cases 
1, 2, 3, 4, 7, 11 were first preserved in RNALater® -ICE Frozen Tissue Transition Solution 
(Ambion Ltd., Huntingdon, UK) prior to RNA extraction (as described above). In spite of 
following the manufacturer’s instructions, the RNALater® - ICE formed a gelatinous 
material in association with the OCT-embedded biopsies which degraded the RNA to 
undetectable levels. For the succeeding samples, RNA was extracted using TRIzol (as 
described in Section 4.2.4.1). RNA extracted from Cases 2, 4, 9, 10, 15 -17, 20-22, 24 - 29 
and 30 were transported to CBS on dry ice and stored at -80ºC until used.  
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4.2.5.2 RNA Analysis 
Phenol from the RNA extraction process can inhibit PCR amplification and therefore all 
samples were ‘cleaned’ using RNeasy MinElute Clean-up Kit (Qiagen). ‘Cleaning’ 
involves mixing the RNA with ethanol and a guanidine-isothiocyanate–containing lysis 
buffer which enables RNA to stick to the silica membrane and the impurities to be washed 
away.
4
  RNA concentrations and integrity was checked using a NanoDrop-1000 
spectrophotometer (Thermo Fisher Scientific, USA) and Agilent 2100 Bioanalyser 
(Agilent Technologies UK Ltd., Berkshire, UK). The quality of RNA affects the efficiency 
of amplification, so poor quality RNA may not amplify efficiently. RNA integrity was 
expressed as an RNA integrity number (RIN) [365].  The Agilent Bioanalyser 
electrophoretically separates and analyses the characteristics of 28S and 18S ribosomal 
RNA to assign the  RIN,  which was  expressed on a scale of 1 to 10 where 1 represents 
totally degraded RNA and 10 represents  intact RNA. RIN values of less than 6 have been 
shown to give spurious results [366]. 
 
Only samples with a clear, clean peak at 28S and 18S RNA, no genomic DNA 
contamination, an A260/A280 ratio of 1.8 – 2.0 and a RIN of 6 and above were considered to 
be suitable for qPCR.  Full sets of RNA that met the above criteria were present for cases 
12, 14-17, 20-22, 24-27, 29 and 30 (n =14).  As these experiments were limited by the 
concentration of RNA available (other than for case 12), they were not duplicated using 
semi-quantitative PCR.  
                                                 
4
 Retrieved from RNeasy MinElute Cleanup Kit (04/10/2010): 
http://www.qiagen.com/products/rnastabilizationpurification/rneasysystem/rneasyminelutecleanup.aspx#Tab
s=t1 
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4.2.5.3  Primers 
Design, optimisation and quality control of the study primers were carried out by CBS 
(data not shown). The primer sequences are listed in Table 4.3 and GAPDH was the HKG 
used as a control.  
 
4.2.5.4  QPCR Procedure 
Based on the standard operating procedures for a SYBR® Green Assay (A. Hawrani, 
CBS), 10 µl of the SYBR® Green PCR Master Mix was added to 4.8 µl of RNAase-free 
water, 0.6 µl each of the forward and reverse primers (300 nMol) making the final volume 
16 µl. This 16 µl aliquot of master mix was placed in each well of a 96-well plate and 4 µl 
of cDNA sample (1:5 dilution of stock) was added.  After the plate was sealed and 
centrifuged for 1 minute at 1000 rpm, it was placed in the ABI 7900HT Fast Real-Time 
PCR System (Applied Biosystems, Cheshire, UK) for thermal cycling. The instrument 
automatically detects and records the fluorescent signals from each well. The data was 
exported in an Excel format.  
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Table 4.3:  Oligonucleotide Sequences of Primers Designed for qPCR Experiments 
Gene 
Sequence   5’ → 3’ 
Forward (above) 
Reverse (below) 
Amplicon 
Size 
 
IL- 8 
CCAGGAAGAAACCACCGGA 
GAAATCAGGAAGGCTGCCAAG 
 
91 bp 
 
IL-10 
GCCAAGCCTTGTCTGAGATGA 
TCACATGCGCCTTGATGTCT 
 
90 bp 
TLR 2 
CTCTCCAAGGAAGAATCCTCCAA 
GCCCTGAGGGAATGGAGTTT 
 
100 bp 
GAPDH 
TGCACCACCAACTGCTTAGC 
GGCATGGACTGTGGTCATGAG 
 
87 bp 
 
 
 
4.2.6 TaqMan® Low Density Arrays  
As discussed in the upcoming results section, gene amplification was sub-optimal using 
semi-QPCR and QPCR techniques which consumed the majority of the available cDNA. 
Therefore, an alternative technique which had the ability to use minute amounts of cDNA 
with relatively high specificity was sought. This was the TaqMan® Low Density Array.  A 
Taqman Low Density Array (Applied Biosystems, Cheshire, UK) is a 384-well 
microfluidic card that enables parallel analysis of a panel of 96 genes by RT-PCR using 
one-quarter the concentration of RNA required for other QPCR techniques.  
 
Like QPCR, TaqMan® assays use fluorescent technology but also include TaqMan® 
probes, engineered to be complementary to a specific sequence in the target gene between 
the forward and reverse primers [367]. The 5’ end of the probe is linked to a ‘reporter dye’  
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and the 3’ end linked to a non-fluorescent ‘quencher’. During PCR, the probe anneals to its 
specific sequence, where the DNA polymerase (AmpliTaq Gold®) cleaves the quencher 
from the 3’ end, allowing the reporter dye to fluoresce. As more probe-specific product 
forms, the fluorescent signal increases. Unlike SYBR Green®, non-specific fluorescent 
signals do not occur, since there is no fluorescence unless the probe is cleaved [367].   
 
TaqMan® Low Density Arrays have been successfully used with archived tissue [368] and 
a similar method of gene expression profiling to quantify inflammatory gene expression in 
acne has been described [325]. For this study, cards were pre-loaded with specific probes 
and primers for a panel of 90 genes involved in human inflammation including IL-8, IL-
10, TNFα and TNFR. TLR2 is not included in this panel. Out of a possible 6 HKGs, 
GAPDH and colony stimulating factor 1 (CSF-1) were used as the endogenous controls. 
Seven cases (2, 14, 22, 24-26 and 30) were analysed with TLDA and the data obtained 
with both HKGs is presented and discussed in parallel. 
 
These experiments were carried out by CBS. As per the protocol, 10 µl of cDNA was 
mixed with 40µl of RNAase free water and 50µl of TaqMan® Gene Expression Master 
Mix (Applied Biosystems, Cheshire, UK). This mixture (100µl) was then pipetted into 
each fill reservoir, allowing the analysis of 48 genes for each aliquot. The card was then 
covered and centrifuged twice at 1,596 rpm for 1 minute to ensure each well was 
adequately filled. The card was then placed in the ABI Prism 7900HT Sequence Detection 
System and allowed to cycle 40 times with the following parameters: 50ºC x 2 min, 94.5 x 
10 min, 97.0 x 30s, 59.7 x 1 min. Each experiment was run in triplicate, yielding a data set 
of 21 experiments for each gene where the dCt values were used for statistical analyses. 
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4.3 Statistical Analysis 
4.3.1 Statistical Analysis for Clinical Study 
Based upon statistical advice, a sample size of 20 was chosen to enable the detection of a 
shift of 0.63 times the standard deviation for within-subject differences giving a power of 
80% at the conventional 5% alpha level (p-value < 0.05). This calculation applies to all of 
the inflammatory markers studied.  Testing the mean of differences between the pre- and 
post-treatment data using probability-probability and quantile-quantile plots revealed that 
they had a Gaussian distribution. Hence, the paired sample t-test was a suitable method for 
analysing the data. Correlations between changes in the variables were analysed using the 
Pearson’s product-moment coefficient. The data was encoded within the statistical 
software package, SPSS version 16. The 2-tailed level of significance was set at 0.05.  The 
data is presented as the mean ± standard deviation (S.D.) where applicable. 
 
Leeds grading is a subjective quantitative scale and prone to marked variations depending 
on the observer [369]. To measure the agreement between the 4 blinded raters, and hence 
usefulness of the scale, the intra-class correlation was used [370]. When compared to the 
kappa coefficient, another statistical technique that is used to calculate inter-rater 
reliability, the intra-class technique was deemed to be the better instrument for 
quantitative, scaled data like the Leeds scores. Intra-class correlations (ICC)  have been 
used in the validation of the Leeds Revised Acne Grading System [341]. Kappa 
coefficients are accepted as more useful for non-quantitative classifications [370]. The ICC 
has a maximum of 1 where 0.7 represents a satisfactory agreement and ≥ 0.9 is considered 
to be very good agreement.  
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A value of 0 describes a correlation that is not above chance. The data is presented as the 
average measure, 95% confidence interval and significance. 
 
 
4.3.2 Statistical Analysis for Laboratory Study 
A repeated measures analysis of variance (ANOVA) with Greenhouse-Geisser correction, 
where applicable, was chosen to determine whether IPL caused a statistically significant 
change in the mean expression of each marker at 3 time points (B1, B2 and B3).  If the 
ANOVA P value (expressed as ‘P’ in this thesis) was significant, it was then appropriate 
for further pair-wise testing between time-points e.g. B1 vs. B3. In these pair-wise tests, 
Bonferroni adjustments corrected for multiple means testing [371]. Values are presented as 
mean ± S.D and the two-tailed significance was set to p < 0.05 (expressed as ‘p’ in this 
thesis).  SPSS version 18 (IBM, Chicago, USA) and Microsoft Excel were used to perform 
statistical analyses. 
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Chapter 5 
 
RESULTS 
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5.  Results  
5.1 The Clinical Effect of 530nm IPL on Inflammatory Acne   
5.1.1 Participants’ Baseline Characteristics  
A total of 190 persons were screened. Of these, the eligible cohort included in the study 
consisted of twenty-eight healthy adult volunteers (18 – 35 years) with mild to moderate 
acne on their backs and Fitzpatrick skin phototypes I - III.  Of 28 patients, 5 were used as 
pilots and 2 dropped out before the final assessment (reason unknown). Consequently, 21 
patients were used for statistical analysis of the lesion counts, Leeds scores and SER. Of 
this cohort, 12 (57.1%) were male and 9 (42.9%) were female. The average age was 24.6 ± 
5.3 years and they had suffered with acne for an average of 9.6 ± 6.8 years.  The average 
Leeds score at baseline was 1.99 (open assessment).  
 
5.1.2 530 nm IPL Significantly Reduces Inflamed Lesions  
As illustrated in Figure 5.1, the lesion counts for case 13 were far outside of the norm. In 
fact, there was a 5.8 fold increase in lesion counts, whereas the mean percentage change in 
lesion counts of the other 20 participants was 0.3-fold.  After seeking statistical advice, it 
was decided that the data for this patient was an outlier and so the results were expressed 
with and without case 13. Cases 13 and 9 had lesion counts in excess of 100 at either time 
point, where the mean lesion count at baseline was 24.05 ± 22.41 and 23.10 ± 34.32 at the 
end of therapy. Thus to illustrate individual trends more clearly, these cases were omitted 
in Fig. 5.1b. 
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At the end of the active treatment phase, the mean change in inflamed lesion counts fell 
significantly (p = 0.023) by 28% (Fig. 5.2). When the outlier was included, there was only 
a 4.0% reduction in inflamed lesions which was not significant (p = 0.88).  
      
 
 
Figure 5.1:  Change in Inflamed Lesion Counts Before and After IPL (a) Case 13 shows a 
marked increase in inflamed lesions, far in excess of that seen for the other cases,   (b) Cases 9 
and 13 have been omitted to illustrate individual trends for the rest of the study cohort.   
(b) 
(a) 
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Figure 5.2:  Mean Changes in Lesion Counts between Baseline (‘1’) and End of Therapy 
(‘2’). Data with and without the outlier is shown. IPL significantly reduced inflammatory 
lesion counts in the final study cohort.  
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5.1.3 530 nm IPL Does Not Significantly Affect Non-inflamed Lesions 
The decrease in non-inflammatory lesions and increase in resolving lesions were not 
significant. A comparison of the mean changes in lesion counts and SER are graphically 
represented (Figure 5.3).  Individual rates before and after a course of IPL are illustrated 
in Figure 5.4. 
 
 
Figure 5.3:  Mean Non-inflamed Lesions Before and After IPL. This graph illustrates                                                
the mean reduction in non-inflamed lesions after IPL therapy, which was not statistically 
significant. 
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Figure 5.4:  Change in Non-inflamed Lesions After IPL. Graph showing change in non-
inflamed lesion counts for the entire cohort. Note the steep rise in non-inflamed lesions for the 
outlier, Case 13. 
 
5.1.4 The Effect of 530nm IPL on Sebum Excretion Rate  
After IPL therapy, the sebum excretion rate fell in 9 patients, remained stable in 9 and 
increased in the remaining 3 cases. The mean SER fell by 35.86% in the cohort of 21 and 
by 33.03% in the cohort of 20 patients (Figures 5.5 and 5.6). Neither reduction was 
statistically significant (p = 0.23).  
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Figure 5.5:  Individual Variations in SER at Baseline and at the End of Therapy.   
 
 
 
Figure 5.6:  Change in Mean SER Before and After IPL. There was a small but non-significant 
reduction in SER. 
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5.1.5 IPL’s Effect on the Revised Leeds Score 
5.1.5.1 Inter-rater Reliability of Leeds Scores 
There was a very good agreement between each blinded assessor for the Leeds grades for 
each photograph (Appendix 2). The correlations for both the baseline and post therapy 
scores came in well above 0.7 and with a significance of p < 0.001 indicating that the 
scores given by the raters were consistent with each other (Table 5.1).   
 
Table 5.1: Inter-rater Reliability for Leeds Scores. The correlations between the scores of the 
four blinded raters show very high levels of concordance.   
 Baseline Score 
1 week after 
Therapy 
Intra-class Correlation 
(average measures) 
0.903 0.843 
 
95% Confidence Interval 
0.812 – 0.956 0.698 – 0. 929 
 
Significance  (p value) 
p < 0.001 p < 0.001 
 
 
5.1.5.2 Blinded vs. Open Assessments 
In the cohort of 21 patients, the differences between the pre- and post-IPL Leeds scores for 
the back did not achieve statistical significance for either the four blinded, (p = 0.667) or 
the candidate’s open assessments  (p = 0.081). The mean improvements in the Leeds score 
with and without the outlier for both the clinical (open) and photographic (blinded) 
assessments are listed in Table 5.2.  Using blinded assessments, 19.04% improved, 23.4% 
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worsened and 12 subjects (57.1%) remained the same. For the open assessments, 
approximately 61.9% experienced an improvement, one seventh (14.3%) deteriorated and 
a quarter (23.8%) of the cohort showed no change.  Both sets of scores show that 
irrespective of the method used, IPL did not significantly improve the acne severity as 
determined by the Leeds grading system. The chest emerged as a suitable internal control 
in the open assessments as the percentage change for the back and chest were very similar 
as were the levels of statistical significance.  
 
Table 5.2: Mean Reductions in Leeds Scores.  The average changes in the Leeds scores are 
listed below for the open and blinded assessments. The assessments without the outlier (n = 
20) are highlighted in blue italics (* denotes statistical significance). 
 
Blinded 
BACK 
Open 
BACK 
Open 
CHEST 
Open 
FACE 
Mean change in 
Leeds Grade 
from baseline 
0.05  ± 0.5 
0.05 ± 0.51 
0.23 ± 0.42 
0.31 ± 0.56 
0.25 ± 0.29 
0.24 ± 0.29 
0.27 ± 1.46 
0.29 ± 1.5 
% Reduction 
from baseline 
- 9.41 % 
- 9.88 % 
35.84 % 
33.04% 
36.84 % 
34.45% 
19.49% 
20.91% 
2-tailed 
Significance 
0.667 
0.667 
0.081 
0.023* 
0.018* 
0.018* 
0.457 
0.458 
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5.1.5.3 Photographic Assessments 
Three cases illustrated in Figure 5.7 represent the overall typical clinical response.  Case 9 
(Figure 5.7a, b) and case 25 (Figure 5.7c, d) show mild improvement in the inflammatory 
appearance of their acne. If the biopsy sites are excluded, there is a small but noticebale 
reduction in the number of lesions. Case 15 (Figure 5.7f, g) appears to have an increased 
number of inflamed lesions at the end of therapy. When cases 15 and 25 opted to return 1 
month after the final IPL treatment, which involved abstaining from sun-exposure and any 
acne therapy, case 15 continued to improve (Figure 5.7h) whilst case 25 relapsed (Figure 
5.7e). Case 9’s third image was not included as she did not opt for further follow up after 
the final IPL irradiation. 
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Naevus  
Excision site 
 CASE 9 (a) 
(h) (g) CASE 15 (f) 
(e) (d) CASE 25 (c) 
Markers for template 
B2 
B1 
B1 
B2 
B3 
B2 
B1 
B3 
B2 B1 
B1 
B2 
(b) Figure 5.7: Differences in Clinical Response 
for 3 Study Subjects. Case 9 (a – b);  Case 25 
(c – e);  Case 15 (f - h) . Case 15 continues to 
improve at 1 month post- but Case 25 shows a 
clear deterioration.  
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5.1.6 Summary of Primary Clinical Outcomes 
Though yellow IPL was able to significantly reduce inflammatory lesions, it did not have a 
clinically appreciable effect on the Leeds score or the sebum excretion rate. The final 
efficacy data is summarised in Table 5.3. 
 
5.1.7 Medium-term Endurance of Yellow IPL  
Within the analysed cohort, 14 subjects returned for follow-up 1 month after their final IPL 
treatment. Of these, 3 subjects (21.4 %) relapsed, while another 3 (21.4%) had an 
improvement in their Leeds score and the remainder experienced no change in their scores. 
Of the 8 subjects evaluated 3 months after their final treatment, 2 maintained their scores 
over the period, and the remainder relapsed. Therefore at the end of 3 months, the medium 
term benefit of IPL therapy was preserved in 2 of 14 subjects (14.3%). Due to the small 
numbers of patients that returned for follow-up, this portion of the study failed to be 
adequately powered, and hence was not statistically tested. 
 
5.1.8 Gender and Acne Duration Do Not Influence IPL Response 
As expected, the duration of the participants’ disease was positively associated with their 
age (p< 0.001).  There was no relationship between the patients’ Leeds scores, inflamed 
lesion counts or non-inflamed lesion counts. Correlations between BMI, changes in the 
SER and the open Leeds score (back) were not found. Likewise, there were no 
relationships between gender, lesion counts, SER or the Leeds score.
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Table 5.3:  Summary of Clinical Outcomes.  The mean reductions without the outlier  (n= 20) are italicised in blue. * denotes  statistical significance 
Parameters 
Inflamed 
Lesions 
Non-inflamed 
Lesions 
SER (µg/cm
2
) 
Leeds Score 
BLINDED 
Leeds Score 
OPEN 
Baseline Assessments 
(mean ± S.D.) 
24.05 ± 22.41 
24.25 ± 22.98 
38.67± 29.25 
39.2 ± 29.91 
16.38± 13.12 
14.53 ± 10.28 
1.36 ± 0.59 
1.38 ± 0.60 
1.99 ± 1.09 
2.04 ± 1.10 
Final Assessments 
(mean ± S.D.) 
23.10 ± 34.32 
17.45 ± 23.13 
37.24 ± 34.31 
32.9 ± 28.5 
13.65 ± 9.72 
13.03 ± 9.54 
1.40 ± 0.55 
1.43 ± 0.55 
1.74 ± 1.11 
1.73 ± 1.13 
Mean Reduction ± S.D. 
0.95  ± 28.1 
6.8 ± 8.69 
1.43 ± 31.2 
6.35 ± 22.11 
5.87 ± 9.70 
4.80 ± 8.58 
0.05  ± 0.5 
0.05 ± 0.51 
0.23 ± 0.42 
0.31 ± 0.56 
Mean % Reduction 
from Baseline 
3.95 % 
28.04 % 
3.70 % 
16.2% 
35.86% 
33.03% 
- 9.41 % 
- 9.88 % 
35.84 % 
33.04% 
2-tailed Significance     
(p value =) 
0.878 
0.002* 
0.836 
0.214 
0.272 
0.501 
0.667 
0.667 
0.081 
0.023* 
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 5.1.9 Adverse Events 
Side-effects included mild to moderate discomfort during treatment, which was easily 
remedied by adjusting the intensity of the air cooling.  One subject had a mild infection at 
their first biopsy site and therefore their 2
nd
 biopsy was omitted to allow complete 
resolution of the first.  
 
5.1.10 Summary of the Clinical Findings  
1. Yellow IPL reduced inflammatory lesions by 28%, which was significant at p = 0.002, 
when the outlier was excluded from the analysis (Section 5.1.2). The 16.4% reduction 
in non-inflamed lesions after IPL was not significant (p= 0.214, Section 5.1.3). 
 
2. The reduction in the SER of 35.1% was not statistically significant (Section 5.1.4). 
The reduction in inflammatory lesions was proportional to the reduction in SER for the 
cohort of 21. Exclusion of case 13 resulted in the p value >  0.05 (Section 5.1.4). 
 
3. There was no significant change in the Leeds score following a course of yellow IPL. 
Quoting the scores from the open assessments, the 33% improvement in the Leeds 
score for the back (p = 0.023) was mirrored by a 34% improvement in the score for one 
internal control, the chest (p = 0.018). Using blinded assessors (Section 5.1.5), the 
Leeds score worsened by 9.9% (p = 0.67). 
 
4. Of the 14 patients that remained in follow up, only 2 maintained remission 3 months 
after the final IPL session. Therefore, any statements about the upper limit of the 
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duration of yellow IPL’s therapeutic effect will have to be restricted to 3 months after 
the final treatment (Section 5.1.6). 
 
5. There was no association between gender and the change in inflamed or non-inflamed 
lesion counts (Section 5.1.7). 
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5.2 Elucidating the Anti-inflammatory Actions of Intense Pulsed 
Light  
5.2.1 Data Presentation 
A combined total of 25 cases were analysed using three molecular assays: semi-
quantitative PCR, SYBR® Green qPCR and TaqMan® low density arrays (TLDA). The 
number of cases where the main target genes were successfully amplified using each 
technique is listed (Table 5.4). Functioning positive controls verified that the experimental 
conditions and primers used were correct. To maximise the data, compensation for ‘RNA 
degradation-related shifts’ in the Ct values [372] and reduced data loss through repeated 
averaging, statistical testing was carried out on the threshold values (dCt) rather than the 
relative quantities (RQ) of the gene expressed.  Unless otherwise stated, the TLDA data 
presented was based on GAPDH as the house keeping gene (HKG) in all 7 cases. Using 
geNorm (a software algorithm used to determine the most stably expressed gene amongst a 
panel of target genes) [373], analysis of the data showed that colony stimulating factor 1 
(CSF1) was also stably expressed in these samples (Appendix 3). Where applicable, the 
CSF1 values are presented alongside GAPDH’s as evidence of the data’s reliability. 
 
 
 
 
 
                                                                                                                             
129 
 
Table 5.4: Target Genes Successfully Amplified in Each Molecular Assay  
Technique 
(Duplicated Cases/ n Cases) 
TLR2 IL-8 IL-10 
 
Semi-qPCR (2/11) 
11 0 0 
 
QPCR (2/14) 
7 3 8 
 
TLDA (7/7) 
Not available 3 7 
 
 
5.2.2 530nm IPL Down-regulates Epidermal TLR2 Expression  
TLR2 was found to be expressed throughout the epidermis (Figure 5.8) with some 
background staining within the dermis. Of the 10 cases studied, 48 hours after IPL (biopsy 
2) epidermal TLR2 expression increased by 5 – 46% in five cases. The other 5 cases 
showed a reduction in epidermal TLR2 expression of 4 – 13% in biopsy 2. Overall there 
was a mean increase in TLR2 expression of 8.57% (p= 0.003).    
 
Statistically, though the mean difference between the integrated optical densities (IOD) 
between the baseline and final biopsies was 2.63%, it was significant at p < 0.001. TLR2 
expression fell from baseline in 7 cases by 0.1 – 14% and increased in Cases 2, 6 and 14 
by 7%, 51% and 67%.  The repeated measures ANOVA P value with Greenhouse-Geisser 
correction was significant (P < 0.001).  .  
 
Figure 5.8 illustrates the IHC images of 2 representative cases (2 and 10).  Note that there 
is a clear up-regulation of TLR2 expression when measured 48 hours after IPL irradiation 
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(B2) that appears to return to baseline levels in Case 2 and falls below baseline expression 
in Case 10 at one week post-therapy (B3).  
 
5.2.2.1 Correlation between IHC and PCR Results 
The 10 cases selected for IHC were also evaluated with semi-quantitative PCR (Figure 
5.9). Integrated density values (IDV) demonstrated a 10.2% (p = 0.84) increase in mean 
TLR2 mRNA expression from baseline at the end of therapy (B3).  There was also a 
34.6% (p = 0.50) increase in TLR2 expression in the 2
nd
 biopsy and an 18.1% (p = 0.84) 
fall a week after the final irradiation (Figure 5.9). 
 
Comparing IHC image analysis data with the semi-qPCR IDV values, there was agreement 
in the up- and/or down regulation of TLR2 in 5 cases (cases 5, 6, 9, 12, 14) and partial 
agreement in the other 5 cases. The mean data for both methods (Semi-quantitative PCR 
and Image analysis) correlated well. Both show an overall increase in TLR2 expression 
when measured 48 hours after IPL irradiation and an approximation to baseline levels 7 
days after the final irradiation (Figure 5.10). The raw data is listed in Appendix 3.   
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Figure 5.8: Effect of IPL on TLR2 Expression in Human Epidermis by IHC.  Two representative cases, 2 and 10, are shown. Note increased 
expression in B2.  Scale bar:  20µm 
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Figure 5.9:  Agarose Gel Images Showing the Effect of IPL on TLR2 Expression.  PCR 
product analysis of biopsies (B1-B3) from cases 1–5 were analysed on a 2% (w/v) agarose gel and 
stained with ethidium bromide and visualised under UV light. Each case is represented as a set of 3 
bands (B1, B2 and B3). Note: kb = kilobase. 
 
 
  
Figure 5.10:  Mean Changes in TLR2 Expression Measured by Semi qPCR and IHC.  IDV 
curve represents Semi-qPCR data and IOD, IHC image analysis data (mean of data for Cases 5, 6, 
9, 12, 14). Average TLR2 expression increases by 10 – 20% in B2 and returns to baseline levels in 
B3 using both methods.    Error bars = SEM; IDV= integrated density values; IOD = integrated 
optical density 
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5.2.3  530nm IPL’s Effects on Inflammatory Cytokine Expression  
5.2.3.1 IPL Does Not Significantly Change IL-8 Expression 
Regarding individual changes, the relative quantities of IL-8 for case 26 were significantly 
higher than the rest of the cohort, but the trend was similar to changes observed in other 
members of the sub-group (Figure 5.11a). Mean IL-8 expression increased in biopsy 2 and 
fell below baseline levels in 4 cases (Cases 2, 24, 25, 30).  In biopsy 3, IL-8 fell to just 
above baseline levels in 2 cases (Case 26 and 22) and to baseline in one case (Case 14), 
and below baseline levels in Cases 2, 24, 25 and 30.  
 
IL-8 expression (mean of all data) increased by an average of 66.42% (p > 0.50, ANOVA 
P = 0.179), when measured 48 hours after IPL irradiation (biopsy 2) but fell to 
approximately 7.9% below baseline (p = 0.434) when assessed 1 week after the fourth and 
final treatment (biopsy 3). See Figure 5.11b. 
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Figure 5.11:  Effect of IPL on IL-8 Expression.  (a) Effect of IPL on IL-8 expression in 
individual cases; (b) Mean change in IL-8 expression over a course of IPL in all cases (error bars 
= SEM, n= 7). 
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5.2.3.2 IPL Down-regulates TNFα and TNF Receptor Expression 
TNFα expression fell by 17.6% (p = 0.031, ANOVA P = 0.006) by the end of therapy. 
Also, TNFR expression fell by 37.6% (p = 0.017, ANOVA P = 0.11) by the end of therapy 
(see Figure 5.12). 
 
 
Figure 5.12: Effect of IPL on TNFα and TNFR Expression. Graph showing down-regulation of 
TNFα and TNFR expression in acne prone skin after treatment with IPL. Data represents a mean of 
all values obtained for the cases examined (Error bars = SEM, n =7). 
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produced data from biopsies 1 (baseline) and 3 (1 week after 4
th
 and final treatment) using 
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this method. For this reason, only SYBR Green® data for biopsies 1 and 3 are presented. 
The TLDA data is also shown in Table 5.5.   
 
Where GAPDH was used as the house-keeping gene, the TLDA data showed that IL-10 
expression increased by 97% (p = 0.96) in B2 which was maintained in B3. Using SYBR 
Green®, IL-10 expression increased from baseline by approximately 114% 
(p > 0.05). Both molecular assays showed a doubling of IL-10 expression after IPL 
irradiation, but this was not statistically significant (Table 5.5). 
 
 
Table 5.5:  Relative Changes in IL-10 Expression.  SYBR Green and TLDA (GAPDH) data 
show that the percentage increase in B3 is comparable using both methods despite different patient 
cohorts.  CSF-1 and GAPDH exhibit similar trends in IL-10 expression using TLDA (RQ = relative 
quantity).   
 
 
IL-10 
 
 
B2 – B1 
 
B3 – B1 
 
B3 – B2 
Technique 
(HKG) 
Cases Analysed 
% RQ change 
(p value) 
% RQ change 
(p value) 
% RQ change 
(p value) 
 
SYBR 
Green® 
(GAPDH) 
 
12, 14, 20, 22, 30 
 
N/A 
 
+ 113.67 % 
P > 0.05 
 
N/A 
TLDA 
(GAPDH) 
2, 14, 22, 24 - 26, 
30 
+ 96.78 % 
P = 1.00 
+ 94.99 % 
P = 0.75 
 
- 0.91 % 
P = 1.00 
 
TLDA 
(CSF-1) 
2, 14, 22, 24 - 6, 
30 
+ 68.19% 
P = 1.00 
+58.06% 
P = 0.71 
 
- 6.02% 
P = 1.00 
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5.2.5 Relationship between In vitro and In vivo Findings  
A key question was whether the clinical change in inflamed acne lesions correlated with 
the change in the expression of inflammatory mediators. Those that achieved statistical 
significance as determined by the ANOVA P value and/or pair-wise comparisons were 
evaluated i.e.TLR2, TNFα and TNFR. A weak negative relationship was found between 
the change in lesion counts and TNFα expression (see Figure 5.13, R2 = 0.253). A linear 
relationship was not observed between the percentage change in lesion counts and TNFR 
(R
2
 = 0.007) or TLR2 (R
2
= 0.008) expression (data not shown).  
 
 
 
Figure 5.13: Correlation between Lesion Counts and TNFα and TNFR. The percentage change 
in lesion counts were plotted against the change in cycle threshold values for each gene (dCT B3-
B1).  
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5.2.6 Summary of Results from Laboratory Study  
A number of pro- and anti-inflammatory molecules were examined to determine the 
mechanism of IPL’s anti-inflammatory effect. The findings are summarised below.   
 
1. Immunolocalisation of TLR2 to the epidermis decreased by a small but significant 
increment of 2.6% (p < 0.001) by the end of therapy. When measured 48 hours after 
the initial exposure (biopsy 2), epidermal expression of TLR2 increased by 8.6% (p = 
0.003).  TLR2 mRNA transcript levels from whole skin biopsies partially agreed with 
the trends noted in the IHC results but the changes were not statistically significant 
(see Section 5.2.2). 
 
2. IL-8 expression increased by 66.4% in biopsy 2 and fell slightly below baseline levels 
in biopsy 3. These changes were not statistically significant (see Section 5.2.3). 
 
3. TNFα and TNFR expression remained stable when measured in B2, 48 hours after the 
first IPL treatment. However, both markers then fell significantly at the end of the 
course of IPL with 18% reduction in TNFα expression (ANOVA P = 0.006, p = 0.031) 
and 38% in TNFR expression (ANOVA P = 0.107, p = 0.017), see Section 5.2.3. 
 
4. IL-10 mRNA expression increased by approximately 100% in B2 and B3. Though 
mean QPCR and TLDA data correlated well, this change was not statistically 
significant (see Section 5.2.4). 
5. Clinical correlation using the data from this subgroup of patients suggests that there is 
a weak negative relationship between percentage change in inflammatory lesions and 
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TNFα expression (see Section 5.2.5, R2 = 0.253).  Thus, those who had deterioration in 
their lesion counts after therapy also tended to have higher TNFα expression post-IPL. 
 
5.3 Study Critique  
5.3.1 Clinical Trial 
The data, though able to produce valid conclusions, may have been coloured by a number 
of inherent biases in the conduct of the study as well as unavoidable patient factors, which 
are discussed in detail below. 
 
5.3.1.1 Clinical Study Strategy 
1. The lesion counts were limited to a 101cm2 area rather than the entire treatment area. 
Inclusion of the entire back may have produced more dramatic changes, approximating 
to that described in the literature. However, based on assessment of the degree of 
variation between trained and untrained lesion counters by Lucky et al. [374], they 
concluded that the use of a trained assessor to count within a defined area reduced 
variability, leading to an average intra-observer concordance rate of  0.8.   Therefore, 
the use of a template to count lesions within a defined area was advantageous.  Further 
evidence is provided by this study’s finding of a more significant reduction in inflamed 
lesions when compared to the Leeds score, making it unlikely that any improvement 
caused by exposure to IPL was under-represented by choosing a defined area for lesion 
counts.  
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2. The large changes in significance after exclusion of the outlier for lesion counts and 
un-blinded Leeds scores probably indicates that had the sample size been larger, its 
effect would have been smaller. The outlier, was using a topical zinc-erythromycin 
combination before entering the study. The marked deterioration in her acne may have 
been a pre-menstrual flare (history not obtained during the study), a late rebound 
response despite completing a 4 week wash-out period or IPL may have had a pro-
inflammatory effect which is alluded to in the final chapters.    
 
3. Clinical Leeds assessments estimated a 33% change in the Leeds grade vs. - 9% for the 
blinded photographic grading. 
a. Utilising medical professionals trained in Leeds grading reduced the bias in the 
scores for each patient [375].  However, in order to maintain blinding, the 
biopsy scars were not highlighted on each patient’s full back photo which may 
have resulted in the patient being given a higher Leeds score than if absent. 
This potentially reduced the observable difference between pre- and post-IPL 
photographs.  This would have been compounded by the fact that this cohort’s 
mean baseline acne severity was 2.04 ±1.10 (open assessment,Table 5.3), 
which is mild and in the absence of complete clearance post-IPL, may not have 
warranted a reduction by a full grade. In a larger commercial trial setting or 
collaborative study, Leeds grading by blinded practitioners at the time of 
presentation rather than with the retrospective use of photographs would have 
been preferable.  
 
b. A weakness of the Leeds Revised Acne Grading System is that it favours 
inflammatory lesions and does not account for their depth, which is only 
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possible through palpation [327]. Thus, in cases where comedones or scattered 
nodules predominate, a photographic evaluation would naturally give a lower 
score than that on clinical examination. This, in addition to investigator bias, is 
the most likely reason for the difference in the percentage change in the scores. 
In spite of this, both clinical and photographic grading yielded the same 
conclusion. Although there was a 30% reduction (approximate) in inflamed 
lesions, IPL was unable to improve the severity of acne to a point that was 
appreciable to the eye as being significant enough to reduce the Leeds score by 
a grade of  ≥ 1. 
 
c. As shown by this study and several others before, the reliable identification of a 
trend utilising a visual scale is possible but the use of a subjective instrument to 
do an objective measure will always be imprecise. This disparity highlights the 
need to use both types of assessment for a truly representative picture of 
improvement or deterioration.   
 
4. The sebum excretion rate is affected by external and internal factors.  
a. As pointed out by the EEMCO guidance, patients with excessive amounts of 
skin surface lipid could saturate the tape, making the reading inaccurate and the 
roughness and relief of the measured area could also impair proper contact with 
the skin [334].  
 
b. Measurement could have been confounded in the one hour waiting period by 
inadvertent removal of sebum by clothing, movement etc. which could not be 
controlled for or guaranteed as constant at baseline and final measurements.  
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c. SER is affected by ambient room temperature, circadian rhythms and hormonal 
status at the time of measurement [112, 376]. Thus, although measurements 
were done in the same room, measurements were done according to patient 
availability and therefore  circadian rhythms were not controlled. This difficulty 
has been described by other researchers like Blume et al. [377] who measured 
sebum excretion rates in male and female acne patients using Sebutape®. 
However, Rode et al. [347], who also assessed 12 non-acne patients, did not 
find any day-to-day variation when the same individuals were measured using 
the Sebumeter® over 2 days.  
 
d. Though assumed to be representative of the entire back, the measured area may 
not be equivalent to other areas on the back. Different areas on the face have 
varied sebum outputs and this may be the case for the back. 
 
e. In response to therapy, the lipid composition can change without a 
corresponding change in the excretion rate [376], therefore SER may not be an 
accurate reflection of IPL’s effect on the sebaceous glands. 
 
5. This trial utilised intra-individual controls, which carries with it inherent biases. 
Though the use of internal controls has its advantages, a more objective approach 
would be to have a placebo controlled or a parallel assignment study comparing IPL 
with an already accepted standard of therapy such as adapalene 0.1% gel. In fact, such 
a study was designed in conjunction with the project presented in this thesis, but the 
lengthy process involved in conducting such a trial dictated that my remit be narrowed 
to that described in this thesis.  The randomised controlled double-blind clinical trial 
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comparing the efficacies of photodynamic therapy (IPL + methyl-aminolaevulinic 
acid), IPL only (IPL + sham cream) and adapalene is being undertaken by other 
researchers [378]. 
 
5.3.1.2 Treatment Parameters 
1. The device settings may have been too gentle to cause a considerable change and 
probably required a longer ‘on time’ e.g. 5 pulses ‘on’ and 5 ‘off’ rather than 5 
pulses ‘on’ and 15 ‘off’.  A suboptimal energy delivery was unexpected as these 
settings were clearly sufficient to clear actinic keratoses when used in conjunction 
with photodynamic therapy (Babilas et al., 2007) and did not seem unreasonable 
when discussed with a co-author of that paper especially where patient tolerability 
was a real concern. The patients who were treated with shorter off times (10 ‘off’) 
and higher fluences (42 J/cm
2
) visibly experienced more pain.  
 
2. Covering the treatment area with ultrasound gel was deemed useful as it reduced 
total internal reflection thus increasing the effective energy absorbed and hence 
treatment efficacy. However, air bubbles within it can cause light scatter and 
dissipate delivered energy [184]. In the context of this study, inadequate time 
between each discharge could have led to heating of the ultrasound gel resulting in 
bubble formation and dissipation of energy.  
 
3. Darker skin types have an increased risk of post-inflammatory hyperpigmentation 
where high temperatures are induced by IPL [379].  Cooling the skin increases the 
energy threshold at which epidermal damage occurs and reduces the pain 
associated with the treatment. Operator controlled cooling however, introduces 
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variability in the amount of energy absorbed by the skin. In the course of 
treatments in this study, patients were cooled prior to and during the IPL sessions. 
Hence, a reduction in the energy absorbed by the skin may have contributed to the 
low complication rates but treatment efficacy possibly suffered as well.  
 
Town et al. [184] found that the measured pulsed durations were as stated on the 
Energist ULTRA™ 610 nm device and the percentage deviation of the cut-off filter 
was small at 2.1%.  The device however, was operating only at 77% of the 
maximum fluence stated by the manufacturer.  No data was given for the 530 nm 
applicator, but a similar level of energy loss is very likely as the only difference 
between the applicators is the filter. Though the active treatment phase spanned 10 
months, just prior to undertaking the study, calibration and servicing was 
performed by the company, hopefully this mitigated any additional deterioration in 
device performance.  
 
4. A narrower light spectrum may have been more efficacious as the spectral output 
of the clinically effective wavelengths would be greater for any given wavelength.  
The IPL applicator spanned an emission spectrum of 530 – 950 nm. Bjerring et al. 
[380] found that 525 – 750 nm IPL was better in improving redness and 555 – 950 
nm IPL was better for pigmentation. Hence, energy distribution across a narrower 
spectrum may have led to increased energy delivery to the skin and possibly a more 
specific, and therefore more identifiable, phototherapeutic response. 
 
5. Unavoidable inter-individual variation: 
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a.  Our skin’s irregular shape and surface in addition to its appendages being 
embedded in a non-homogenous dermis makes its optical properties complex 
and varied and hence, dosimetry estimations are difficult.  
 
b. Physiological factors such as menses, gender, acne duration and baseline 
severity influence the lifespan of inflamed lesions [381]. Of course, other 
studies of this nature would also have been affected by these general patient 
factors. 
 
5.3.2 Laboratory Investigations 
The changes in TLR2, TNFα, TNFR, IL-10 expression in response to IPL irradiation 
represents a small subgroup of the entire study cohort. Also, the TNFR ANOVA P value 
fell just outside the threshold of significance and IL-10 mRNA expression after IPL 
irradiation showed a clear increase without statistical import. Thus, an important biological 
phenomenon may have been missed and conclusions will have to be made cautiously. A 
number of factors may have contributed to this: 
 
1. The difficulties of extracting high quality RNA from complete sets of 3 biopsies 
per case resulted in small numbers being suitable for molecular evaluation. Hence, 
the data has very likely suffered from several type II errors (finding no statistical 
significance when in fact there is one). A larger cohort of suitable samples may 
have uncovered greater consistency between the ANOVA and pair-wise testing p 
values.  
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2. The high threshold values (Ct = 35- 40) required to observe any amplification of 
this study’s inflammatory target genes above background for semi-qPCR, qPCR 
and TLDA demonstrate that these cytokines were expressed in very minute 
quantities, which is not unusual for clinically normal skin. However, the relative 
success of the TaqMan® probes, which required a quarter of the cDNA required 
for SYBR Green® attests to the superiority of this assay and the specificity of the 
probes despite published literature attesting otherwise [364, 382]. In hindsight, the 
63 biopsies assessed using SYBR Green® and Semi-qPCR would have been far 
better served if they were assessed via TLDA from the outset.  
 
3. It would have been useful to correlate the changes in TLR2, TNFα and TNFR 
expression in the same subset of patients. However, due to the factors described 
above, this was not possible.  
 
4. RNA was extracted from whole skin biopsies (this included dermis and subcutis) 
whereas immunohistochemical assessment of TLR2 expression was confined to the 
epidermis. Thus, molecular evaluation of a whole skin biopsy may have precluded 
accurate detection of an epidermal phenomenon accounting for the lack of absolute 
correlation between the two assays.  
 
5. In this study, the biopsy taken 48 hrs after the 1st irradiation was to give a snapshot 
of the early biological effect of IPL and the 3
rd
 biopsy taken 7 days after the last 
irradiation aimed to show the cumulative effect of IPL on acne-prone skin.  
However, during the intervening time points, inflammatory cytokine and receptor 
expression may have varied significantly. Measurement at these time points may 
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have provided a more accurate account of IPL’s effect on acne prone skin. 
However, this would have required more than 3 biopsies in each patient, making 
this an unfavourable and unrealistic alternative.  
 
6. Yellow IPL probably has differential effects on various structures within the skin. 
An alternative approach would have been to determine IPL’s effect on the 
epidermis, pilosebaceous follicle, dermis and subcutis. Though technically 
challenging, immunohistochemical identification of these cytokines or 
microdissection of each structure followed by RNA extraction could have provided 
these answers.  
 
7. Byun et al.’s study [255] also found that IL-10 expression measured with semi-
quantitative PCR did not reveal a statistical difference after yellow IPL. ELISA 
however, was able to detect a significant increase in IL-10 protein [255]; hence 
protein quantification rather than mRNA transcript levels may have also yielded 
significant results in this study. 
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Chapter 6 
 
DISCUSSION 
530nm IPL: A Therapeutic Alternative for Acne 
Vulgaris 
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6. 530nm IPL: A Therapeutic Alternative for 
Acne Vulgaris 
 
6.1 Clinical Study Discussion 
The clinical aim of this project was to examine the ability of IPL to cause a discernible 
change in acne severity by assessing its effect on inflamed and non-inflamed lesion counts, 
SER and the Leeds scores.   
 
6.1.1 Lesion Counts 
The observed 28% decrease in the number of inflamed lesions was significant despite a 
static Leeds score. The degree of improvement seen in this trial was similar to a blue-light 
study previously done in this Department  (Cardiff University) [52]. Using Clear Light™ 
(Lumenis Ltd., Yokneam, Israel; 407–420 nm; 20 mWcm-2 or 75 Jcm-2) twice weekly for 4 
weeks, Ammad et al. [52] noted a 26% reduction in inflammatory lesions that was 
statistically significant. Of note, they also observed a significant reduction in non-inflamed 
lesions which was not seen in this study.  Of course, the two light sources are not directly 
comparable as they have different action spectra. In a more closely related study, Barikbin 
and colleagues [383] conducted an open split-face trial in 15 Persian females (Fitzpatrick 
skin types II – III) with moderate – severe facial acne.  They aimed to assess whether the 
pulse duration (55 ms and 101 ms) of a 572 nm IPL (Kemedical Hair & Skin IPL, λ= 400 
– 900 nm, Peak λ= 572 nm, 35 J/cm2) affected treatment efficacy. Treatments were 
administered weekly for 5 weeks.  Both pulse durations produced a 30% reduction in 
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inflamed and non-inflamed lesions (p = 0.0003 and p = 0.005 respectively) when assessed 
at week 5.   Though our study did not detect a statistically significant reduction in non-
inflammatory lesions, both studies report very similar percentage improvements in 
inflamed lesion counts, in spite of different treatment sites and baseline severities.  
 
Compared to other studies utilising yellow IPL, this trial is, to some extent, an 
improvement. In a split face trial by Yeung et al. [10], an Asian cohort was treated with 
full-face adapalene and half-face 530–750 nm IPL +/- MAL-PDT. Another cohort reported 
by Chang et al. [14] was treated with full-face benzoyl peroxide and half-face IPL. Neither 
yellow IPL–adapalene nor yellow IPL-benzoyl peroxide as dual therapy gave any 
additional improvement when compared to adapalene or benzoyl peroxide alone. The lack 
of a significant effect after yellow spectrum IPL can be attributed to the co-administration 
of active therapy or to a sufficiently minute clinical effect of IPL that can be masked by 
partially efficacious topical agents.  
 
Conversely, Sami et al. [218] and Choi et al. [181] report improvements of 41% and 66% 
in inflamed lesions, exceeding that noted in this study. Here, patients received a month of 
weekly 550 -1200 nm IPL sessions and inflamed lesions were counted one month after the 
final IPL irradiation [218]. Taking their treatment regimes into account, both of these 
studies report cumulatively higher energy deliveries to the skin either through more 
frequent treatments (Sami et al.) or higher energies (Choi et al.) than those used in this 
trial.  
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6.1.2 Sebum Excretion Rate (SER) 
The 35.9% mean reduction in SER was not significant (p = 0.50). Orringer et al. [219] 
were also unable to objectively find a marked reduction in the SER after yellow light 
irradiation as was the case for Pollock et al. [238], who used a 532 nm light source with 
ALA-PDT to treat 30 cm
2
 areas on the backs of 10 acne patients. The success of 
incoherent red light in significantly reducing the SER [333, 384], with or without ALA-
PDT, suggests that yellow light’s inability to substantially affect the SER may be related to 
its depth of penetration.  
 
Studies have suggested that the relationship between SER and acne severity is not linear. 
Sebum production can be strongly influenced by dihydrotestosterone, a metabolite of 
testosterone through the action of the enzyme 5α reductase (see Chapter 1).  Leyden et al. 
[385] conducted preliminary studies evaluating the sebo-suppressive effects of a 5α-
reductase inhibitor (Compound A). They found that Compound A reduced SER levels by 
45% in normal individuals. A follow-on double-blind randomised clinical trial comparing 
the efficacies of Compound A + minocycline to minocycline alone, did not find a 
statistically significant difference between the two groups [385].  Unfortunately, SER 
levels were not reported for this portion of the study.  Walton et al. [386] measured the 
SER in 20 pairs of identical and fraternal twins. Interestingly, they found that whilst the 
SER was equivalent in identical twins (but not in non-identical twins), the severity of their 
acne did not significantly correlate. Serup [338] also reported that the SER did not 
correlate with acne severity in his cohort of 24 Danish medical students. 
 
A recent publication from Choi et al. [387] attempted to dispel this view. They measured 
the facial casual sebum levels using a Sebumeter® (SM815, C+K, Köln, Germany) in 914 
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Korean acne patients. A significant and positive correlation between sebum casual levels 
and lesion counts (inflamed and non-inflamed) was found. Though significant, the r values 
for inflamed and non-inflamed lesions when measured in the U-zone of the face were r = 
0.120 and r = 0.079 respectively. This study was relatively large suggesting that it was 
sufficiently powered to detect a small but statistically significant difference. Pearson’s 
correlation coefficients (r values) range between +1 and -1. Thus, even though these 
results are intuitive, r values less than ± 0.20 are not considered to show a relationship 
above chance and hence are negligible [371]. Hopefully, investigators will continue to 
study this subject in order to confirm how SER correlates with acne severity.  
 
The authors of a small study (n = 6) published in 1969, Beveridge and Powell [332], 
proposed that while tetracycline does not affect the sebum secretion rate, it alters the 
sebum composition, which may then account for the clinical improvement seen in these 
patients 8 weeks after starting therapy. Powell and Beveridge (1970) [388] published 
another comparative study, which evaluated the differences in SER and sebum 
composition between males with and without acne vulgaris.  As before, they reported that 
the SER did not differ significantly between the two groups but acne subjects had higher 
levels of aliphatic alcohols in their sebum [388].  UVA can alter the composition of skin 
surface lipids by photo-oxidising squalene and producing mono-hydroperoxides, which 
have an uncertain role in pathogenesis [389]. Thus, in responders, it is possible that yellow 
IPL may exert its anti-inflammatory effects by altering the sebum composition, but in the 
absence of definitive studies, this only remains a theory.   
 
These investigations propose a few scenarios about the role of SER in acne pathogenesis 
and clinical efficacy evaluations. SER, though linked to acne pathogenesis may not be 
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directly related to acne severity. Other conditions associated with excessive sebum 
production e.g. Parkinson’s disease, are not clinically associated with acne and, despite the 
same SER levels in identical twins, there is no correlation with acne severity. Rather, 
sebum composition appears to play a significant role in acne pathogenesis and could be the 
true target of light and antibiotic therapies. The modulatory properties of diet and the 
relative ‘linoleic acid deficiency’ proposed as contributors to the onset of inflammatory 
acne support this theory. Alternatively, where light therapy is able to induce a reduction in 
the sebum excretion rate, the accompanying improvement in acne may be a reflection of a 
reduction in the substrate for bacterial fatty acid production. Studies utilising newer, 
refined techniques for sebum assessment are required to clarify this debate. 
 
6.1.3 Leeds Score 
The Leeds scores of our cohort did not reflect a significant improvement in their global 
acne severity. As noted with the earlier Leeds technique (1984) [346] and the Leeds 
Revised Acne Grading System, problems arise when grading patients with large numbers 
of comedones and isolated lesions. This has probably added a significant amount of 
variability to these clinical trial results as the assessors were unable to appreciate a change 
in the depth of the lesions and were not informed of the biopsy scars in order to preserve 
blinding. In fact, Gibson also encountered this problem when comparing clinical and 
photographic methods [340]. 
 
Nonetheless, where blinded assessments showed a deterioration of 9.4% in the Leeds 
score, open assessments did not reveal any improvement over the control area (chest), 
indicating this trial was not significantly disadvantaged by using this technique. It was also 
observed that patients with higher Leeds scores remained relatively worse. Likewise, 
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Leheta et al. [390] surmised that patients with milder acne had more appreciable 
improvement in their acne after six PDL (RegenLite Laser,  585 nm, 350 µs, 7 mm spot, 3 
J/cm
2
) treatments. When compared to either 25% TCA peels or a topical tretinoin and 
benzoyl peroxide combination, Leheta et al. concluded that there was no statistical 
difference between the benefits gained from either modality.   
 
6.1.4 Long-term Efficacy 
For any treatment regime, a major concern is the duration of its efficacy.  In all the studies 
that included an extended follow-up (Sami et al. [218], Goldberg et a.l [230], Elman & 
Lask [240] and Choi et al. [181]), an on-going reduction in inflamed lesion counts 8 weeks 
after the final treatment  was noted. Conversely, Papageorgiou et al. [229] and Santos et al. 
[391] did not.  Though the number of patients followed at the end of this study was too 
small for statistical testing, 79% of these patients maintained or had an improvement in 
their Leeds score (open assessment) 4 weeks after the final IPL session, but by the 3
rd
 
month 75% of the patients had relapsed.  
 
6.1.5 Therapeutic Endpoints for 530nm IPL  
Del Rosso [328] advocates the use of ‘efficacy, tolerability and safety’ as therapeutic 
endpoints for acne rather than ‘clear’ or ‘almost clear’. Assessing tolerability and safety, 
IPL scores highly. The single adverse event in a cohort of 28 patients was a mild skin 
infection caused by the biopsy procedure and not the IPL treatment.  However, regarding 
the main parameter (efficacy), an average of 40% of patients had an improvement in their 
open Leeds score, but only 19% improved when assessed blindly (lesion counts fell by 
28%).  Lee et al.’s letter [392] describes the treatment of 18 patients with facial acne using 
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a 560 nm IPL and 3% liposomal ALA-PDT. When measured a week after the final 
treatment, inflammatory lesion counts fell by 36%, representing a minimal improvement 
on our results particularly because an exogenous photosensitizer was used to augment the 
effect of the IPL. 
 
Whilst Barikbin et al. [383] quoted similar reductions in lesion counts (30%, p= 0.0003)  
to that found in this study, Choi et al. [181] and Sami et al. [218] both used yellow 
spectrum IPL with greater success. They cited reductions in inflamed lesions of 41% (p < 
0.05) and 55% (p < 0.05) respectively. It must be noted however that Sami et al.’s cohort 
received a mean total of 10 irradiations and lesion counts were measured 1 month after 
therapy whereas in Choi et al.’s study, lesion counts were assessed 1 week post-therapy. In 
our study, 79% of patients assessed 1 month after treatment either maintained their 
improvement or continued to improve, suggesting a sustained cutaneous anti-inflammatory 
process.   Pulsed dye lasers (585 and 595 nm) have wide variations in their efficacies. 
They have been ineffective in a non-purpuric mode [219], reduced lesion counts by 49% as 
monotherapy [393] or, boasted efficacies ranging from 38% with ALA-PDT [394] to 84% 
when combined with a 1,450 nm diode laser [247]. These figures suggest that there may be 
a ceiling to yellow-spectrum light’s efficacy in acne, even when administered at high 
intensities. However, in combination with other modalities such as heat energy [240], high 
levels of acne clearance is achievable.  If 530 nm IPL is used as an adjunct to conventional 
therapy, responders may enjoy up to 3 months of remission but also require re-treatment at 
regular intervals to maintain improvement.  
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6.2 Laboratory Study Discussion 
The laboratory arm of this project aimed to determine whether IPL exerted its 
photodynamic and photoimmunologic effects through down-regulation of TLR2, IL-8, 
TNFα, TNFR and up-regulation of IL-10.  At the end of therapy, there was a small (2.6%, 
p < 0.001) but significant decrease in TLR2 expression accompanied by significant 
reductions (17.6%, p = 0.006 and 37.6%, p = 0.017) in TNFα and TNFR expression 
respectively.  The 97% rise in IL-10 expression was sustained in B2 and B3 but this was 
not significant. SYBR green data from another subset of patients also showed a 2-fold but 
insignificant increase in IL-10 expression at the end of therapy.  
 
The increase in mean TLR2 expression in biopsy 2 juxtaposed to the lack of a 
corresponding peak in TNFα expression would suggest that TNFα suppression was not a 
direct result of IPL’s effect on TLR2 signalling. Thus, considering the original hypotheses, 
the ability of IPL (at 530 nm) to reduce inflammatory acne lesions is probably through a 
photo-immunomodulatory rather than a photodynamic mechanism. The correlation 
between percentage changes in lesion counts and TNFα (R2 = 0.253) but not TLR2 
expression, suggests that this theory may be plausible. IL-8 is a cytokine regularly blamed 
for the main inflammatory events noted in acne but it was not significantly affected by IPL 
treatment. This observation offers one potential reason for the nominal efficacy of IPL (at 
530 nm) in inflammatory acne and highlights, within the scope of these results, that IPL 
does not produce blanket immunosuppression. The findings are discussed in more detail 
below, followed by a modified hypothesis for the mechanism of action of IPL and 
suggestions for future study. 
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6.2.1 Effect of 530 nm IPL on TLR2 Expression 
6.2.1.1 Variation in TLR2 Expression between Individuals 
The mean effect of IPL was to reduce TLR2 expression but across the entire cohort there 
were variations in response. Koreck et al. [395] looked at four loss-of-function mutations 
in the TLR2 and TLR4 genes in 63 Caucasian patients with acne and 38 without. In 101 of 
these patients, they found no difference between the frequencies of these mutations in 
these two groups, neither could they link the presence or absence of the mutation with 
clinical severity. No mention is made of statistical advice prior to this study, so the sample 
may have been too small to pronounce a verdict on the entire population of acne sufferers. 
However, they did admit that other unidentified polymorphisms may be responsible for the 
difference between subjects with acne and those without [395].   
 
As highlighted in Chapter 3, numerous molecules and sub-pathways are involved in TLR2 
signalling. Variation in any of the proteins within these complex pathways can explain the 
variability in TLR2 expression after IPL irradiation noted in this study.  Where warranted, 
step-wise investigation of the pathway in suitable models may elucidate other sources of 
polymorphism within the population. 
 
6.2.1.2 TLR2 Up-regulation 
At the 48-hour juncture, TLR2 expression was modestly but significantly increased in our 
study cohort. Is this because IPL is pro-inflammatory or does it generate TLR2 ligands 
from photodynamically destroyed P. acnes? Does IPL uniformly cause an elevation in 
TLR2 expression at the same time point after each treatment and of similar magnitude?  
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Complete explanations for many of these questions remain undefined but probable answers 
can be deduced from evidence currently available in the literature.  
 
6.2.1.3 TLR2 Expression is Inducible – Photothermal Actions of IPL 
It has been previously shown in vitro that the consequence of TLR2 stimulation is a 
reciprocal up-regulation in its expression. An et al. [396] incubated mouse dendritic cells 
with lipopolysaccharides isolated from E. coli strains and they observed that TLR2 as well 
as TLR4 and TLR9 expression were increased when measured 2 hours after exposure to 
LPS. This up-regulation was short lived as its expression started to fall 3 hours after 
exposure, returning to baseline levels 6 hours after LPS exposure [396].  Chang et al. [397] 
performed similar experiments using a human cervical epithelium cell line (HeLa) and 
Trichomonas vaginalis as the ligand. TLR2 expression was up-regulated after exposure to 
T. vaginalis.  In both studies, co-incubation of their chosen cell lines with NF-κB 
(pyrrolidinecarbodithoic, PDTC) and MAPK (PD98059, SB203580) inhibitors 
successfully suppressed TLR2 expression [396, 397].  
 
These observations suggest that TLR2 is inducible, through both NF-κB and MAPK 
pathways. This induction is usually followed by a down-regulation of its expression at a 
later time point. Hence our in vivo finding of TLR2 up-regulation followed by down-
regulation at a later time point after IPL irradiation is in keeping with the literature. But, a 
challenge remains in defining how 530nm IPL might be generating a TLR2 ligand. One 
likely explanation is IPL photothermal induction of heat shock proteins. HSP60 and 
HSP70 are both able to activate the Toll/IL-1 receptor signalling pathway in PBMCs and 
murine macrophages [398-400] so their up-regulation may explain this effect. 
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6.2.1.4 TLR2 Down-regulation without IL-10 Up-regulation 
When assessed one week after the fourth and final IPL irradiation, TLR2 epidermal 
expression was 2.6% (p < 0.001) below that measured at baseline, which was surprisingly 
significant in spite of the small margin. So, is this reduction biologically noteworthy and is 
it related to the reduction in inflammatory lesions?  
 
In the absence of a statistically significant change in IL-10 mRNA expression, it is difficult 
to attribute TLR2 and TNFα suppression to IL-10 up-regulation.  Equally, if TLR2’s pro-
inflammatory pathway was activated by 530 nm IPL, the increased TLR2 expression in B2 
should have been accompanied by a similar increase in IL-8 and TNFα expression but 
TNFα expression remained stable in B2.  
 
Studies involving IL-10 protein assays after UV light irradiation have described an 
increase in IL-10 expression [41, 401].  Barr et al. [401] exposed 71 patients with skin 
types I and II to simulated solar radiation. Protein assays of suction blister fluid taken at 
different time intervals revealed significantly up-regulated IL-10 levels at the 15 hour 
mark coinciding with increases in soluble TNFR, a negative regulator of TNFα signalling 
[401]. Whilst it is understood that the mechanism of action of UV light differs from 530 
nm pulsed light, the expected sequence of IL-10 up-regulation, accompanied by transient 
TNFα up-regulation followed by a significant down regulation of TNFα does not occur in 
our study.  Whilst, the small numbers involved in this study may have impacted on the 
lack of statistical significance obtained for IL-10 expression in this study, it is also possible 
that another mechanism, not identified by these methods, may be responsible for the 
observed anti-inflammatory response. 
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6.2.2 IPL’s Effect on TNFα Expression 
In this study cohort, TNFα expression fell by 17.6% (p = 0.006) when measured a week 
after the final IPL session. This was accompanied by a down-regulation of TNFR by 
37.6% (p = 0.017) in the same cohort of patients. Byun et al. [255] exposed HaCaT cells to 
555-950 nm IPL and found that 48 hours after exposure, TNFα mRNA levels did not 
increase significantly. Thus, the absence of a reciprocal rise in TNFα expression after 
exposure to IPL in biopsy 2 is in keeping with their in vitro findings. 
 
On the other hand, Byun et al. [255] also reported an increase in TNFα protein expression 
as measured by ELISA as well as an increase in IL-10 protein.  Thus, clarification of 
changes in TNFα levels in biopsy 2 could be achieved by extending the experiment to 
include quantification of protein expression through ELISA or western blotting. If this 
showed an increase in TNFα protein expression, patients may experience an initial 
worsening of their acne prior to the later improvement. This study did not evaluate interim 
lesion counts, Leeds scores or record subjective assessments of their acne severity and 
hence this may be an avenue for future study. Alternatively, TNFα’s static expression 
could be multifaceted where IPL activates both stimulatory (via TLR2) and inhibitory (via 
IL-10 and TGFβ1) signalling cascades. 
 
Yellow IPL as an anti-TNF agent, may have potential to prevent and/or reduce acne 
scarring caused by MMP release in addition to its action against inflammation. Any anti-
sebocytic effect is a more distant possibility as we, along with previous investigators, did 
not detect a significant reduction in SER. 
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6.2.3 Transforming Growth Factor-β as the Unidentified Anti-inflammatory 
Mediator 
Earlier (see Chapter 3), TGFβ was identified as a potential IPL-modifiable target. TGFβ is 
a well-known immuno-regulatory molecule implicated in the modulation of TNFα [402], 
toll-like receptor [403] and heat shock protein [404] signalling pathways. Yellow light 
sources such as the pulsed-dye laser [13, 405] and IPL [406] have been shown to increase 
TGFβ expression in the context of acne and photo-rejuvenation. Hence, the results noted in 
this study could be secondary to IPL’s ability to manipulate this molecule.   
 
6.2.3.1 TGFβ and TLR2 
The mechanism by which TGFβ1 regulates TLR2 activity and expression is still being 
studied. TGFβ not only counter-regulates TLR2 by stimulating MyD88 degradation [407] 
but may also be pro-inflammatory [408].  
 
Mikami et al. [403] conducted a series of in vitro and in vivo experiments in a human 
cervical cell line (HeLa) and BALB/c mouse tissues in an attempt to determine whether 
TGFβ receptor stimulation also regulated TLR2 expression. They found that TGFβ1 
positively regulated TLR2 expression via two mechanisms: (i) TGFβ receptor I/ II 
(TGFβR I/II) signalling through Smad3 and Smad4 stimulating the NF-κB pathway and 
(ii) TGFβR signalling suppressing p-38 MAPK signalling, which in turn normally acts by 
suppressing TLR2 transcription [403]. Therefore, 530nm IPL could also indirectly up-
regulate TLR2 expression by initially inducing TGFβ1 [403] accounting for the rise in 
TLR2 mRNA noted in biopsy 2.  
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Unfortunately, effects of TGFβ on TLR2 signalling is far from simple as it depends upon 
the context within which it was triggered and the cell type. In odontoblasts, TGFβ1 
suppresses TLR2 expression [409] and in endometrial tissue, TGFβ1 inhibits neutrophil 
degranulation stimulated by TLR ligand binding [410]. Sumiyoshi et al. [402] tried to 
determine whether TNFα and IFNγ’s pro-inflammatory effects in Th2 cells could be 
antagonised by TGFβ1 supplementation. They found that TGFβ1 was able to suppress pro-
inflammatory cytokine production, especially via Smad3 signalling TGFβ’s stimulatory 
effect on TLR2 expression through p38 MAPK inhibition in cervical epithelial cells as 
described by Mikami et al. [403] also contributes to the confusion, as TGFβ seems to 
antagonise its own up-regulation.  In macrophages, TLR2-dependent IL-10 transcription is 
activated via the p38 MAPK pathway [318] and IL-10 can increase TβRII expression on 
activated T-cells enhancing their responsiveness to TGFβ [411]. Thus, comparisons 
between TGFβ publications have to be restricted to similar cell types to reduce ambiguity 
in their interpretation.  
  
6.2.3.2 TGFβ, Heat Shock Proteins and IPL’s Anti-inflammatory Action 
Using the skin biopsies from this study, a colleague has been examining the effect of IPL 
on all three isoforms of TGFβ (TGFβ1, 2 and 3) and their signalling molecules, Smad1, 2 
and 3 [412]. Thus far, in agreement with the literature [402],  Mohammad Ali et al. [412, 
413] have found that 530 nm IPL significantly increased TGFβ1 via Smad3 signalling but 
appears to have no effect on TGFβ2 or TGFβ3. This up-regulation of TGFβ1 could be 
through a direct mechanism or indirectly via HSP60 induction, based on studies by Zanin-
Zhorov et al. [404]. In their experiments, CD4
+
 CD25
+
 T-reg cells were cultured with 
HSP60, which activated the TLR2 signalling pathway within the T-reg cells, stimulating 
the release of TGFβ and IL-10.  Dermal fibroblasts isolated from human foreskin 
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irradiated with 560 – 1200 nm IPL secreted more TGFβ1 (measured 48 hours after 
irradiation) at higher IPL fluence (72 J/cm
2
) than at 27 J/cm
2
. Through western blotting, it 
was observed that steadily increasing fluence caused significant inhibition of MAPK 
phosphorylation [414]. This corresponded with the increase in TGFβ1 secretion at higher 
fluence.  
 
In a study by Huang et al. [414], use of a MAPK/JNK inhibitor (SP600125) resulted in a 
35.6% reduction in TGFβ1 secretion and a 3-fold increase in MMP-1 secretion whereas, 
use of a p38-MAPK inhibitor (SB203580) caused a 2.6 fold increase (p < 0.05) in TGFβ1 
secretion[414]. Overall, these results suggest that activation of the p38-MAPK pathway by 
IPL irradiation is partially responsible for increased TGFβ1 secretion [415]. 
 
Our results demonstrated up-regulation of TLR2 48 hours after IPL irradiation at an 
average fluence of 40 J/cm
2
. Hence IPL may preferentially activate the TLR2 – MAPK 
signalling pathway rather than the TLR2 – NF-κB pathway leading to TGFβ1 up-
regulation.  This theory may account for the lack of a significant increase in inflammatory 
cytokine mRNA transcripts despite an increase in TLR2 expression.  
 
 6.2.4 Summary 
Based on the arguments made above, the laboratory findings from this study may be 
explained as follows: 
 
1. The initial up-regulation of TLR2 could be a result of IPL’s ability to induce HSP 60, 
HSP70 and possibly other HSPs.  The transient peak may represent the natural history 
of TLR2 expression when induced by light irradiation. 
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2. TLR2 induction does not seem to be related to photodynamic destruction of P. acnes 
but objective studies would be required to confirm this. 
 
3. The down-regulation of TLR2 noted 7 days after the fourth and final IPL session is not 
associated with IPL’s anti-inflammatory activity.  
 
4. The absence of IL-10 induction could be due to the chosen technique used to detect its 
up-regulation. Nonetheless, the absence of meaningful changes in IL-10 expression 
could be one of the underlying mechanisms for the limited efficacy noted in this trial. 
 
5. Initial stability in TNFα mRNA levels could be artificial and may be associated with 
increased protein expression without an increase in transcription. Alternatively, the 
observed stability could be secondary to simultaneous activation by TLR2 and 
suppression by TGFβ1.  
 
6. TGFβ1 has pleiotropic properties. Based on the quoted studies, TGFβ has been shown 
to induce and suppress TLR2 expression. In complementary but separate studies on 
this cohort, TGFβ1 is significantly up-regulated. The observed increase in TGFβ1 post-
IPL is the most probable candidate for the observed reduction in TLR2 and TNFα 
expression at the end of therapy.  
 
7. IPL’s ability to suppress TNFα transcription may be the reason for the reduction in 
inflamed lesions. Through further investigation, IPL parameters may be manipulated to 
improve seborrhoea and scarring by extending its anti-TNFα properties.  
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6.2.5 IPL’s Mechanism of Action: An Evolving Hypothesis  
These results show that 530 nm IPL irradiation may significantly reduce TNFα and TLR2 
expression in an acne patient.  The molecules inciting these changes were not identified in 
the experiments outlined but are theorised to involve HSPs and TGFβ1, thus an updated 
view of IPL’s theorised mechanism of action is given below. It is described in three stages, 
similar to the description of the evolution of an inflammatory acne papule in Chapter 1.  
 
6.2.5.1 Initiation 
In an acne prone patient, IPL irradiation of the epidermis leads to induction of heat shock 
proteins in the keratinocytes and dendritic cells. These HSPs bind to TLR2, already up-
regulated in response to P. acnes moieties. HSP binding to TLR2 activates both the NF-κB 
and MAPK pathways, especially the p38 MAPK pathway. The p38 MAPK pathway is the 
preferred route for TLR2’s anti-inflammatory activity inducing TGFβ1 and IL-10 secretion 
(though not shown to be significantly up-regulated). This might explain the suppression of 
the expected TNFα up-regulation in response to TLR2 activation. HSPs may also induce 
TGFβ1 secretion directly through an undefined mechanism.  
 
6.2.5.2 Progression 
Within 4 - 48 hours, HSP activation of the TLR2-MAPK signalling pathway results in a 
positive feedback mechanism, further increasing TLR2 expression – protecting the skin 
against further injury. At this juncture, TGFβ1 protein expression is maximal within the 
epidermis and Langerhans cells. TGFβ1 binds to its receptor activating the Smad3 and 
MAPK pathways. Through the Smad pathway, NF-κB, the pro-inflammatory arm of TLR2 
signalling is inhibited. A possible route is through binding of Smad3 to the AP-1 promoter 
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region, a transcription factor shared by TGFβ, TLR2 and TNFα.  Simultaneous stimulation 
the NF-κB pathway maintains TNFα transcription, reflected as stable expression levels. 
However, HSPs also stimulate the JNK-MAPK pathway, limiting TGFβ induction. This 
results in an attenuation of TGFβ1’s anti-inflammatory properties. But, where TGFβ 
induction is sufficiently high and TNFα inhibition is maximal, inflamed acne papules are 
pushed towards their resolution phase clinically manifested as a reduction in inflamed 
lesions.  Several treatments are required to achieve this effect with a suitable treatment-
free period in between to prevent significant tissue injury and a pro-inflammatory, pro-
apoptotic response.  
 
6.2.5.3 Resolution 
Days after irradiation, TLR2 and TGFβ signalling is abolished through de-phosphorylation 
of the kinases within their pathways, proteasomal degradation of activated factors and 
removal of their transcription factors including p38 MAPK, Smad3 and NF-κB from the 
nucleus. Thus, TLR2 and TGFβ1 expression return to baseline levels. Suppression of the 
inflammatory cascade within keratinocytes and other inflammatory cells, results in a 
sustained reduction of TNFα transcription and its receptor, TNFR.  
 
The modified hypothesis is summarised in Figure 6.1. The details of the signalling 
pathways, NF-κB, MAPK and Smad, are omitted for clarity.   
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Figure 6.1: Updated Hypotheses 
for IPL’s Mechanism of Action in 
Acne.  IPL may stimulate HSP 
release from keratinocytes, thus 
activating TLR2 signalling and TLR2 
expression. TGFβ1 is also up-
regulated by HSPs primarily through 
the p38 MAPKs. TGFβ1 via Smad3, 
inhibits NF-κB nuclear localisation, 
inhibiting TNFα expression. Through 
p38 MAPK, TGFβ1 later suppresses 
TLR2 expression. 
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6.3 Future Studies 
Although this study only showed partial benefit from yellow IPL, further investigation into 
the use of IPL as an anti-acne agent is warranted.  Any future studies should aim to clarify 
the questions raised by this project, especially with respect to the IPL’s hypothesised 
mechanisms of action as suggested below:  
 
1. Lee et al.’s study [392] suggests that the addition of a photosensitizer augments the 
efficacy of 560 nm IPL. Thus, an extension to this study would be to determine 
whether the addition of a photosensitizer (e.g. 5-ALA, liposomal ALA or MAL) 
would increase the efficacy 530 nm IPL.  
 
2. The possibility of IPL altering sebum composition was discussed. Assessment 
would require simultaneous quantitative and qualitative sebum analysis which is 
possible using the Sebutape® method [146, 389, 416]. Robosky et al. [417] 
promoted the use of nuclear magnetic resonance imaging in favour of high 
performance liquid chromatography for sebum composition analysis due to its 
higher sensitivity.  
 
3. There was doubt whether IPL was able to photodynamically destroy P. acnes. 
Therefore, measuring the effect of 530 nm IPL on P. acnes using methods such as 
fluorescence photography [239, 418] and bacterial colony counts. Currently, there 
is some controversy regarding whether the follicular orange-red fluorescence 
observed represents a sebaceous component or coproporphyrin products from P. 
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acnes [68, 419]. This uncertainty advocates a heavier reliance on reproducible 
high-yield techniques to isolate P. acnes for colony counting.   
 
4. Laboratory studies showed that TLR2 was initially up-regulated without a 
significant change in IL-10 or IL-8 cytokines. However, TLR2 and cytokine 
expression were measured using two different techniques. Thus, the inability to 
confirm the absence of IL-10 up-regulation and IL-8 down-regulation at the protein 
level, dictates that quantification of IL-10 and IL-8 protein expression in response 
to IPL irradiation is paramount.  
 
5. If these cytokines are significantly altered, then IPL-induced reduction in TLR2 
expression may have a greater impact on acne resolution than illustrated in these 
experiments. Later, possibly through in vitro block-and-replacement studies, using 
inhibitors of the TLR2 pathway may help to clarify whether IPL’s modulation of 
the TLR2 pathway is essential for its anti-inflammatory activity. If it is involved, is 
it via the NF-κB and/or the MAPK signalling pathways? The updated hypothesis 
proposes that the MAPK pathway is more heavily involved in IPL’s anti-
inflammatory activity. Use of specific NF-κB and MAPK inhibitors could help to 
locate its preferred signalling pathway i.e. IKK, p38, JNK or ERK. 
 
6. In a similar manner, strong circumstantial evidence suggests that TGFβ1 up-
regulation is crucial for IPL’s anti-inflammatory actions, but this remains unproven 
as TGFβ1 up-regulation may be contributing solely to its mechanism of action in 
photo-rejuvenation. Studies confirming the dependence of IPL’s anti-inflammatory 
actions (in acne) on TGFβ1, possibly through the use of TGFβ signalling inhibitors, 
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measurement of downstream cytokines, Smad nuclear localisation and acne 
models, would aid in this  clarifying  this question.  
 
7. Heat shock proteins were hypothesised to be initiators of IPL’s anti-inflammatory 
response through the MAPK pathway. Thus, studies to confirm whether heat shock 
proteins are induced by IPL in acne patients would be useful. Following 
clarification, do these HSPs have a direct role in regulating TLR2, TNFα and 
TGFβ1 expression in acne? Does this extend to the control of TNFR and TGFβ 
receptor expression? These molecules have already been studied in acne patients, 
and indeed, in our study cohort. Therefore, immunohistochemical techniques, 
western blotting and DNA-shift assays (to assess nuclear translocation) are 
techniques that could be used to address these questions. 
 
8. Isotretinoin can inhibit TNFα expression in cultured sebocytes [304]. In this study, 
IPL was shown to have anti-TNFα properties, and caused a 35% reduction (p > 
0.05) in the SER.  Thus, it would be interesting to determine whether IPL also 
reduces TNFα expression in sebaceous glands.   
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6.4 530nm IPL’s Fate in Acne Management 
Inevitably, many questions about acne remain. Though unfailingly common, why does 
acne affect some people and not others? Why does it persist until middle age in a minority 
of patients? Why do some people develop scars and others don’t? Is acne a constellation of 
diseases rather than a single entity? Why is P. acnes so heavily implicated in acne vulgaris 
in favour of other skin commensals [50, 420]?  A reduction in bacterial counts is not 
directly correlated with treatment efficacy and the development of an attenuated P. acnes 
vaccine [421] has not gained popularity.  As shown in this trial and several others [219, 
332, 422], a reduction in the sebum excretion rate (SER) is not necessarily associated with 
a clinical improvement in acne. Even with isotretinoin, SER returns to baseline levels after 
a few months but the anti-acne effect is still sustained [423].  Androgenic suppression 
reduces SER, but as a monotherapy it is not very useful in acne [385].  Broad spectrum 
anti-inflammatories like prednisolone tend to provide only transient relief and encourage 
acneiform lesions. Even genetic susceptibility provides only partial evidence as identical 
twins with equivalent SERs can have varying acne severities [386].   
 
In light of the partial successes in treating acne, 530 nm IPL was proposed as a possible 
therapeutic alternative, sufficiently unexplored to warrant further investigation into its 
likely molecular mechanisms of action.  In this thesis, the laboratory studies described 
suggest that IPL is anti-inflammatory as it was able to down-regulate TLR2 and TNFα 
expression. However, we also observed counter-productive properties of IPL such as an 
inability to suppress IL-8 expression and significantly induce IL-10. The absence of a 
significant involvement of these two cytokines suggests that other signalling pathways are 
responsible for the observed effects on TNFα and TLR2. Heat shock proteins and TGFβ1 
were offered as reasonable candidates that primarily utilised the anti-inflammatory MAP 
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kinase pathways rather than the pro-inflammatory NF-κB pathways.  Their signalling 
pathways are intertwined, complex and not likely to be clarified in a single set of simple 
experiments.  Thus, each stage probably needs to be re-examined separately to assess their 
relevance and importance in IPL’s photo-immunomodulatory functions.  
 
Considering the implications of translational medicine’s ‘bench-to-bedside’ ethos, the 
physician and the patient are primarily concerned about IPL’s clinical efficacy. Here, it 
seems reasonable to conclude that the modest improvements seen with yellow IPL as 
monotherapy reflect that it is only marginally helpful for inflammatory acne. Webster’s 
commentary [424] on a randomised trial assessing the efficacy of PDL in acne [393] 
expressed concern that the observed clinical improvement, though not insignificant, would 
disappoint many patients [424].  Likewise, it has not been demonstrated that yellow IPL is 
a viable treatment option as monotherapy. If presented as an alternative to patients, 
suitable candidates should have mild inflammatory acne, have exhausted other 
conventional forms of treatment and/or use it in combination with an accepted anti-acne 
agent.  Thus far, advice about long-term remission will have to be confined to a maximum 
of 3 months until further studies are done to confirm or disprove this. Unlike UVA and 
UVB [169, 425], no long-term sequelae from the repeated irradiations with IPL or other 
visible light sources have been reported. Nonetheless, the frequency of repeated therapy 
should be undertaken carefully with a clear management strategy and a defined end-point. 
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Patient Information Sheet 
 
An analysis of the action of intense pulsed light on inflammatory 
 markers and sebaceous gland function in mild to moderate acne  
vulgaris lesions 
 
Dear Sir or Madam, 
 
You are being invited to take part in a research study to find out how intense pulsed light 
(IPL) clears ‘spots’ (called ‘acne’). Before you decide, it is important for you to understand 
why the research is being done and what it will involve.  Take the time to read the following 
information carefully and discuss it with others such as your family or family doctor. If you 
wish, Dr. Marisa Taylor & Sister Anne Thomas, who are both involved in this project, would 
be happy to speak to you. Their telephone numbers and email addresses are written on the 
last page of this leaflet.  
 
Thank you for taking the time to read this.  
 
What is Intense Pulsed Light (IPL)? 
The visible or ‘white’ light that we see consists of all the colours of the rainbow.  Laser 
machines produce only one colour of light. Intense Pulsed Light (IPL) is NOT a laser 
machine.  Its light is made up of different colours or shades of the same colour of light.  This 
is referred to as being ‘broad-spectrum’. This light is produced in short bursts or pulses 
hence the term “intense pulsed light’’. 
IPL acts on (i.e. ‘targets’) specific things in the skin like pigments, chemicals and collagen. 
Depending on the machine settings, IPL can target the dark pigment found in hair, and 
hence it is useful in hair removal.  It can also target the red pigment in blood and therefore 
can help to reduce the appearance of red spots and veins on the skin. 
IPL machines can give out blue, green, yellow and red light. The machine’s settings can be 
changed to produce only the colours that are most beneficial to you. In acne, blue light acts 
on chemicals called porphyrins. These porphyrins are made by the bacteria that cause acne. 
Through blue light’s action of these porphyrins, the bacteria are either weakened or killed.  
Red light can go deeper in the skin than blue light, and in some studies it has been shown to 
reduce the number and size of the oil-producing glands. These oil-glands are also involved 
in causing acne.  
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It is important to note that unlike sunlight, IPL machines have filters that remove ultraviolet 
(UV) light. Therefore the bad effects of UV light that cause skin wrinkling and cancer are 
removed.   
What is the purpose of the study? 
Over the past few years, doctors, mostly in Europe and the United States, have said that 
light therapy is helpful in treating ‘spots’ -  which are also called ‘acne’.  Also, studies 
looking at the skin cells affected by acne have said that there are high levels of substances 
within and around the cells that cause the redness, pain and oiliness associated with acne.  
However, there is not much known about how IPL acts on these substances to bring about 
the changes that we see on the skin.  
 
Why have I been chosen? 
You have been chosen because you have been identified by your doctor as having acne on 
your back. Or, because you answered our advertisement, we have sent more information to 
you about this project. 
 
Do I have to take part in the study?  
Participation in this study is entirely up to you.  If you decide to take part, you will be given 
this information sheet to keep and asked to sign a consent form. However, if for any 
reason, you would like to withdraw from the study, after agreeing to join, you are free to 
do so at any time. Withdrawal will not affect your standard of care or ability to receive 
treatment from any hospital or your GP. 
 
Reports from this study will not contain any personally identifiable information about you, 
so it will remain completely confidential. 
 
 
What will happen to me during this study? 
We expect you to be involved in this study for no longer than 9 weeks.  
 
The light (IPL) treatments may cause a mild stinging or burning sensation. Some say that it 
feels similar to the sensation of an elastic band being snapped against the skin. During the 
treatment, we will place a cooling gel on skin that is going to be treated before giving the 
light. This should help to reduce any discomfort you may experience. Only your back will be 
treated. 
 
Your acne or ‘spots’ are caused by different cells and chemicals. These cells and chemicals 
cause blackheads and red and painful bumps to come up.  It is possible to see these cells 
and chemicals under the microscope. We are going to look to see if treating your spots with 
IPL makes any difference as early as one day after your treatment starts. Also, we will look 
at these cells again at the end of treatment.  
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A small sample of skin, called a ‘biopsy’, will be taken from your back before, during and 
after your IPL treatments. The area will be fully numbed before the biopsies are taken and 
dressed.  This procedure is usually quick and almost pain-free. You should not have any pain 
after the pain-killer has worn off.   
 
After it has fully healed, you may find it has left a small scar that does not tan. Please note 
that 3 biopsies will be taken over the duration of this study. 
 
There is a simple diagram and notes below to help us explain to you in what order  
things will happen and how long they are expected to take.  
 
 
 DAY 2:  Baseline tests  
 Informed consent obtained 
 Medical history completed 
 Photographs   
 Oiliness of back 
 Biopsy from back  (#1) 
 Appointment for treatment given 
 
Acne on BACK 
DAY 1     
 Medical history taking to see if you can 
take part in this study 
 Date given for initial appointment  
 Take home information sheet to decide  
 
IPL GROUP   (1 HOUR) 
 Light treatment once every 2 weeks for a total of 4 
treatments 
 Biopsy ( # 2)  2 - 3 days after 1st  IPL treatment 
 Week 9:  
o Repeat photos, test for oiliness & skin 
biopsy (# 3). 
 
 (6 visits over 9 weeks) 
If you agree to participate in the study 
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What do I have to do? 
Please protect your back from getting tanned while you are helping us in this study. You can 
do this easily by wearing a shirt that covers your back during the day time and staying out 
of direct sunlight when possible. Extra measures include wearing a sunscreen formula that 
says ‘non-comedogenic’ and has a sun protection factor (SPF) at least 15 to your back 
before going out in the sun.  
 
Being in the sun or on a sunbed causes your skin to produce more pigment, which we 
call a ‘tan’. Also, the pigments in sun-tanning lotions leave extra pigment in your skin.  
As said before, IPL works by ‘targeting’ pigments in and on the skin.  Hence, IPL 
treatment of your skin while you have a deep tan may result in much worse side-
effects e.g.  a bad ‘sun-burn’ effect, blisters, darkening or lightening of the skin that 
was treated. Therefore, please do not sunbathe while you are helping us in this study, 
even if you are wearing a sun protection cream. 
 
Certain medications may cause you to be more sensitive to light, which can affect your 
response to the treatments used in this study. Therefore, please make us aware of any 
medications or herbal supplements that you are currently taking and any that you might be 
prescribed during the course of your treatments 
 
 
What do I have to do after the biopsy has been taken? 
After your biopsies are taken, please keep the dressing on and keep the area dry for 24 
hours.  A separate information sheet about how to care of your biopsy site will given to 
you. Sometimes a stitch may be needed after the biopsy is taken. If you do get one, please 
have it removed in 7 to 10 days at your GP’s office. 
 
.  
What are the alternatives for treatment? 
There are many treatments that are now available from your local pharmacy or through 
your doctor.  If you are using creams such as benzoyl peroxide, azelaic acid, nicotinamide 
on your face for your spots you may continue to do so. If you are on tablets for your acne 
e.g. minocycline we will ask you to wait until these have worn out of your system before 
entering you into this study.  
 
Please do not use any medication or medicated soaps on your back, unless we have 
prescribed it for you. If you are given treatment for your skin e.g. steroids or antibiotics to 
be taken by mouth by another doctor, please tell us about it as soon as possible. This is so 
that we can decide if it affects your IPL treatments. We may be able to suggest a suitable 
alternative for that medication while you are helping in this study.  
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More detailed information on acne and its treatment is available on the British Skin 
Foundation’s website at: http://www.britishskinfoundation.org.uk/standard.aspx?id=208  
 
What are the possible benefits of taking part? 
Your acne may get better. IPL is also used to help sun-damaged skin appear younger and 
more even-toned, with a smoother texture.  Therefore, you might or might not receive 
some of these benefits. Also, it is hoped that results from this study will help us to better 
understand the benefits (or otherwise) of this type of treatment. Therefore in the future, 
you will help doctors and patients to decide if this is a good treatment option for them 
based on our findings. 
 
You will not be expected to pay for the special investigations required for this study. Your 
IPL treatments will be provided at no cost to you throughout the period of the study. You 
will be paid a flat fee to cover the cost of transportation to see us.  
 
You will be given a form to complete for our records. This money will be paid to you by the 
end of study.  
 
What are the side-effects of any treatment received when taking part?  
For IPL, many patients experience little more than warmth, burning or tingling during 
treatment. Other effects include mild to moderate pain, redness and mild swelling of the 
area for up to a week. Especially in darker-skinned individuals, temporary darkening of the 
treated area has been noted. Uncommonly, some have said that their acne worsened and 
the area became infected.  
 
The biopsy may be painful, get infected or heal with an enlarged scar (‘keloid’).  However, if 
the area is taken care of properly, these complications are unusual. If you have a tendency 
to get keloids, please let us know as it would not be in your best interests to participate in 
this study. 
 
Contact names and numbers are listed below if you are concerned in any way or have an 
emergency related to this study. 
 
What if I get pregnant or is there anything else I should know? 
If you are a female of child-bearing age, you may be asked to have a pregnancy test before 
taking part to exclude the possibility of pregnancy. Women who can become pregnant must 
consistently use effective birth control during the course of their treatment. Please use 
methods such as condoms or a non-hormonal intrauterine device, rather than hormonal 
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methods such as the pill or implants beneath the skin, since the hormones in them can 
affect the results of this study.  
 
It is very unlikely that IPL treatments are harmful to the unborn child, but if you become 
pregnant while in this study, please inform us as soon as possible using the contact 
information below. Likewise, it is highly unlikely that this treatment will have any negative 
effect on a man’s sperm causing damage to a foetus. 
 
Due to the non-invasive nature of this treatment, it should not affect your life or private 
medical insurance. However, you should check with your provider to make sure that 
assisting us with this study does not affect your coverage. 
If we discover a condition of which you were previously unaware, we will inform your GP 
and re-assess your ability to participate in this study. 
 
 
What if new information becomes available? 
Sometimes during the course of a research project, new information becomes available 
about the treatment being studied. If this affects the study, your research doctor will tell 
you about it and discuss with you whether you can/ want to continue in the study. If you 
decide to continue in the study, you will be asked to sign an updated consent form.  
 
 
What happens when the research study stops? 
Unfortunately, IPL is offered in Europe and the United States for acne, but is not yet 
available on the NHS in the UK. Therefore it is not available to public patients on the NHS.  If 
you require further help for your acne after the end of the study, please return to your 
usual GP or dermatologist. 
 
 
What if something goes wrong? 
If you have a complaint about the way you have been dealt with by a member of staff, 
please inform the investigators listed below. Your complaint will be investigated and dealt 
with according to standard disciplinary proceedings.  
 
In the event of an emergency or other concerns related to this study, please use the contact 
details below. 
 
If you are harmed by taking part in this project, there are no special compensation 
arrangements. If you are harmed by someone’s negligence, then you may have grounds for 
legal action but you may have to pay for it. Regardless of this, if you wish to complain, or 
have any concerns about any aspect of the way you have been approached or treated 
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during the course of this study, the normal National Health Service complaints mechanisms 
should be available to you.  
 
Will my taking part in this study be kept confidential? 
All the information that is collected about you during the course of this research will be 
kept strictly confidential.  
 
Only staff members directly involved in your care will have access to it and these will be 
secured in a locked room within the department. Your files will be identified only by your 
study number and gender so that you cannot be recognised from it. Your GP would 
probably like to know about your participation in this study, but we will inform them only if 
you give us your permission for this to be done and your GPs contact information. 
 
What about my photographs?  
These will be stored on a secure laptop owned by Cardiff University, kept in the 
Dermatology Department that is accessible only to the members of the study team. A back-
up copy will also be held on the University Hospital of Wales’ FotoWeb site in a password 
protected area – this means that only special members of the study team will have a 
password allowing them to access this site.  Of course, since it is your back, it is very 
unlikely that anyone would be able to identify you from the picture. 
 
 
What will happen to the results of this study? 
The results of this study will be published in reputable medical journals and in an academic 
thesis. The results will not contain any personally identifiable information about you.  
Due to the nature of this study, we may use your photographs to illustrate the outcomes of 
your treatment in these publications and for teaching purposes. We will not use them 
without your permission. Therefore, you will be asked to give your consent for this 
separately. 
 
 
Who is organising and funding the research? 
Cardiff University, through the Department of Dermatology, is sponsoring and funding 
 this study.  Your doctor is not being paid for including you in this study. 
 
 
Who has reviewed the study? 
To ensure your safety and that the highest research standards are being met, the Cardiff & 
Vale Research & Development Committee and the South East Wales Research Ethics 
Committee have reviewed this study’s protocol and information sheet. They are satisfied 
that they are in accordance with the latest version of the ethical principles for human 
research.  
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Contacts for Further Information 
If you have any queries, or experience injuries or adverse events related to this study please 
contact any of the persons below during working hours: 
 
Professor Andrew Finlay (Principal Investigator) 
Work: (0) 2920 742615  Email: FinlayAY@cardiff.ac.uk 
 
Dr. Maria Gonzalez (Academic Supervisor)   
Work: (0) 2920 744398    Email: gonzalezml@cardiff.ac.uk 
 
Sister Anne Thomas (Research Sister) 
Work: (0) 2920 742672   Email: thomasag1@Cardiff.ac.uk 
 
Dr. Marisa Taylor (Project Coordinator)  
Work: (0)2920 745876   Mobile: 07722502563 (for emergencies) 
 Email: taylorm4@cardiff .ac.uk 
 
 
Dermatology Department 
3rd Floor Glamorgan House 
University Hospital of Wales 
Heath, Cardiff 
CF14 4XN 
Fax: (0) 2920 744312 
 
 
Remember, you will get a copy of this information sheet and consent form to keep. Thank 
you again for agreeing to help with this study. 
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Consent Form 
CONSENT FORM 
 
 
 
 
 
 
Title of Project: An analysis of the action of intense pulsed  
light on inflammatory markers and sebaceous gland function 
in mild to moderate acne vulgaris lesions 
 
Name of Researchers: Prof. Andrew Finlay, Dr. Maria Gonzalez,  
Dr. Rebecca Porter, Dr. Marisa Taylor 
 
                                                                                                                        Please initial box 
 
1. I confirm that I have read and understand the information sheet dated April 14, 
2008, Version 2 for the above study and have had the opportunity to ask 
questions.   
 
2. I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving a reason. My legal rights and medical care will not be 
affected. 
 
3. I understand that sections of any of my medical notes may be looked at by those 
named above or from regulatory authorities where it is relevant to my taking part 
in research. I give permission for these individuals to have access to my records.     
                   
4. I agree to take part in the above study. 
 
 
 
 
 
CANDIDATE  
NUMBER 
 PATIENT D.O.B (dd/mmm/yyyy) 
0            
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5. I agree to my GP or family doctor being informed that I am taking part in this 
study. 
 
6. I agree for my photographs to be taken and stored as outlined in this patient 
information sheet 
 
 
7. I agree for my photographs to be used in medical publications and for teaching 
purposes.             
 
 
________________________ ____________________ 
Name of Patient Signature  Date 
 
 
_________________________ ____________________ 
Name of Person taking consent Signature  Date 
(if different from researcher) 
 
 
_________________________ ____________________ 
Researcher                                              Signature  Date 
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FURTHER CONSENT FOR ANALYSIS OF SKIN BIOPSIES 
                                                                                                                       Please initial box 
 
1. I consent to a skin biopsy for the purpose of this research study.  
 
2. I consent to the following tests being done on my biopsy samples. I understand 
that the results will be used mainly for the purpose of the current study, but my 
doctors may use these results in another study. 
 
a. Inflammatory markers & cytokines including but not limited to: MMP-1, 
IL-8, β-defensin 2   
 
b. Sebum markers including but not limited to: Scd, cEPB 
 
c. Inflammatory cells including but not limited to: neutrophils, macrophages, 
lymphocytes 
 
3. I consent for any remaining skin samples to be stored securely in the Dermatology 
Laboratory, University Hospital of Wales, Cardiff for future tests as detailed 
above or mentioned below. 
 
4.  Please initial to tests you consent to on your skin from the list below: 
a. I agree to my sample being used in case more unforeseeable tests are 
required in future for this research, depending on the results of my current 
biopsy results e.g. additional inflammatory markers 
 
b. I would like to be contacted before further tests as mentioned in 4a are 
done on the stored sample for research purposes. 
 
c. I consent to further tests being done on the stored sample without being 
contacted.  
 
d. I agree that the laboratory can anonymise my stored sample for future 
research and the monitoring of the quality of the results. I understand that 
these results may not have any direct benefit in the evaluation of my 
disease.            
 
________________________ ____________________ 
Name of Patient Signature  Date 
_________________________ ____________________ 
Name of Person taking consent Signature  Date 
(if different from researcher) 
_________________________ ____________________ 
Researcher                                              Signature  Date 
 
 
 
 
 
 
 
 
 
 
 209 
 
Advertisement 
 
Do you have a problem with spots (also called ‘acne’) on your back?  Do you have 
problems getting your creams onto your back? Or maybe you’re not keen on using 
creams and tablets for your spots.  Would you like to try something different?  If so, 
you may wish to think about taking part in a study which aims to improve our 
understanding of how a light treatment, called intense pulsed light, works to get rid 
of spots. Intense pulsed light has been used extensively in Europe and the United 
States to treat acne, but is not currently available through the National Health Service 
(NHS). 
 
ALL participants’ backs will be treated with this new light treatment, free of cost.  
This research project will take place at the Department of Dermatology, University 
Hospital of Wales.   
 
 
For more information please call or write to: 
Dr. Marisa Taylor  
Study Coordinator 
Department of Dermatology, 3rd Floor Glamorgan House 
School of Medicine, Heath Park, Cardiff University, CF14 4XN 
Tel: (0)29 2074 5876   Fax: (0)29 2074 4312 
Email: TaylorM4@cf.ac.uk 
 
OR 
 
Sister Anne Thomas  
Research Sister 
Department of Dermatology, 3
rd
 Floor Glamorgan House 
School of Medicine, Heath Park, Cardiff University, CF14 4XN 
Tel: (0)29 2074 2672   Fax: (0)29 2074 4312 
Email: ThomasAG1@cardiff.ac.uk 
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Questions in Online Questionnaire 
 
1. Email address 
2. Full Name 
3. Address and Postcode 
4. Do you have acne on your back? 
5. Have you read the patient information sheet? 
6. Skin type: How easily do you tan? 
a. I burn and do not tan 
b. I burn first and  tan after 
c. I tan easily and burn sometimes 
d. I tan easily and  burn rarely 
e. I  tan and do not burn 
7. Have you had IPL treatments before? 
a. If so, when? 
8. Do you have eczema? 
a. Where? 
9. Do you have any other medical conditions? 
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Appendix 2  
 
 
 Summary of Clinical Studies of Visible Incoherent Light in Acne 
 Leeds Revised Acne Grading System (back) 
 UHW Medical Photography Protocol for Acne Study 
 Leeds Assessment Data (Blinded) 
 Excel Sheet with Raw Clinical Data 
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Summary of Clinical Studies of Visible Incoherent Light in Acne 
Table 2:  The Use of Blue Light in Acne: A Summary 
KEY: * - ‘Patient features’ listed as: average age, skin type (if given), acne severity (if given), site (if given); § - number completed study / number enrolled 
(if given); contrlld – controlled; F/U – follow-up; INF – inflammatory; NI – non-inflammatory; n.s. – not significant; PIH – post-inflammatory 
hyperpigmentation; R – randomised; S/B – single blind; S/F – split face; tx – treatment; uncontrlld – uncontrolled; wks – weeks ↑- increase; ↓ - decrease; ↔ - 
no change; ♀ - female ; ♂ - male 
 
 
AUTHOR, 
REFERENCE  
PATIENT  
FEATURES* 
N =  
§
 
STUDY 
TYPE 
LIGHT SOURCE 
(S) 
IRRADIATION 
VALUES 
REGIME 
STUDY 
DURATION 
FINDINGS 
BLUE LIGHT        
Kawada et al. J 
Dermatol Sci 
2002. 30: 129-
135.  
N= 26/30 
 
22 yr 
27 ♀, 3 ♂ 
 
Mild – mod 
acne 
 
Face   &/or 
back 
Open 
Clearlight ™ 
 
407- 420 nm 
90 mW/cm
2
, 
 
20 x 20 cm
2
 
Bi-weekly 
x 5 wks 
9 weeks 
At week 5: 
6/30 no change or worse acne grade 
INF: (papules + pustules) mean ↓ 71.3% 
NI: ↓57.8% 
Total counts: ↓64% 
 
1 month post-tx in 17/30 patients: 
Total counts:  ↑6% 
Ammad et al. J 
Cosmet 
Dermatol 2008. 
7: 180-188  
 
N= 21 
 
Mild - Mod 
Face 
Single-blind 
uncontrlld 
 
 
Clearlight 
 
415 - 425 nm, 
 
Peak emission 
420 nm 
 
 
70 -90 W/cm
2
 
 
20x 20 cm area 
 
Time: 14 min 
 
 
Bi-weekly 
x 4 wks 
 
4 weeks 
At week 4: 
Acne grade: ↓ 1.64 ± 1.19 to 1.35 ± 1.28 (*p= 
0.001)  17.7% 
 
INF: 47.71±26.97 to 35.33±28.63 (*p=0.001) 
26.0% 
 
NI:  23.86 ± 23.42 to 19.43 ± 24.15 (p=0.06) 
18.6% 
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AUTHOR, 
REFERENCE  
PATIENT  
FEATURES* 
N =  
§
 
STUDY 
TYPE 
LIGHT SOURCE 
(S) 
IRRADIATION 
VALUES 
REGIME 
STUDY 
DURATION 
FINDINGS 
DLQI : 6.1± 4.17 to 4.0 ± 3.24 (*p=0.001) 
 
P. acnes colony count change n.s. 
Elman et al.  J 
Cosmet Laser 
Ther 2003. 5: 
111-117  
3 trials: 
10, 13  & 23 
recruits 
1. 
S/F dose-
response 
study (10) 
2. Full-face 
open trial 
(13) 
 
3. S/F 
double -
blind 
contrlld 
study (23) 
Clearlight 
 
Narrow band 
420 nm 
8 -15 min 
Bi-weekly 
x 4 wks 
 
12 weeks 
Study 1, week 4: no difference between 8 min and 
12 min irradiation times 
 
Study 2 (full-face open trial): 
Week 4 INF: 77% responded, 59% 
Week 8 INF: 92% responded, 81% 
 
Study 3 (S/F blinded trial): 
Week 4 INF:  mean  60% and 30% for control 
side. 
Steady  at wks 2 (59%), 4 (61%) and 8 (53%) 
after tx. 
Omi  et al. J 
Cosmet Laser 
Ther 2004. 6: 
156-162  
N= 28 
 
28.1 y 
 
Burton 
grades 1-5 
Open 
Clearlight ™ 
(410 - 420 nm) 
200 mW/cm
2
 
 
25 - 30 cm 
distance 
Bi-weekly 
x 4 wks 
4 weeks 
 
3 months 
(for 9/20 ) 
At week 4: 
Total lesion count: ↓64.7%  (p <0.01) 
P. acnes cultures & PCR levels:  ↔ 
↓Moisture (p< 0.001)  & ↑sebum (p< 0.001) 
 
2 months post- tx: 
6/20 patients had sustained improvement 
 
Tzung et al. 
Photoderm 
Photoimmunol 
Photomed 2004. 
20: 266-269. 
N= 28/31 
 
21 ± 4 y 
 
18 ♀, 10 ♂ 
 
Type 
III - IV 
 
S/B, S/F 
controlled 
 
F-36 W/Blue V, 
Waldmann 
 
420 ± 20 nm 
15 cm distance 
 
 
40 J/cm
2
 
 
Bi-weekly 
x 4 wks 
4 wks 
At week 4: 
Control side had 10% improvement 
‘Peak’ improvement on tx side = 52%. 
Most improvement in papules & pustules. (p< 
0.001) 
4 patients worsened 
 
Significant worsening of nodulocystic lesions 
weeks 4 and 8 (p= 0.026) 
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AUTHOR, 
REFERENCE  
PATIENT  
FEATURES* 
N =  
§
 
STUDY 
TYPE 
LIGHT SOURCE 
(S) 
IRRADIATION 
VALUES 
REGIME 
STUDY 
DURATION 
FINDINGS 
Mild -severe 
 
 
P. acnes fluorescence unchanged. Only treated side 
assessed. 
Morton et al. J 
Dermatolog 
Treat 2005. 16: 
219-223 
N= 30 
18 yr 
14♀, 16♂ 
Mild - mod 
Face 
 
Omnilux Blue™ 
(LED) 
 
409 - 419 nm 
48 J/cm
2
 x 
10 - 20 min 
 
40 mW/cm
2 
5 - 10 cm 
distance 
Bi-weekly 
x 4 wks 
12 wks 
2 months post-tx: 
INF: ↓60%   (p = 0.001) 
NI: 2%  (no change) 
 
 
Gold et al. J 
Drugs 
Dermatol 2005. 
4: 64(67) 
N= 18/34 
31 yr 
 
Types II–VI  
Mild - mod 
R S/B pilot 
Blu-U™ 4170 
(12)     vs. 
1% clindamycin 
solution (13) 
 
Bi-weekly 
x 4 wks 
x 1000 s 
 
Clinda 
2x daily 
8 wks 
Week 4, 1% Clindamycin vs. Blu-U: 
INF:  30% vs. 36% (n.s.) 
NI:  14% vs. 21% (n.s.) 
 
In 9/34 who continued follow-up to week 8, 
changes in counts for either group did not reach 
significance. 
Tremblayet al.  
J Cosmet Laser 
Ther 2006. 8: 
31-33 
N= 43/45 
 
26 yrs 
 
31 ♀, 14 ♂ 
 
Types I -IV 
 
Mild - mod 
Open 
Omnilux Blue™ 
415 nm 
48 J/cm
2
 x 20 
min 
Bi-weekly x 
4 – 8 wks 
12 weeks 
No lesion counts recorded 
At 8 weeks: 
20% had complete clearing 
Mean global score: 2.9 (i.e. 51- 75% improvement), 
an 8% ↓ from week 4. 
 
10% dissatisfied with outcome 
50% “very satisfied”  with outcome 
Comments: ↓skin oiliness 
Noborio et al. 
Photoderm 
Photoimmunol 
Photomed 2007. 
23: 32-34 
 
N= 8/10 
 
29.7 years 
 
8 ♀, 2 ♂ 
 
III – IV 
 
Open 
 
 
 
 
 
MultiClear™ 
405 - 420 nm 
 
 
Spot size : 73 x 
23mm 
 
Fluence: 4 
J/cm
2
 per pulse 
(6 passes per 
area) 
 
Once or 
twice 
weekly 
x  12.4 tx 
(average) 
Until 
‘satisfac-tory 
results’ 
 
80% improved after an avg. of 12.4 tx. 
 
Severity scores at enrolment; 2 (1), 3 (1), 4 (6), 6 
(2). No change for subject at grades 2 or 3 (drop 
outs). 
 to grade 2 for everyone else. 
 
Allen & Smith facial acne severity scores 
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AUTHOR, 
REFERENCE  
PATIENT  
FEATURES* 
N =  
§
 
STUDY 
TYPE 
LIGHT SOURCE 
(S) 
IRRADIATION 
VALUES 
REGIME 
STUDY 
DURATION 
FINDINGS 
Burton 2 - 4 Burton’s scale for acne on body 
Kumaresan, 
M. & Srinivas, 
C.  Indian J 
Dermatol 2010. 
55: 370-372 
N= 10 
 
4 ♀, 6 ♂ 
 
Types IV-VI 
 
Michelson: 
22.4/ 27 
Blinded 
assessor 
IPL (Vcare 
Medical Sys, 
India) 
 
420 nm cut-off 
R face:  5 
pulses, 6ms 
delay 
L face: auto 
mode, pulse 
width 12 ms 
Fluence: 15 – 
21J 
Once 
weekly x 4 
weeks 
4 weeks 
Lesion counts not recorded 
Michelson Acne Severity Index (MASI): 
Mean improvement: 49.2 – 56.7%. 
 
Burst pulse more efficacious than single pulse 
mode. Both caused statistically sig. improvement in 
acne (no P values given). 
 216 
 
Table 3:  Red Light and Combination Blue & Red Light in Acne: A Summary 
KEY: * - ‘Patient features’ listed as: average age, skin type (if given), acne severity (if given), site (if given); § - number completed study / number enrolled 
(if given); contrlld – controlled; F/U – follow-up; INF – inflammatory; NI – non-inflammatory; n.s. – not significant; PIH – post-inflammatory 
hyperpigmentation; R – randomised; S/B – single blind; S/F – split face; tx – treatment; uncontrlld – uncontrolled; wks – weeks ↑- increase; ↓ - decrease; ↔ - 
no change;♀ - female ; ♂ - male 
 
AUTHOR, 
REFERENCE 
(YR) 
PATIENT  
FEATURES*  
N = 
§
 
STUDY 
TYPE 
LIGHT SOURCE 
(S) 
IRRADIATION 
VALUES 
REGIME 
STUDY 
DURATION 
FINDINGS 
RED LIGHT        
Na et al. 
Dermatol Surg 
2007. 33: 1228-
1233 
N = 28/30 
 
23.6 yr 
 
23 ♀, 7 ♂ 
Mild – mod 
R S/B S/F  
Hand held 
 
SoftLaser SL30 
 
635- 670 nm 
 
Cumulative dose:  
604.8 Jcm
-2
 
 
Irradiance: 6 mW 
 
15 min 
twice daily 
x 8 weeks 
 
16 weeks 
Week 8, treated vs. untreated sides: 
INF: 66% vs. ↑74% 
NI: ↓59% vs.↓3%  (p< 0.005) 
Total lesion count: ↓55% 
95% (21/22) relapse at 8 weeks post tx. 
Zane et al. 
Photoderm 
Photoimmunol 
Photomed 2008. 
24: 244-248 
N = 15 
 
22.4 yr 
Types I - IV 
Moderate 
acne 
Face and 
trunk 
Open 
Waldmann PDT 
Lamp, 
600 – 750 nm 
 
Face:  
20 mW/cm
2
, 
 
20 J/cm
2
  
x 8 mins 
 
40 cm distance 
Bi-weekly 
x  4 wks 
12 weeks 
No lesion counts 
Global Acne Grading System (GAGS) used 
At week 4: 
Face  GAGS:   50% (p < 0.05), maintained 2 
months post-tx 
Sebum  (C+K SM810):  43.8% (p <0.05) 
Moisture (C+ K TEWL):  55.2%  
(p < 0.05)     pH: no change 
 
At week 12: 
 GAGs, sebum and TEWL maintained.  
RED & BLUE 
LIGHT 
       
Papageorgiou 
et al.  Br J 
Dermatol 2000. 
142: 973-978 
N = 82/ 107 
 
14 - 50 yrs 
 
S/B contrlld 
study 
 
 
Hand-held  
Blue light (27): 
415 nm 
Blue + red light 
4.23 mW/cm
2
 
blue &  
2.67 mW/cm
2
 for 
red light 
15 min 
daily  
 
x 12 weeks 
12 weeks 
Blue – red combo superior to blue alone and BP, 
however no statistical significance. 
 
At week 12 (Blue + red vs. blue only): 
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AUTHOR, 
REFERENCE 
(YR) 
PATIENT  
FEATURES*  
N = 
§
 
STUDY 
TYPE 
LIGHT SOURCE 
(S) 
IRRADIATION 
VALUES 
REGIME 
STUDY 
DURATION 
FINDINGS 
 Mild - mod  (30): 415nm 
and 660nm 
Cool white light 
(25) 
 
Benzoyl 
peroxide  (25) 
 
Cumulative dose: 
320 J/cm
2 
&  
202 J/cm
2
 
INF:  76% vs. 63% 
NI: 58%  vs. 45% 
 
S/E: dryness and itch especially in BP group (8 
ppl vs. 2 in other tx grps), acne flare even across 
groups (2 each), headache; rash seen in treatment 
grps. 
Goldberg, D. & 
Russell, B. 
J Cosmet Laser 
Ther 2006. 8: 
71-75 
N= 22/24 
 
Types II - V  
 
Mild - severe 
 
Facial acne 
 
415 nm blue 
light LED 
 
633 nm red 
light LED 
Blue light x 20 
min, 48 J/cm
2
 
 
 Red light x 20 
min,  96 J/cm
2
 
Bi-weekly  
x 4 wks 
 
Red light 
alternating 
with blue 
12 weeks 
Microdermabrasion done before each tx. 
At week 4:  
Mean lesion count:  46% (p=0.001) 
 
At week 12:   
Mean lesion count:  81% (p=0.001).  
 
Comedones did not respond as well as 
inflammatory lesions 
Severe acne slightly better response than mild 
acne.  
Lee et al. Lasers 
Surg Med 2007. 
39: 180-188 
N = 24/27 
22.5 yr 
20 ♀, 4 ♂ 
 
Mild – 
moderately 
severe  
 
Face 
 
1. Omnilux 
blue™  
415 ± 5 nm  
 
2. Omnilux 
revive™   
633± 6 nm  
 
 
1.  40 mWcm
-2
  
x 20 min 
 
 
2.  80mWcm
-2
  
x 20 min 
Bi-weekly  
x 4 wks 
 
Red light 
alternating 
with blue  
 
  
12 weeks 
8 weeks post-tx:  
INF :↓77.9%   &  NI: -↓34.3% in 87.5% patients 
 
Moisture and sebum unchanged. Melanin ↓by red 
(p< 0.005) and ↑ blue light (p > 0.1). 
 
Improved skin texture. 
Nodulocystic lesions said to respond. 
Sadick  et al. 
 J Drugs 
Dermatol 2008. 
7: 347-350 
N = 19/21 
 
14-21 yr 
 
Mild - mod 
Open 
uncontrlld 
Omnilux clear-
U ™  
 
Handheld, 
contact  
LED area: 60 mm 
x 50 mm 
 
Blue x 20 min,  
40 mW/cm
2
,  
Bi-weekly  
x 4 wks 
 
Red light 
alternating 
12 weeks 
8 weeks post-tx: 
 
Mean INF:  69% (p > 0.001)? 
Mean NI:  12% 
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AUTHOR, 
REFERENCE 
(YR) 
PATIENT  
FEATURES*  
N = 
§
 
STUDY 
TYPE 
LIGHT SOURCE 
(S) 
IRRADIATION 
VALUES 
REGIME 
STUDY 
DURATION 
FINDINGS 
acne 
 
Face 
 
Blue 415 nm 
 
Red  633 nm 
48 J/cm
2
  
 
Red x 30 min, 
70 mW/cm
2
, 
126 J/cm
2
  
with blue  
Subjective rating: 68% had ‘marked’ or 
‘moderate’ improvement. 
 
No differences in response with acne severity 
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Table 4:  Yellow and Broad-spectrum Light in Acne: A Summary 
KEY: * - ‘Patient features’ listed as: average age, skin type (if given), acne severity (if given), site (if given); § – number completed study / number enrolled 
(if given); contrlld – controlled; F/U – follow-up; INF – inflammatory; NI – non-inflammatory; n.s. – not significant; PIH – post-inflammatory 
hyperpigmentation; R – randomised; S/B – single blind; S/F – split face; tx – treatment; uncontrlld – uncontrolled; wks – weeks ↑- increase; ↓ - decrease; ↔ - 
no change;♀ - female ; ♂ - male 
 
AUTHOR, 
REFERENCE  
PATIENT  
FEATURES* 
N =  
§
 
STUDY 
TYPE 
LIGHT SOURCE 
(S) 
IRRADIATION 
VALUES 
REGIME 
STUDY 
DURATION 
FINDINGS 
YELLOW 
LIGHT 
       
Chang et al. 
Dermatol Surg 
2007. 33: 676-
679 
 
 N = 30 
 
25.7 yr 
 
30 ♀  
 
Mild-mod 
acne  
 
Type III - IV  
R S/B S/F  
 
Ellipse flex IPL 
(530- 750 nm) 
 
2.5ms pulse 
duration 
 
 
 
Skin type II:  
8 J/cm
2
  
 
Skin type IV:  
7.5 J/cm
2 
 
1 every 3 wks 
x 3 sessions 
12 weeks 
BP gel used on entire face, a confounder. 
 
Korean acne grading system; no comedones 
included.  Lesion counts not reported. 
 
At week 12 (week 3 post-tx):  
No difference b/wn IPL + BP and BP alone. 
( 3.2 vs. 3.1) 
Skin tone and pigmentation improved on IPL 
side. 
 
S/E: PIH in 3/30, lasted 2 weeks 
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AUTHOR, 
REFERENCE  
PATIENT  
FEATURES* 
N =  
§
 
STUDY 
TYPE 
LIGHT SOURCE 
(S) 
IRRADIATION 
VALUES 
REGIME 
STUDY 
DURATION 
FINDINGS 
Sami et al.  
J Drugs 
Dermatol 2008. 
7: 627-632 
 
N= 45 
 
29 yr 
27♀, 18♂  
 
Types III - IV 
R S/F S/B  
Compara-
tive study 
1. IPL (Epi-
C/plus®, Italy) 
550 – 1200 nm 
2.5 x 4.5 cm 
spot  (15) 
 
2. Pulsed dye 
laser, 595 nm 
(15) 
 
3. Blue-red 
LED  470 nm  
& 623 nm (15) 
1. 22J/cm
2
; 30 
ms pulse 
 
2.  6- 8 J/cm
2
; 
0.5 ms pulse;  
7mm spot 
 
3. Blue = 
10 mW/cm
2
   
     vs. 
Red =  
40 mW/cm
2
  
1.  Weekly  
 (6.0±2.05 
sessions) 
 
2.  Weekly  
(4.1±1.39 
sessions) 
 
3. Biweekly x 
30 min  
(10.0±3.34 
sessions) 
 
 Until 
≥90% 
‘clearance’ 
achieved. 
Lesion counts for control side of face not 
reported.  
Non-inflammatory lesions not counted. 
 
Inflammatory lesion count improvement 
from baseline at 1 month vs. 1 month post-
tx: 
IPL:   41.7% vs. 94.3% (p < 0.05) 
PDL:  73.8% vs. 98.9% (p < 0.05) 
Blue-red LED:  35.6% vs. 91% (p < 0.05) 
Choi et al.  
J Eur Acad 
Dermatol 
Venereol 2010. 
24: 773-780 
N = 20 
 
26 yr 
 
19 ♀, 1♂ 
 
Types III - V 
R S/F S/B  
Ellipse flex IPL 
(530- 750 nm) 
 
2.5ms pulse 
duration 
 
2. PDL 585 nm 
(Cynergy, 
Cynosure) 
1. 7.5 -8.3 
J/cm
2
, triple 
pulse, 9 ms 
delay, double 
pass 
 
2. 10mm, 
40ms, 8-10 
J/cm
2
 
 
Once every 2 
weeks x 4 
weeks 
12 weeks 
Follow up 
at weeks 1, 
4, 8 and 10  
Improvement with both modalities, almost a 
dead heat between IPL and PDL 
 
Reduction in inflammatory lesion counts 1 
month post tx &  2 months post-tx: 
IPL:   66.7% & 55% (p < 0.05) 
PDL:  62% vs. 86% (p < 0.05) 
 
Reduction in non- inflammatory lesion 
counts 1 month post tx &  2 months post-
tx: 
IPL:   33% & 43% (p < 0.05) 
PDL:  47% vs. 59% (p < 0.05) 
 
BROAD 
SPECTRUM 
       
Sigurdsson et 
al. Dermatology 
1997. 194: 256-
N = 23/30 
 
23.5 ± 5.2 yrs 
S/B,   
Full face/ 
Split- back 
Phillips 
HP3136  
 
1. Full-
spectrum + 
UVA: 
Thrice weekly  
x 20 min   
 
7 weeks 
 
Assessments at treatments 0, 6, 12 & 20. 
 
Those that dropped out, improvement at tx 
 221 
 
AUTHOR, 
REFERENCE  
PATIENT  
FEATURES* 
N =  
§
 
STUDY 
TYPE 
LIGHT SOURCE 
(S) 
IRRADIATION 
VALUES 
REGIME 
STUDY 
DURATION 
FINDINGS 
260. 
 
 
 
 
15♂, 15♀  
 
Mild - mod  
 
Face ± back ± 
chest.  
 
Face = 1 unit 
 
Chest & back 
divided into 2 
tx areas 
or chest 
 
 
 
1. Phillips 
HPA 
400W 
 
2. Phillips 
HPM-10 
400W + 
390 nm 
filter 
 
3. Green light 
+ UV & 
blue light 
filter 
 
N.B. Peak 
wavelengths not 
explicitly stated   
 
Max. skin temp 
40 - 41˚ C 
 
(UVA) 5 
J/cm
2
: 
(violet/blue)  
16 J/cm
2
: 
(green)  
9 J/cm
2  
- 17 fields 
treated 
 
2. Violet light:  
0.5 J/cm
2
: 20 
J/cm
2
: 5 J/cm
2
 
- 20 fields 
treated 
 
3. Green light:  
0 : 0.5 J/cm
2
: 
50 J/cm
2 
- 19 fields 
treated 
 
 
40 cm distance 
Total 20  
sessions 
 
 
 
12 comparable to others who completed 
study. 
 
Mean  severity score at week 7: 
Violet light - 30%(p < 0.02) 
Green - 22% (p< 0.05)  
Full spectrum - 14% (n.s.) 
 
After session 20: 
Significant reductions only for inflamed 
lesions 
 
Full-spectrum - ↓50%  (p <0.01) 
Violet light - 51% (p <0.01) 
Green light  - 24% (n.s.) 
 
Intra-patient comparisons of both sides of 
back and/or chest revealed no significant 
differences. 
 
Patient opinion on severity score correlated 
with physician (no values). 
 
Conclude: violet light most effective. 
Monotherapy with visible light not possible. 
 
Elman, M. & 
Lask, G.  
J Cosmet Laser 
Ther 2004. 6: 
91-95 
N= 19 
 
19 yr 
 
12♂, 7♀  
Mild - mod 
Open 
prospective
/Full face 
Clear Touch™  
430 - 1100 nm 
 
Predominantly 
green/yellow 
light + heat 
3.5 J/cm
2
  
(per pulse)   
 
35 ms pulse 
width   
 
 Bi-weekly  
x 4 wk 
12 weeks 
At 1 month post-tx: 
INF:  74 ± 20% 
NI:  79 ± 22% 
 
At 2 months post-tx: 
INF: ↓ 87 ± 17% 
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AUTHOR, 
REFERENCE  
PATIENT  
FEATURES* 
N =  
§
 
STUDY 
TYPE 
LIGHT SOURCE 
(S) 
IRRADIATION 
VALUES 
REGIME 
STUDY 
DURATION 
FINDINGS 
 energy 22 x 55 mm 
spot  
NI:- ↓ 85 ± 25% 
 (no p values) 
 
Patient avg. rating of improvement ‘good’ 
vs. physicians ‘very good’.  
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Leeds Revised Acne Grading System (Back) 
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UHW Medical Photography Protocol for Acne Study  
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Leeds Assessments (Blinded) 
 Leeds Scores from blinded assessors        
CASE Chantal1 Babar 1 
Ausama 
1 Basra 1 AVG 1 
Chantal 
2 Babar 2 
Ausama 
2 Basra 2 AVG 2 Delta score  
% 
change 
6 1 1 1 1 1 1 1 1 1 1 0 0 
7 2 3 3.5 1 2.375 2 3 3.5 1 2.375 0 0 
9 3 3 3 3 3 2 2 3 2 2.25 -0.75 -25 
10 1 1 1 1 1 1 1 1 1 1 0 0 
11 1 1 1 1 1 1 1 1 1 1 0 0 
12 1 1 1 1 1 1 1 1 1 1 0 0 
13 1 1 1 1 1 1 1 1 1 1 0 0 
14 1 1 1 1 1 1 1 1 1 1 0 0 
15 1 1 1 1 1 2 3 2 2 2.25 1.25 125 
16 2 2 2 1 1.75 1 1 2 1 1.25 -0.5 
-
28.571429 
18 1 1 1 1 1 1 1 1 1 1 0 0 
20 1 1 1 1 1 1 1 1 1 1 0 0 
21 1 1 1 1 1 1 1 1 1 1 0 0 
22 2 2 2 1 1.75 2 1 1 1 1.25 -0.5 
-
28.571429 
23 1 1 1 1 1 2 2 2 1 1.75 0.75 75 
24 1 1 1 1 1 1 1 1 1 1 0 0 
25 3 1.5 2 3 2.375 2 1 1 2 1.5 -0.875 
-
36.842105 
26 1 1 2 2 1.5 2 1 2 2 1.75 0.25 16.666667 
27 1 1 1 1 1 1 1 1 1 1 0 0 
29 1 1 1 1 1 2 2 1 1 1.5 0.5 50 
30 2 2 2 1 1.75 3 2 3.5 2 2.625 0.875 50 
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 Leeds Scores from blinded assessors        
                   
AVG 
Score 1.380952 1.357143 1.452381 1.238095 1.357143 1.47619 1.380952 1.52381 1.238095 1.404762 0.047619048 9.4134145 
STD 
DEV  0.669043 0.654654 0.740013 0.624881 0.593303 0.601585 0.669043 0.858432 0.436436 0.546158 0.499180877 37.604462 
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Raw Clinical Data 
Raw Open Leeds Scores for Full Cohort of Patients  (piloted and drop out cases highlighted) 
CASE Back leeds Back 2nd δ back 
Face 
grade 
Face 
2nd δ Face Chest grade Chest 2nd δ Chest 
6 1.5 0 1.5 0 0 0 1    
10 3 2 1 0.5 0.25 0.25 0.5 0.5 0 
15 3 2 1 5 0.5 4.5 0 0 0 
18 1.5 0.75 0.75 0 0 0 0 0 0 
26 2.75 2 0.75 1 1 0 0.5 0.25 0.25 
11 1 0.5 0.5 3 1 2 0 0 0 
16 2 1.5 0.5 0 0 0 0.5 0 0.5 
22 2.5 2 0.5 4 6 -2 1.5 1 0.5 
27 1.5 1 0.5 0 0 0 0 0 0 
29 2.5 2 0.5 4 1.5 3.5 2.5 2 0.5 
21 0.75 0.5 0.25 0.5 0 0.5 0.25 0 0.25 
25 2.5 2.25 0.25 0.5 0 0.5 0 0.25 0 
7 3.5 3.5 0 0.5 1 -0.5 2 1.5 0.5 
9 4 4 0 6 7.5 -1.5 2 2 0 
12 1 1 0 0.5 1 -0.5 1.5 0.5 1 
14 0.5 0.5 0 0.25 0.5 -0.25 0 0 0 
30 4 4 0 0.5 1 -0.5 0.5 0.5 0 
20 0.75 1 -0.25 1 1.5 -0.5 0.5 0 0.5 
24 1.5 2 -0.5 0.25 0 0.25 0.5 0 0.5 
13 1 2 -1 2 2 0 0.5 0 0.5 
23 1 2 -1 0 0 0 0 0 0 
1 4     0     2     
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Raw Open Leeds Scores for Full Cohort of Patients  (piloted and drop out cases highlighted) 
2 2     2     1     
3 1     0     1     
4 1.5     0.25     1     
5 0.5 1 -0.5 0 0 0 0 0.5 -0.5 
8 1.5     0.5     1     
19 1     0     0.5     
AVG 
28 1.901785714    1.151786    0.741071429    
SD 28 1.095739404    1.686465    0.731190502    
              
AVG 
21 1.988095238 1.738095238 0.25 1.404762   0.27380952 0.678571429   0.25 
SD 21 1.093949812 1.105317235 0.62249498 1.846409  1.46395176 0.771130895  0.29244883 
             
AVG 
20 2.0375 1.725 0.3125 1.375  0.2875    0.23684211 
SD 20 1.098069478 1.132358972 0.567050309 1.889201   1.50060295     0.29431753 
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Raw SER Data for Full Cohort of Patients  (piloted and drop out cases highlighted) 
CASE 
Sebum 
1 
Sebum 
2 sebum3 1st Avg CASE 
2nd 
sebum 
2nd 
sebum2 
2nd 
sebum 3 2nd Avg δ sebum 
6 6 9 5 6.67 6 3 9 4 5.33 1.34 
10 29 36 25 30 10 26 37 28 30.33 -0.33 
15 31 41 40 34 15 32 9 17 17.33 16.67 
18 1 1 1 1 18 7 12 7 8.67 7.67 
26 12 20 7 13 26 31 10 20 20.33 -7.33 
11 6 6 4 5.33 11 15 48 17 26.67 21.34 
16 2 2 0 1.33 16 0 5 1 2 -0.67 
22 16 20 20 18.67 22 9 12 16 12.33 6.34 
27 13 19 20 17.33 27 9 7 10 8.67 8.66 
29 9 5 7 7 29 3 3 8 4.67 2.33 
21 19 43 27 29.67 21 5 5 9 6.33 23.34 
25 21 23 17 20.33 25 8 13 5 8.67 11.66 
7 11 17 11 13 7 15 9 11 11.67 1.33 
9 13 7 16 12 9 24 24 22 23.33 -11.33 
12 4 6 5 5 12 3 3 6 4 1 
14 17 25 17 19.67 14 25 21 16 20.67 1 
30 7 6 3 5.33 30 2 1 0 1 4.33 
20 31 45 17 31 20 35 34 28 32.33 -1.33 
24 9 15 16 13.33 24 6 9 4 6.33 7 
13 37 62 61 53.3 13 24 21 33 26 27.3 
23 9 7 5 7 23 11 9 10 10 3 
1 8 13 8 9.67 1 3 1 4 2.67 7 
2 30 27 46 34.3 2 65 73 80 72.6 -38.3 
3 7 15 11 11 3 8 5 14 9 2 
4 18 12 11 13.67 4 15 18 17 16.67 -3 
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5 30 31 23 28 5 52 51 42 48.33 -20.33 
8 15 19 38 24 8           
19 14 11 12 12.33 19           
AVG 28    17.03321     16.76654   
SD 28    12.23281     16.08255   
              
AVG 21    16.37905     13.65048 5.872381 
SD 21    13.11553     9.720177 9.698687 
               
AVG 20    14.533     13.033 4.801 
SD 20       10.28291         9.540773 8.581469 
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Raw Lesion Count Data for Full Cohort of Patients  (piloted and drop out cases highlighted) 
inflamm 
1 
inflamm 
2 
δ 
Inflamm % δ Infl 
Resolving 
1 
Resolving 
2 
δ 
resolved CASE N-Inf 1 N-Inf 2 
δ non-
inf   
15 18 -3 -20%     6 9 19 -10   
53 34 19 36%  4   10 55 31 24   
11 9 2 18% 3 8 -5 15 78 38 40   
4 4 0 0% 2 4 -2 18 17 20 -3   
27 10 17 63% 1 4 -3 26 55 43 12   
17 9 8 47%  1   11 18 15 3   
12 3 9 75% 4 4 0 16 110 85 25   
54 31 23 43% 0 1 -1 22 77 95 -18   
6 7 -1 -17% 0 2 -2 27 12 11 1   
24 8 16 67% 1 3 -2 29 42 19 23   
11 2 9 82% 3 1 -2 21 11 32 -21   
28 8 20 71% 6 0 6 25 56 19 37   
36 32 4 11%  17   7 9 40 -31   
100 103 -3 -3%  14   9 71 102 -31   
30 37 -7 -23%  2   12 42 19 23   
2 3 -1 -50% 1 0 1 14 37 4 33   
15 7 8 53% 1 2 -1 30 12 14 -2   
9 0 9 100% 1 3 -2 20 12 8 4   
20 12 8 40% 3 4 -1 24 56 29 27   
20 136 -116 -580% 0 0 0 13 28 125 -97   
11 12 -1 -9% 1 2 -1 23 5 14 -9   
60 43 23 38%       1 6 3 3   
24 39 -15 -63%       2 12 103 -91   
28 5 23 82%       3 16 20 -4   
11 9 2 18%       4 10 1 9   
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Raw Lesion Count Data for Full Cohort of Patients  (piloted and drop out cases highlighted) 
6 21 -15 -250%       5 3 12 -9   
14             8 61       
16       0     19 10       
23.71429   -0.06536      33.21429  -2.38462   
21.09565   1.356612      28.53634  33.36235   
               
24.04762 23.09524 0.952381 0.001863      38.66667 37.2381 1.428571   
22.41534 34.31604 28.10423 1.389704      29.25121 34.30729 31.19547   
               
24.25 17.45 6.8 0.291956      39.2 32.85 6.35   
22.97796 23.13229 8.691193 0.415544         29.90617 28.51828 22.11281   
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Appendix 3   
 
 
 
 TLR2 IHC Image Analysis Data  
 TLR2 Semi-qPCR Densitometry Data  
 TLDA Data with CSF-1 as the Housekeeping Gene 
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TLR2 IHC Image Analysis Data 
TLR2 Image Analysis Data (Image Pro Plus) Mean scores for image analysis   
Case  B1 B2 B3     Case AVG B1 AVG B2 AVG B3 
2a 0.215 0.265 0.204    2 0.2007 0.2469 0.215   
2b 0.209 0.239 0.221    3 0.2503 0.2159 0.213   
2c 0.19 0.24 0.221    4 0.2321 0.2178 0.232   
2d 0.189 0.243 0.213    5 0.2563 0.2097 0.237   
3a 0.255 0.226 0.228    6 0.1673 0.2154 0.253   
3b 0.253 0.227 0.217    9 0.2457 0.2353 0.156   
3c 0.249 0.203 0.198    10 0.2086 0.28 0.203   
3d 0.244 0.207 0.208    12 0.2334 0.246 0.04   
4a 0.229 0.209 0.226    14 0.1935 0.2827 0.328   
4b 0.236 0.215 0.245    18 0.2489 0.2252 0.225   
4c 0.232 0.229 0.233          
4d 0.231 0.218 0.224    AVG 0.2237 0.2375 0.21   
5a 0.265 0.227 0.225          
5b 0.261 0.209 0.218    % change B1 vs B2 B2 vs B3 B3 vs B1 
5c 0.254 0.176 0.245     6.1824 -11.5 -6.032   
5d 0.245 0.226 0.26          
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TLR2 Image Analysis Data (Image Pro Plus) Mean scores for image analysis   
6a 0.186 0.207 0.261          
6b 0.123 0.238 0.235          
6c 0.18 0.236 0.256          
6d 0.181 0.181 0.259          
9a 0.272 0.235 0.216          
9b 0.247 0.246 0.173          
9c 0.247 0.222 0.15          
9d 0.217 0.239 0.085          
10a 0.208 0.312 0.208          
10b 0.208 0.277 0.2          
10c 0.205 0.266 0.206          
10d 0.214 0.264 0.197          
12a 0.228 0.258 0.042          
12b 0.247 0.244 0.065          
12c 0.227 0.243 0.037          
12d 0.232 0.238 0.016          
14a 0.19 0.288 0.343          
14b 0.177 0.318 0.327          
14c 0.202 0.255 0.329          
14d 0.205 0.292 0.314          
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TLR2 Image Analysis Data (Image Pro Plus) Mean scores for image analysis   
18a 0.246 0.231 0.232          
18b 0.254 0.221 0.218          
18c 0.25 0.216 0.22          
18d 0.245 0.233 0.228          
AVG 0.224 0.238 0.21          
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TLR2 Semi-qPCR Densitometry Data 
 
Densitometry  Data from Agarose Gel Images (SemiqPCR) using Alpha Imager  
CASE TLR2 B1 TLR2 B2 TLR2 B3 
1 0.068456 1.671763 0.628743 
2 1.564153 0.733494 0.672913 
3 0.24395 1.668062 0.863118 
4 0.242567 0.082767 0.006374 
5 1.519897 0.027824 0.044103 
6 0.012827 0.086629 1.564121 
9 0.677026 0.166702 0.598754 
10 1.795397  0.070617 
12 2.26179 3.535246 5.729383 
14 0.66413 5.29467 1.276844 
18 0.946663 0.428601 0.117073 
        
AVG 0.908805091 1.3695758 1.052003909 
     
% change B2-B1 B3-B1 B3-B2 
  50.70071831 15.75682395 -23.18760969 
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TLDA Data with CSF-1 as HKG 
TLDA Data with CSF-1 as the House-keeping Gene   
GAPDH       IL-10       
Case B1 B2 B3 Case B1 B2 B3 
2a -4.762 -4.57 -3.844 2a 7.345 4.105 3.801 
2b -4.72 -4.129 -4.214 2b 4.8 4.526 4.681 
2c -4.943 -3.821 -3.835 2c 6.331 5.212 4.57 
14a -3.289 -3.91 -3.981 14a 9.809 3.225 6.63 
14b -4.273 -3.659 -4.071 14b 5.108 3.863 5.903 
14c -4.06 -3.276 -4.292 14c 2.959 4.031 5.783 
22a -4.709 -3.727 -4.468 22a 2.243 5.607 3.44 
22b -4.028 -4.168 -3.844 22b 3.005 4.805 2.862 
22c -4.059 -4.047 -5.584 22c 3.204 3.065 3.897 
24a -4.584 -3.443 -4.067 24a 4.567 8.84 3.376 
24b -4.311 -3.361 -3.721 24b 4.077 4.816 3.311 
24c -4.293 -3.783 -4.168 24c 4.077 8.869 3.523 
25a -4.597 -4.65 -5.123 25a 4.116 3.281 4.712 
25b -4.605 -4.442 -3.923 25b 3.273 4.505 4.306 
25c -5.069 -5.276 -5.206 25c 4.736 4.825 3.386 
26a -4.296 -4.611 -4.375 26a 4.37 4.418 4.322 
26b -4.393 -4.971 -4.461 26b 3.999 4.676 2.945 
26c -4.192 -4.825 -4.519 26c 5.743 2.977 3.063 
30a -3.967 -4.295 -4.367 30a 3.012 2.886 4.136 
30b -3.891 -4.171 -4.14 30b 2.948 3.326 2.729 
30c -3.622 -3.845 -4.617 30c 4.35 3.387 4.042 
 
  
 239 
 
 
TLDA Data with CSF-1 as the House-keeping Gene 
  
TNF       TNFR       
Case B1 B2 B3 Case B1 B2 B3 
2a 3.098 2.604 3.615 2a 2.598 3.559 4.808 
2b 2.831 3.248 4.621 2b 3.223 3.589 4.921 
2c 4.457 3.627 1.509 2c 3.668 3.419 4.446 
14a 1.921 2.736 3.856 14a 2.973 6.688 5.109 
14b 4.433 3.904 3.337 14b 4.265 4.004 3.919 
14c 2.076 7.096 5.169 14c 3.724 7.096 3.464 
22a 2.338 3.336 3.613 22a 2.455 4.023 7.615 
22b 3.514 3.703 3.655 22b 3.243 5.412 5.781 
22c 3.367 4.242 3.178 22c 3.572 10.079 2.513 
24a 2.812 4.405 7.9 24a 2.307 3.211 3.637 
24b 3.31 3.748 5.129 24b 2.863 2.619 4.074 
24c 3.951 3.479 8.066 24c 2.926 5.267 4.605 
25a 2.946 3.307 4.666 25a 5.215 1.991 3.914 
25b 2.104 2.54 3.446 25b 3.877 3.289 3.214 
25c 3.49 2.75 1.693 25c 4.648 3.405 4.725 
26a 4.164 3.717 1.757 26a 3.078 3.544 5.537 
26b 2.433 2.611 4.951 26b 2.748 0.841 5.86 
26c 3.315 2.063 2.552 26c 3.293 3.306 3.689 
30a 2.828 1.955 2.226 30a 3.243 3.835 3.01 
30b 2.584 3.149 4.142 30b 4.282 4.799 4.782 
30c 2.829 3.085 4.01 30c 4.999 7.748 3.188 
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TLDA Data with CSF-1 as the House-keeping Gene   
IL-8       STAT-3     
Case B1 B2 B3 B1 B2 B3 
2a 7.409 6.923 5.283 -1.058 -1.814 -0.823 
2b 4.183 5.644 10.026 -0.615 -1.406 -0.905 
2c 3.739 7.294 10.187 -0.965 -1.952 -0.708 
14a 5.491 3.53 5.714 -1.269 -0.414 -0.522 
14b 5.687 3.948 5.483 -0.667 -1.151 -0.468 
14c 6.449 7.096 6.784 -1.734 -0.809 -0.119 
22a 4.793 4.338 7.615 -0.931 -0.608 -0.6 
22b 10.058 6.972 5.444 0.026 0.009 -0.827 
22c 9.975 6.827 4.326 -0.149 -0.02 -0.945 
24a -0.82 8.84 -1.808 -1.057 -0.768 -0.924 
24b 0.302 2.494 3.167 -0.274 -0.621 -0.524 
24c -0.915 -4.538 3.211 -0.999 -0.443 -0.533 
25a 10.191 6.493 7.9 -1.507 -1.414 -1.136 
25b 3.637 4.89 9.351 -1.968 -0.775 0.093 
25c 3.571 6.607 8.066 -1.956 -1.623 -1.403 
26a 8.674 3.571 4.553 -1.04 -1.476 -1.879 
26b 8.547 5.426 5.787 -1.02 -1.873 -1.762 
26c 8.796 3.526 4.841 -1.095 -1.204 -2.058 
30a 3.664 5.872 8.493 -0.753 -1.245 -1.269 
30b 2.973 5.528 8.883 -1.57 -1.164 -1.274 
30c 4.063 5.927 8.061 -0.826 -1.661 -1.384 
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